f hoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom troper ecnanif e roche finance report finance brief key result sale core operate profit margin cer growth sale pharmaceutical diagnostic group change sale chf chf chf cer ifrs result sale operating profit net income net income attributable roche shareholder dilute eps chf dividend share chf core result research development core operating profit core eps chf free cash flow operate free cash flow free cash flow change chf chf chf cer net debt capitalisation debt equity propose board director cer constant exchange rate percentage change constant exchange rate calculate simulation reconsolidate result constant exchange rate average rate year end december definition cer core result core ep earning share exclude noncore item global restructuring plan amortisation impairment goodwill intangible asset allow assessment actual result underlie performance business income statement group operating result division show ifrs core basis core concept fully describe page reconciliation ifrs core result give free cash flow assess group ability generate cash require conduct maintain operation indicate group ability generate cash finance dividend payment repay debt undertake merger acquisition activity free cash flow concept internal management business free cash flow concept fully describe page reconciliation ifrs cash flow free cash flow give therefinance report roche group finance brief roche roche group report solid overall result underlie business show resilience pandemic environment sale grow constant exchange rate cer ifrs net income increase cer core earning share increase cer appreciation swiss franc currency adverse impact result express swiss franc sale group sale increase cer chf billion decline chf term pharmaceutical sale decline cer mainly impact biosimilar notably impact covid pandemic leading reduce hospitalisation outpatient visit growth new medicine lead tecentriq hemlibra ocrevus perjeta kadcyla additional sale actemraroactemra partly compensate decline diagnostic sale show growth cer sale covidrelate test notably cobas sarscov pcr test sarscov rapid antigen test offset decline routine testing portfolio operating result core operating profit increase cer chf billion decline chf term research development expenditure grow cer chf billion core basis despite pandemic environment focus oncology neuroscience immunology therapeutic area research development cost represent group sale ifrs operating result include noncore expense pretax chf billion major factor chf billion amortisation charge intangible asset chf billion restructuring cost chf billion impairment goodwill intangible asset release litigation provision result income chf billion nonoperating result finance cost ifrs decreased cer chf billion early debt redemption loss chf billion low interest expense income tax expense ifrs increased cer chf billion effective core tax rate increase mainly impact resolution tax dispute net income ifrs net income increase cer chf billion chf term drive operating result core earning share increase cer chf chf term cash flow operate free cash flow chf billion decrease cer underlie cash generation remain strong decrease cer arising increase net work capital high investment inlicense alliance arrangement free cash flow decrease cer chf term chf billion drive low operate free cash flow financial position net working capital increase cer drive increase inventory division net debt decrease chf billion chf billion free cash flow offset dividend pay outflow transaction equity instrument gross debt increase cer chf billion credit rating remain strong moodys aa standard poor aa shareholder return proposal increase dividend chf share represent th consecutive year dividend growth result payout ratio subject agm approval total shareholder return tsr represent combined performance share nonvoting equity security roche group finance report roche group finance brief inside cover finance brief financial review roche group consolidated financial statement note roche group consolidate financial statement general accounting principle current liability operating segment information provision contingent liability revenue debt net financial expense equity attributable roche shareholder income taxis subsidiarie merger acquisition noncontrolle interest global restructuring plan employee benefit property plant equipment pension postemployment goodwill benefit intangible asset equity compensation plan inventory lease account receivable earning share nonvoting marketable security equity security cash cash equivalent statement cash flow noncurrent asset risk management current asset relate party account payable list subsidiary associate noncurrent liabilitie significant accounting policy report roche management internal control financial report statutory auditor report multiyear overview supplementary information roche security roche holding ltd basel financial statement note financial statement appropriation available earning statutory auditor report finance report financial review roche group financial review roche group result finance brief inside cover sale billion chf core operating profit billion chf cer growth sale net income attributable roche shareholder billions chf core eps chf covid pandemic outbreak pose unprecedented challenge healthcare system globe roche group respond challenge pharmaceutical diagnostic business march diagnostic division launch cobas sarscov pcr test run highvolume fully automate cobas cobas system base pcr technology instal major hospital laboratory world roche diagnostic continue complement portfolio pointofcare test sarscov rapid antigen test pharmaceutical division actemraroactemra adopt country treatment guideline treat patient severe covid pneumonia august roche group announce partner regeneron develop manufacture distribute investigational neutralise antibody combination roche group business far prove largely resilient difficult environment pandemic negative impact underlie business roche group division restriction lead reduce hospitalisation outpatient visit impact routine diagnostic testing lead low level prescription medicine notably require medical professional infusion injection time major manufacturing supply chain issue far occur group plan drug launch filing pivotal phase iii trial readout pivotal trial start largely track despite pandemic roche group research development spending increase additionally inlicensing transaction asset acquisition lead addition intangible asset chf billion pharmaceutical division chf billion diagnostic division roche group report sale growth constant exchange rate cer core operate profit growth ifrs net income increase prior period include significant goodwill writeoff core ep increase appreciation swiss franc currency adverse impact result express swiss franc compare constant exchange rate percentage point sale percentage point core operating profit percentage point core eps pharmaceutical division sale low biosimilar erosion especially pronounce covid effect global uptake new medicine continue strong partly compensate effect diagnostic division sale covidrelated test total chf billion drove increase divisional sale offset decline routine testing portfolio roche group financial review finance report operate free cash flow chf billion decrease cer drive increase net work capital high investment inlicense alliance arrangement free cash flow chf billion low reason appreciation swiss franc significant negative impact free cash flow measure express chf term group maintain sufficient liquidity support ongoing business activity position meet financial obligation divisional operating result pharmaceutical diagnostic corporate group chf chf chf chf sale core operate profit margin sale operate profit margin sale operate free cash flow margin sale divisional operating result development result compare pharmaceutical diagnostic corporate group sale increase cer core operating profit increase cer margin percentage point increase operating profit increase cer margin percentage point increase operate free cash flow increase cer margin percentage point increase extent covid pandemic negatively affect sale business describe follow section impact covid pandemic sale pharmaceutical division chf billion chf billion decrease cer drive biosimilar competition notably pandemic reduced hospitalisation outpatient visit growth new product additional sale actemraroactemra grow partly compensate decline new product major growth driver tecentriq hemlibra ocrevus perjeta kadcyla contribute additional chf billion cer new sale tecentriq sale high chf billion growth region launch rollout hemlibra continue sale reach chf billion sale ocrevus high chf billion perjeta sale chf billion increase growth china kadcyla sale grow mainly high demand europe biosimilar version herceptin avastin mabtherarituxan enter market second half sale product chf billion cer low europe biosimilar version avastin come market mid significant factor sale decline avastin second half diagnostic division report sale chf billion increase cer sale covidrelated test chf billion cer exclude decline routine testing portfolio restriction major growth area molecular diagnostic grew drive cobas sarscov pcr test centralise point care solution sale decrease attributable reduction routine testing volume covid pandemic partly offset sale sarscov rapid antigen test diabetes care sale decrease continued overall contraction blood glucose monitor market covid effectsfinance report financial review roche group pharmaceutical division core operating profit remain stable cer sale decline royalty operating income decrease chf billion low product disposal gain comparative period cost sale decrease low inventory writeoff product mix factor productivity improvement low collaboration profitsharing expense market distribution cost decrease include activity support ongoing product launch rollout notably tecentriq ocrevus perjeta cost decrease reduced spending marketing activity partly attributable covid pandemic low personnel expense research development cost grow oncology franchise remain primary area activity growth spending drive latestage investment ophthalmology personalise healthcare neuroscience significant inlicensing transaction asset acquisition bring external innovation roche group result intangible asset addition chf billion pharmaceutical division diagnostic division core operating profit increase cer ahead sale growth cost sale grow additional product volume high shipping rate marketing distribution cost stable low spending result covid restriction cost containment measure offset high personnel expense inventory writeoff research development cost increase increase spend covid product development project cardiac disease digital solution ifrs operating profit increase cer pharmaceutical division include chf billion income following release litigation provision ifrs operating profit increase chf billion diagnostic division prioryear figure include goodwill impairment charge chf billion relate diabetes care business result include chf billion amortisation impairment intangible asset chf billion expense global restructuring plan operate free cash flow chf billion decrease cer increase net work capital high investment inlicense alliance arrangement development sale negative impact operate free cash flow pharmaceutical division diagnostic division see improvement cash generation free cash flow chf billion decrease cer lower operate free cash flow express chf term free cash flow measure strong negative impact appreciation swiss franc financing cost decrease cer ifrs basis chf billion early debt redemption loss chf billion low interest expense current year attributable early repayment debt second half group effective core tax rate increase compare mainly impact resolution tax dispute reduce group effective core tax rate percentage point percentage point net income increase cer ifrs basis chf billion core basis chf billion drive case operating result net income attributable noncontrolle interest increase ifrs basis core basis increase contribution chugai overall group result roche group financial review finance report income statement change change chf chf chf cer ifrs result sale royalty operating income revenue cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest eps basic chf eps diluted chf core result sale royalty operating income revenue cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core ep basic chf core eps diluted chf page definition core result core epsfinance report financial review roche group impact covid pandemic roche medicine diagnostic test test detect virus march cobas sarscov pcr test detect active infection sarscov receive fda emergency use authorization available market accept ce mark hospital reference laboratory run test roche diagnostic highvolume fully automate cobas cobas system base pcr technology instal major hospital laboratory world september sarscov rapid antigen test use pointofcare setting symptomatic asymptomatic people launch market accept ce mark test help healthcare professional identify sarscov infection people suspect carry virus result typically ready minute addition serve valuable initial screening test individual expose sarscovinfected patient highrisk environment september cobas sarscov influenza ab test use cobas system receive fda emergency use authorization available market accept ce mark test available cobas liat system pointofcare set december highthroughput elecsys sarscov antigen test automate laboratory assay intend aid diagnosis active sarscov infection launch market accept ce mark filing fda emergency use authorization test detect immune response elecsys antisarscov antibody test receive fda emergency use authorization available market accept ce mark test design help determine patient develop antibody sarscov exposure virus test run roche diagnostic cobas e analyser widely available world september elecsys antisarscov antibody test launch market accept ce mark fda emergency use authorization subsequently receive immunology test target antibodie spike protein quantitatively measure antibodie people expose sarscov play important characterise vaccineinduce immune response sale covidrelated test chf billion cer sale cobas sarscov pcr test combine covidrelated test molecular diagnostic chf billion cer launch sarscov rapid antigen test late september combine relate test centralise point care solution reach chf billion cer investigate treatment option actemraroactemra adopt country treatment guideline treat patient severe covid pneumonia march pharmaceutical division initiate global phase iii clinical trial investigate safety efficacy actemraroactemra tocilizumab covidassociate pneumonia result covacta empacta study publish submit publication p eerreviewe journal upload datum sharing platform follow initial interaction health authority pharmaceutical division continue monitor evolve clinical evidence actemraroactemra setting include combination antiviral remdesivir ongoing phase iii remdacta study addition trial independently lead clinical trial multiple medicine include actemraroactemra take place world remapcap recovery trial uk time write actemraroactemra approve clinical treatment covid pneumonia sale actemraroactemra chf billion increase compare increase partnership collaboration august group announce partner regeneron pharmaceuticals inc regeneron develop manufacture distribute casirivimab imdevimab investigational neutralise antibody combination addition investigate nonhospitalise patient casirivimab imdevimab currently study phase iiiii clinical trial treatment covid hospitalise patient phase iii openlabel recovery trial hospitalise patient uk phase iii trial prevention covid household contact infect individual term agreement regeneron distribute casirivimab imdevimab roche group responsible distribution outside november regeneron announce antibody combination receive emergency use authorization roche group financial review finance report october group announce partner atea pharmaceuticals inc atea develop manufacture distribute investigational novel oral antiviral phase ii study treatment hospitalise patient moderate covid ongoing phase ii outpatient setting start january addition develop postexposure prophylactic setting december group announce partnership moderna inc moderna utilise elecsys antisarscov antibody test modernas mrna vaccine research trial facilitate quantitative measurement sarscov antibodie help establish correlation vaccineinduce protection level antireceptor bind domain rbd antibodie impact roche group business result revenue covid pandemic impact group revenue absolute amount phase follow factor affect sale portfolio pharmaceutical diagnostic business impact varied product geography restriction local travel public gathering discourage patient visit physician health practice hospital especially affect elderly patient hospital health practice experience certain level disruption lead delay cancellation patient visit especially noncritical procedure certain level forward purchase quarter doctor write prescription long period minimise patient visit pharmacy patient distributor stock anticipation restriction potential supply chain disruption factor manifest high level sale prior restriction impose follow low level sale second quarter slow recovery beginning end second quarter restriction progressively ease certain country recovery continue quarter year reimposition restriction country fourth quarter negative effect recovery quarterly development sale compare yearonyear growth cer q q q q year pharmaceutical division diagnostic division roche group pharmaceutical division overall impact covid negative restriction lead reduce hospitalisation outpatient visit impact routine diagnostic testing lead low level prescription medicine partly compensate additional sale actemraroactemra negative impact strong medicine regular visit health practice hospital need example infusion injection sale lucentis ocrevus oncology portfolio particularly affect oncology portfolio heavily impact biosimilar erosion ongoing rollout tecentriq hemlibra continue strongly uptake hemlibra impact extent pandemic diagnostic division pandemic negative impact sale portfolio compensate sale covidrelate test notably cobas sarscov pcr test sarscov rapid antigen test pandemic lead reduction overall diagnostic testing translate reduce instrument placement laboratory solution business reduce sale reagent consumable delivery covidrelated test lead certain buildup inventory december notably recently launch sarscov rapid antigen test sale covidrelated test chf billion cer manufacturing supply despite supply logistic challenge covid pandemic roche group able continue deliver medicine diagnostic possible patient broad range disease area exceptional condition date limited disruption group continually monitor situation certain level volatility purchasing pattern note significantly impact supply chainfinance report financial review roche group announcement new clinical trial potential increase demand actemraroactemra pharmaceutical division ramp manufacturing capacity increase globally available supply manufacture investment relation partnership regeneron total additional capital expenditure relate covidrelated project pharmaceutical division chf million roche group ensure coordinated global overview additional supply request provision medicine manage country level accord local rule regulation close collaboration authority diagnostic division ramp production capacity supply chain covidrelate testing product scaleup fast possible additional capital expenditure diagnostic division chf million roche group commit deliver test possible limit supply deliver test area immediately effective test ship production site location appropriate infrastructure place testing begin delay research development roche group plan drug launch filing pivotal phase iii trial readout pivotal trial start largely track group continuously monitor ongoing study term miss dose overall datum integrity group development team take significant effort protect study continue support health authority ultimate impact depend length severity pandemic pandemic prolong duration launch new clinical trial progress ongoing clinical trial delay restriction medical facility patient defer visit simply volunteer operating result major impact operating profit come abovementione factor revenue overall operating expense impact extent covid pandemic impact partly offset additional cost incur area infrastructure distribution cost spending travel congress particular decline marketing distribution cost drive general slowdown marketing activity include low travel cost reduce attendance congresse significant cost idle manufacturing capacity inventory writeoff attribute directly pandemic construction project incur minor cost delay restriction core result group change core result concept result covid pandemic specific covidrelated impact refer include ifrs core result note core result exclude noncore item global restructuring plan amortisation impairment goodwill intangible asset regardless cause liquidity financial position liquidity financial position roche group remain sound exceptional period liquidity group continue strong cash generation ability free cash flow chf billion decrease cer free cash flow compare partly investment inlicense alliance arrangement result cash outflow chf billion roche continues enjoy strong longterm investmentgrade credit rating aa standard poor aa moodys group commit credit line financial institution total usd billion available backstop line commercial paper program december debt draw credit line group renegotiate major contract liquidity reason group observe significant increase credit risk covid pandemic bad debt expense overdue receivable remain relatively low level financial position december describe previously significant bad debt writeoff inventory directly attribute covid factor intangible asset impairment charge chf billion incur result delay clinical trial partly cause covid spark therapeutic haemophilia programme impairment issue note goodwill intangible asset directly attribute pandemic impairment issue directly attribute pandemic note financial asset volatility global market correspond impact carry value investment hold fair value similarly certain volatility fair value pension asset discount rate half situation largely stabilise end year exceptional funding payment group pension plan currently foresee roche group financial review finance report group result continue merger acquisition spark therapeutic december group acquire control interest spark therapeutics inc spark therapeutic publicly own company base philadelphia pennsylvania list nasdaq stock market spark therapeutic fully integrate commercial company commit discover develop deliver gene therapy spark therapeutic report pharmaceutical division cash purchase consideration usd billion equivalent chf billion annual financial statement allocation purchase price record balance sheet provisional half identification valuation intangible asset asset liability complete accordingly provisional amount record balance sheet december restate set note annual financial statement result value intangible asset increase chf billion defer tax asset chf billion defer tax liability chf billion consequent decrease goodwill chf billion asset acquisition roche group acquire control interest promedior inc promedior inflazome ltd inflazome tmema ltd tmema lexent bio inc lexent bio pharmaceutical division stratos genomics inc stratos genomic diagnostic division total initial cash consideration chf billion additional contingent payment base achievement performancerelate milestone chf billion relate promedior asset acquisition group obtain right promedior entire portfolio include phase iiiready asset prm recombinant human pentraxin molecule treatment idiopathic pulmonary fibrosis ipf chf billion relate inflazome asset acquisition group obtain right inflazome entire portfolio compose clinical preclinical orally available small molecule nlrp inhibitor transaction qualify business combination ifrs account addition intangible asset cash flow business combination asset acquisition include settlement contingent consideration arrangement form free cash flow detail give note annual financial statement alliance transaction group complete licensing agreement sarepta therapeutics inc sarepta announce december group acquire exclusive right launch commercialise srp sarepta investigational microdystrophin gene therapy duchenne muscular dystrophy dmd outside initial payment result recognition chf billion intangible asset chf billion equity investment july group announce collaboration blueprint medicine corporation blueprint medicine codevelopment cocommercialisation right pralsetinib gavreto investigational precision therapy latestage development people retaltere nonsmall cell lung cancer nsclc type thyroid cancer solid tumour term agreement group initial payment chf billion chf billion recognise intangible asset chf billion equity investment party cocommercialise pralsetinib group responsible commercial activity outside gavreto approve treatment adult metastatic retfusionpositive nsclc september treatment people advance metastatic retmutant retfusionpositive thyroid cancer december august group enter licensing agreement regeneron pharmaceuticals inc regeneron party collaborate develop manufacturing regeneron investigational covid antibody combination casirivimab imdevimab latestage clinical trial treatment prevention sarscov infection term agreement company commit dedicate certain manufacturing capacity casirivimab imdevimab year regeneron distribute casirivimab imdevimab group responsible distribution outside initial payment november regeneron announce antibody combination casirivimab imdevimab receive emergency use authorization usfinance report financial review roche group october group enter licensing agreement atea pharmaceuticals inc atea party codevelop atea orally administer directacte small molecule antiviral covid patient initial payment chf billion recognise intangible asset approve atea distribute option request group support group responsible global manufacturing distribution outside significant transaction include upfront payment chf billion arrakis therapeutic strategic collaboration licensing agreement discovery rnatargete small molecule rsm drug broad set target pharmaceutical division research development area upfront payment chf billion vaccibody worldwide collaboration licensing agreement develop dnabase individualised neoantigen cancer vaccine base vbneo multiple tumour type addition upfront payment chf billion vividion therapeutic right vividion proteomic screen platform proprietary small molecule library target novel e ligase range oncology immunology therapeutic target upfront payment chf billion ucb right ucbs investigational monoclonal antibody drug develop potential treatment patient alzheimer disease total inlicense alliance transaction complete result intangible asset chf billion recognise chf billion total cash outflow chf billion include sarepta blueprint medicine equity investment payment chf billion relate dicerna pharmaceutical transaction treatment chronic hepatitis b virus infection total chf billion include pharmaceutical division operate free cash flow chf billion diagnostic division operate free cash flow chf billion sarepta blueprint medicine equity investment include free cash flow treasury activity transaction additional payment base achievement performancerelate milestone profitshare royalty arrangement global restructuring plan group continue implementation global restructuring plan initiate prior year global restructuring plan cost incur millions chf diagnostic site consolidation plan total global restructuring cost employeerelate cost site closure cost divestment product business reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental case total cost roche group financial review finance report diagnostic division strategy plan diagnostic division incur cost chf million mainly employeerelate cost site consolidation employeerelate cost mainly optimisation enable function drug product network site closure cost include impairment reversal chf million global restructuring plan major item include employeerelate cost chf million mainly outsource operational activity global share service centre external provider drive business transformation efficiency gain total global restructuring cost chf billion detail give note annual financial statement impairment goodwill intangible asset pharmaceutical division pharmaceutical division record impairment charge intangible asset chf billion major impairment charge chf billion come partial impairment intangible asset spk novel gene therapy treatment haemophilia acquire spark therapeutic acquisition impairment result delay clinical trial partly impact covid pandemic leading reduce sale expectation addition charge chf billion relate partial impairment product intangible asset luxturna market gene therapy treatment patient inherit retinal disease mutation copy rpe gene acquire spark therapeutic acquisition impairment result reduce sale expectation diagnostic division impairment charge chf billion relate goodwill avl medical instrument geneweave acquisition detailed note annual financial statement impairment intangible asset diagnostic division impairment charge chf billion pharmaceutical division diagnostic division record impairment charge chf billion major charge chf billion partial writeoff goodwill relate diabetes care business detail give note annual financial statement legal environmental case base development litigation notably accutane case provision previously hold release resulted income chf billion significant development affect financial result detail give note annual financial statement net income earning share ifrs net income increase chf term cer core eps increase cer decrease chf core basis exclude noncore item global restructuring cost amortisation impairment goodwill intangible asset merger acquisition alliance arrangement net income attributable noncontrolle interest increase ifrs basis core basis increase contribution chugai overall group resultsfinance report financial review roche group net income change change chf chf chf cer ifrs net income reconcile item net tax global restructuring plan intangible asset amortisation goodwill intangible asset impairment merger acquisition alliance transaction legal environmental case pension plan settlement transitional effect swiss tax reform normalisation equity compensation plan tax benefit core net income supplementary net income ep information give page include calculation core eps reconcile core result group publish ifrs result financial position financial position change change chf chf chf cer pharmaceutical net work capital longterm net operating asset diagnostic net work capital longterm net operating asset corporate net work capital longterm net operating asset net operating asset net debt lease liability pension income taxis nonoperate asset net total net asset provisional balance sheet amount restate final accounting spark therapeutic acquisition note annual financial statement compare start year swiss franc appreciate currency dollar strong effect additionally japanese yen brazilian real significant effect group net operating asset negative translation impact partly offset group level natural hedge group dollardenominate debt exchange rate give roche group financial review finance report net work capital increase significantly division pharmaceutical division inventory increase drive active management ensure product availability launch supply net liability position receivablespayable decrease settlement accrual record end diagnostic division inventory increase ongoing rollout covidrelate product notably recently launch sarscov rapid antigen test trade receivables increase sale growth overall longterm net operating asset increase inlicense alliance arrangement asset acquisition add chf billion pharmaceutical division chf billion diagnostic division intangible asset partly offset impairment goodwill intangible asset decrease net debt drive free cash flow chf billion offset annual dividend payment chf billion outflow transaction equity instrument chf billion net pension liability high follow decrease discount rate region net tax asset increase mainly taxis pay exceed income tax expense defer tax effect pension plan lease liability chf billion increase mainly additional office space rent flatiron health free cash flow free cash flow change change chf chf chf cer pharmaceutical diagnostic corporate operating free cash flow treasury activity taxis pay free cash flow page definition free cash flow detailed breakdown group operate free cash flow chf billion decrease cer increase net work capital high investment inlicense alliance arrangement pharmaceutical division low sale increase research development spend negative impact operate free cash flow partly offset low spending marketing distribution diagnostic division sale growth positive impact operate free cash flow free cash flow chf billion decrease cer lower operate free cash flow high financial longterm investment partly offset low interest pay low taxis paidfinance report financial review roche group pharmaceutical division operating result pharmaceutical division operating result change change chf chf chf cer ifrs result sale royalty operating income revenue cost sale marketing distribution research development general administration operate profit margin sale core result sale royalty operating income revenue cost sale marketing distribution research development general administration core operate profit margin sale financial position net work capital longterm net operating asset c net operating asset c free cash flow b operate free cash flow margin sale page definition core result b page definition free cash flow c provisional balance sheet amount restate final accounting spark therapeutic acquisition note annual financial statement roche group financial review finance report sale overview pharmaceutical division sale therapeutic area change sale sale chf chf cer oncology immunology neuroscience haemophilia ophthalmology infectious disease therapeutic area total sale biosimilar competition covid pandemic overall negative impact division sale general dampen sale covidrelated restriction begin second quarter hospitalisation outpatient visit decrease particularly impact sale ocrevus hemlibra lucentis mabtherarituxan new product sale continue partly compensate increase competition biosimilar notably mabtherarituxan herceptin avastin covid impact actemraroactemra sale increase drive adoption treatment guideline patient severe covid pneumonia sale growth new product drive continue rollout tecentriq hemlibra ocrevus perjeta kadcyla contribute additional chf billion cer new sale tecentriq sale grow chf billion high demand major eu market launch rollout hemlibra continue japan major eu markets sale reach chf billion increase ocrevus continue growth development sale increase chf billion sale uptake ocrevus hemlibra especially adversely affect covid pandemic perjeta sale china major driver growth kadcyla sale grow mainly high demand europe patient switch new standard care follow positive readout katherine study october biosimilar competition negative impact continue erosion herceptin mabtherarituxan avastin global sale product fall chf billion cer total sale chf billion decrease covid pandemic impact sale product notably china mabtherarituxan sales china affect follow price update inclusion national reimbursement drug list nrdl biosimilar version herceptin avastin mabtherarituxan enter market second half combine sale product chf billion cer low sale herceptin mabtherarituxan europe decline chf billion cer sale avastin europe decline chf billion cer second half biosimilar version avastin enter market sale oncology therapeutic area decrease biosimilar competition herceptin avastin mabtherarituxan describe partially compensate growth tecentriq perjeta tecentriq sale grow region high demand major eu market rollout japan perjeta sale increase growth china kadcyla alecensa show continue postlaunch growth region sale immunology grow actemraroactemra xolair increase respectively increase actemraroactemra sale mainly drive adoption medicine country guideline treat patient severe covid pneumonia mabtherarituxan sale immunology decrease drive impact covid pandemic biosimilar entry lucentis sale decline affect covid restriction disrupt ophthalmology practice limit patient access infectious disease sale lower low sale tamiflu rocephinfinance report financial review roche group product sale pharmaceutical division sale change sale sale chf chf cer oncology avastin perjeta herceptin mabtherarituxan tecentriq kadcyla alecensa gazyvagazyvaro xeloda polivy tarceva total oncology immunology actemraroactemra xolair esbriet mabtherarituxan pulmozyme cellcept total immunology neuroscience ocrevus madopar total neuroscience haemophilia hemlibra total haemophilia ophthalmology lucentis total ophthalmology infectious disease tamiflu rocephin total infectious disease therapeutic area activasetnkase mircera neorecormonepogin total therapeutic area total sale total mabtherarituxan sale chf million chf million split oncology immunology therapeutic area roche group financial review finance report avastin advance colorectal breast lung kidney cervical ovarian cancer relapse glioblastoma liver cancer combination tecentriq avastin regional sale change sale sale chf chf cer united states europe japan international total sale sale decrease launch biosimilar europe sale decrease biosimilar competition second half year competitive pressure notably germany france italy japan sale decrease government price cut biosimilar competition international region main driver sale decline canada ocrevus relapse form multiple sclerosis rm primary progressive multiple sclerosis ppm ocrevus regional sale change sale sale chf chf cer united states europe international total sale continuously grow demand indication growth drive new return patient high proportion sale come return patient europe international region ocrevus continue strong uptake launch notably france germany canada spain sale ocrevus impact covid treatment administer intravenous infusion require hospital visit case cancel delay pandemic restriction mabtherarituxan nonhodgkin lymphoma nhl chronic lymphocytic leukaemia cll follicular lymphoma fl pemphigus vulgaris pv rheumatoid arthritis ra certain type antineutrophil cytoplasmic antibody ancaassociate vasculitis mabtherarituxan regional sale change sale sale chf chf cer united states europe japan international total sale sale low biosimilar erosion market contraction covid pandemic restriction sale decrease decline oncology immunology segment drive covid sale international region low decline china follow price update inclusion national reimbursement drug list nrdl decline brazil japan sale decrease biosimilar competitionfinance report financial review roche group franchise herceptin perjeta kadcyla phesgo herpositive breast cancer herpositive metastatic advanced gastric cancer herceptin herceptin regional sale change sale sale chf chf cer united states europe japan international total sale perjeta regional sale change sale sale chf chf cer united states europe japan international total sale kadcyla regional sale change sale sale chf chf cer united states europe japan international total sale phesgo regional sale change sale sale chf chf cer united states total sale sale franchise decrease chf billion herceptin sale lower drive biosimilar launch start second half mid japan europe sale perjeta grow increase drive china early breast cancer metastatic breast cancer setting sale perjeta grow growth early breast cancer set partly offset covid restriction kadcyla sale increase notably early breast cancer set kadcyla sale benefit positive readout katherine study patient switch new standard care roche group financial review finance report actemraroactemra rheumatoid arthritis ra systemic juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis giant cell arteritis actemraroactemra regional sale change sale sale chf chf cer united states europe japan international total sale sale increase growth drive adoption actemraroactemra country treatment guideline treat patient severe covid pneumonia major contributor sale increase russia india spain clinical study covacta empacta evaluate safety efficacy actemraroactemra patient severe covid pneumonia carry result available healthcare authority tecentriq advanced bladder cancer advanced lung cancer initial therapy nonsquamous nonsmall cell lung cancer nsclc extensivestage small cell lung cancer pdlpositive triplenegative breast cancer unresectable metastatic hepatocellular carcinoma tecentriq regional sale change sale sale chf chf cer united states europe japan international total sale sale grow growth region notably high sale drive new indication extensivestage small cell lung cancer pdlpositive triplenegative breast cancer unresectable metastatic hepatocellular carcinoma europe sale grew mainly drive germany hemlibra haemophilia hemlibra regional sale change sale sale chf chf cer united states europe japan international total sale global rollout hemlibra continue sale continue strong uptake especially europe strong demand noninhibitor segment covid restriction cause slowdown growth miss patient visit affect potential new patient existing patient remain treatmentfinance report financial review roche group xolair moderate severe persistent allergic asthma aa chronic idiopathic urticaria ciu xolair regional sale change sale sale chf chf cer united states total sale sale increase drive indication xolair remain market leader large allergic asthma indication lucentis wet agerelate macular degeneration wamd macular oedema follow retinal vein occlusion rvo diabetic macular oedema dme diabetic retinopathy dr lucentis regional sale change sale sale chf chf cer united states total sale sale decrease approve indication covid pandemic cause disruption hospital ophthalmology practice patient delay treatment restriction activasetnkase acute ischaemic stroke ais acute myocardial infarction ami activasetnkase regional sale change sale sale chf chf cer united states international total sale sale higher increase demand tnkase covid pandemic injection administration method easy use alecensa alkpositive nonsmall cell lung cancer nsclc alecensa regional sale change sale sale chf chf cer united states europe japan international total sale global uptake continue increase sale region international main growth driver china sale benefit nrdl list roche group financial review finance report esbriet idiopathic pulmonary fibrosis ipf esbriet regional sale change sale sale chf chf cer united states europe international total sale sale grew drive increase use indication ipf pharmaceutical division sale region change sale sale chf chf cer united states europe japan international total sale united states sale decrease drive combined fall herceptin avastin mabtherarituxan sale launch biosimilar market contraction covid particularly mabtherarituxan hemlibra continue strong uptake launch november actemraroactemra sale increase use hospitalise patient severe covid pneumonia tecentriq sale increase growth new indication ocrevus sale increase drive new return patient demand partly dampen covid effect sale franchise decrease drive low herceptin sale partially offset sale increase kadcyla notably early breast cancer set lucentis sale decrease covid impact europe sale grow new product sale compensate biosimilar competition herceptin mabtherarituxan avastin impact covid pandemic tecentriq sale continue grow increase follow successful launch notably germany continue uptake europe hemlibra ocrevus show strong uptake particular france germany japan sale decrease drive low sale avastin herceptin mabtherarituxan negatively affect biosimilar competition government price cut decline partially compensate recently launch product include tecentriq hemlibra perjeta grow launch additional indication early breast cancer international sale increase drive china russia strong uptake china perjeta alecensa partially offset nrdl price update covid impact sale increase china base effect reduction level channel inventory sale rest international region increase growth new product perjeta ocrevus tecentriq hemlibra kadcyla alecensa actemraroactemra offset decline herceptin mabtherarituxan sale russia grow inclusion tecentriq kadcyla perjeta herceptin national oncology program adoption actemraroactemra countrys covid treatment guideline launch hemlibra ocrevusfinance report financial review roche group pharmaceutical division sale e lead emerge market change sale sale chf chf cer brazil china india mexico russia south korea turkey total sale competition generic medicine biosimilar group pharmaceutical product generally protect patent right intend provide group exclusive marketing right country patent right vary scope duration group required enter costly litigation enforce patent intellectual property right loss market exclusivity major product patent expiration challenge generic medicine biosimilar non comparable biologic reason material adverse effect group business result operation financial condition introduction generic biosimilar noncomparable biologic version similar medicine typically result significant reduction net sale relevant product manufacturer typically offer version low price patent expiry integral group business model future growth remain driven innovation late information clinical study include annual report detail group product development portfolio available download httpwwwrochecomresearchanddevelopmentwhowearehowweworkpipelinehtm intellectual property biologic involve multiple patent patent timeline individual product difficult exact date patent expiry biologic medicine group basic primary patent mabtherarituxan herceptin avastin expire eu secondary patent right subcutaneous formulation mabtherarituxan herceptin expire addition recent approach patent expiry lucentis impact sale product biosimilar competition mabtherarituxan herceptin avastin europe japan estimate negative impact chf billion cer main impact sale fall chf billion cer covid pandemic negative impact overall market notably mabtherarituxan united states biosimilar version herceptin avastin launch mid biosimilar version mabtherarituxan late sale product chf billion low cer prior period decline sale product affect covid pandemic certain impact overall market particularly mabtherarituxan europe biosimilar version mabtherarituxan herceptin launch europe mid mid respectively market eu country major factor continue sale decline chf billion cer product europe biosimilar version avastin come market europe mid significant factor decline sale chf billion cer avastin europe second half japan japan biosimilar version mabtherarituxan herceptin launch sale impact government price cut biosimilar version avastin launch late colorectal cancer indication nonsmall cell lung cancer indication sale product combine lower impact competition government price cut roche group financial review finance report product sale affect biosimilar launch change chf chf cer comment mabtherarituxan biosimilar launch late herceptin biosimilar launch mid avastin biosimilar launch mid mabtherarituxan europe biosimilar launch mid herceptin europe biosimilar launch mid avastin europe biosimilar launch mid mabtherarituxan japan biosimilar launch early herceptin japan biosimilar launch mid avastin japan biosimilar launch late colorectal nonsmall cell lung cancer indication sale mabtherarituxan herceptin avastin disclose previous section include regional breakdown summarise table note previous section yearonyear movement drive regular price volume change impact covid pandemic biosimilar competition factor overall picture total mabtherarituxan herceptin avastin sale change division sale division sale chf chf cer united states europe japan international total sale operating result pharmaceutical division royalty operating income change chf chf cer royalty income income outlicense agreement income disposal product total ifrs core basis royalty operating income decrease cer royalty income increase settlement gain chf million compensate low income expire cabilly patent royalty income venclexta venclyxto sale outside increase royalty income lucentis sale outside lower decrease utlicense income lower milestone income income product disposal decrease income chf million sale right lexotan bactrim dormicum partially compensate income chf million sale global right rocaltrol exclude china japan valium high profitshare income increase sale venclextavenclyxto usfinance report financial review roche group pharmaceutical division cost sale change chf chf cer manufacturing cost good sell period cost royalty expense collaboration profitshare agreement impairment property plant equipment cost sale core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core cost decrease cer percentage sale cost sale decrease percentage point manufacturing cost sale decrease sale decline inventory writeoff product mix factor productivity improvement royalty expense low decrease royalty expense relate expire cabilly patent partially offset increase sale certain royaltybearing product notably ocrevus collaboration profitsharing expense decrease drive low sale mabtherarituxan impairment property plant equipment idle plant recognise restructuring cost mainly relate resource flexibility initiative amortisation charge go rozlytrek product intangible asset start amortise product launch second half luxturna product intangible asset spark therapeutic acquisition impairment charge relate luxturna reduce sale expectation pharmaceutical division marketing distribution change chf chf cer marketing distribution core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core cost decrease cer percentage sale decrease comparative period major marketing distribution activity include support rollout tecentriq ocrevus perjeta support launch activity cost decrease mainly general slowdown marketing activity include low expense congress covid restriction cost decrease associate low personnel expense include low headcount cost field force restructuring cost relate transformation initiative pharmaceutical division research development change chf chf cer research development core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core cost increase cer percentage sale increase percentage point oncology franchise remain primary area research development cancer immunotherapy portfolio key driver neuroscience immunology represent significant area spend growth spend drive latestage investment ophthalmology personalise healthcare neuroscience spend spark therapeutic flatiron health amortisation charge higher notably exercise priority review voucher impairment charge mainly result delay clinical trial spark therapeutic haemophilia intangible asset roche group financial review finance report addition pharmaceutical division acquire product intangible development technology inlicense transaction asset acquisition total add chf billion intangible asset major item payment chf billion sarepta exclusive right launch commercialise srp sarepta investigational microdystrophin gene therapy duchenne muscular dystrophy dmd outside chf billion blueprint medicine license collaboration agreement group obtain codevelopment cocommercialisation right pralsetinib gavreto blueprint medicine investigational precision therapy latestage development people retaltere nonsmall cell lung cancer nsclc type thyroid cancer solid tumour investment include payment chf billion atea chf billion inflazome asset acquisition chf billion promedior asset acquisition section merger acquisition alliance transaction detail pharmaceuticals division general administration change chf chf cer administration pension past service cost gain loss disposal property plant equipment rightofuse asset business taxis capital taxis general item general administration core basis global restructuring plan merger acquisition alliance transaction legal environmental case pension plan settlement total ifrs basis core cost increase cer percentage sale increase administration cost high mainly recently acquire spark therapeutic flatiron health foundation medicine business taxis capital taxis increase primarily relatively low cost brand prescription drug fee general item increase low personnel cost restructure cost relate business transformation initiative income legal environmental case relate release accutane litigation provision roche pharmaceutical chugai subdivisional operating result pharmaceutical subdivisional operating result million chf roche pharmaceutical chugai pharmaceutical division sale external customer division core operate profit margin sale external customer operate profit margin sale external customer operate free cash flow margin sale external customer pharmaceutical division total core operating profit operating profit include elimination chf minus million unrealised intercompany gain roche pharmaceutical chugai chf minus million cer report japanese yen sale chugai external customer decrease sale division increase chugai core operating profit increase high royalty income roche pharmaceutical high gross profit sale division partially offset high research development cost operate free cash flow chugai increase cer mainly result strong operating performance partially offset increase net work capital appreciation swiss franc japanese yen adverse impact approximately percentage point chugai core operating profit group consolidated result express swiss francsfinance report financial review roche group financial position pharmaceutical division net operating asset movement movement change change transaction cta chf chf chf cer chf chf trade receivables inventory trade payable net trade work capital receivables payable net work capital property plant equipment rightofuse asset goodwill intangible asset provision longterm asset net longterm net operating asset net operating asset provisional balance sheet amount restate final accounting spark therapeutic acquisition note annual financial statement absolute movement consolidated balance report swiss franc split actual transaction translate average rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give annual financial statement reconciliation balance sheet information give currency translation effect balance sheet amount compare start year swiss franc appreciate currency dollar strong effect additionally japanese yen brazilian real significant effect net operating asset pharmaceutical division result net negative translation impact exchange rate give net work capital net working capital increase net trade work capital high inventory higher drive active management ensure product availability launch supply trade receivables increase compare start year increase temporarily extend payment term note interim result june settle second half net liability position receivables payable decrease follow settlement accrual record end longterm net operating asset overall longterm net operating asset increase increase intangible asset low provision intangible asset addition inlicense transaction asset acquisition pharmaceutical division chf billion include chf billion pay sarepta exclusive right launch commercialise sarepta investigational microdystrophin gene therapy duchenne muscular dystrophy dmd outside furthermore roche pay chf billion blueprint medicine codevelopment cocommercialisation right pralsetinib gavreto investigational precision therapy latestage development people retaltere nonsmall cell lung cancer nsclc type thyroid cancer solid tumour additional intangible asset purchase asset acquisition inflazome promedior upfront payment atea arrakis therapeutic vaccibody vividion therapeutic ucb section alliance transaction capital expenditure include manufacture investment japan switzerland germany site development switzerland chugais research facilities yokohama japan total additional capital expenditure covidrelate project pharmaceutical division chf million provision decrease release accutane litigation provision cash settlement past royalty relate pdl inhibitor litigation roche group financial review finance report free cash flow pharmaceutical division operate free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment principal portion lease liability pay investment intangible asset operate free cash flow sale page definition free cash flow detailed breakdown pharmaceutical division operate free cash flow decrease cer chf billion cash generation business measure operating profit net operating cash adjustment low sale increase research development spend negative impact operate free cash flow partly offset low spending marketing distribution net working capital absorb additional chf billion cash largely drive high inventory settlement payable reason describe financial position section capital expenditure higher prior year response covid pandemic investment intangible asset significantly high include payment sarepta chf billion blueprint medicine chf billion new inlicense alliance transaction atea arrakis therapeutic vaccibody vividion therapeutic ucb payment dicerna pharmaceutical transaction section alliance transaction appreciation swiss franc significant negative impact free cash flow measure express chf termsfinance report financial review roche group diagnostic division operating result diagnostic division operating result change change chf chf chf cer ifrs result sale royalty operating income revenue cost sale marketing distribution research development general administration operate profit margin sale core result sale royalty operating income revenue cost sale marketing distribution research development general administration core operate profit margin sale financial position net work capital longterm net operating asset net operating asset free cash flow b operate free cash flow margin sale page definition core result b page definition free cash flow sale overview diagnostic division sale business area change sale sale chf chf cer centralise point care solution molecular diagnostic diabetes care tissue diagnostic total sale diagnostic division report overall sale growth cer chf billion covid pandemic contrasting impact different part business molecular diagnostic report sale growth launch cobas sarscov pcr test centralise point care solution sale decrease reduction routine testing volume partially offset launch covid testing product second half diabete care sale decline continue overall contraction blood glucose monitor market impact covid pandemic roche group financial review finance report sale covidrelated test chf billion cer offset decline routine testing drive diagnostic division annual growth sale covidrelate test molecular diagnostic chf billion cer consist mainly cobas sarscov pcr test launch march remain chf billion cer covidrelated test sale centralise point care solution sarscov rapid antigen test launch september centralise point care solution regional sale change sale sale chf chf cer europe middle east africa emea north america rest world total sale overall sale decrease combine effect healthcare centre deprioritise routine care allocate resource covid preparedness effort patient avoid healthcare centre fear exposure covid emea decline routine testing business compensate sale growth pointofcare covid testing product north america decline offset custombiotech business rest world sale lower notably china low immunodiagnostic reagent sale compensate pointofcare covid testing sale molecular diagnostic regional sale change sale sale chf chf cer europe middle east africa emea north america rest world total sale overall sale rise sale growth drive launch cobas sarscov pcr test march cobas sarscov influenza ab test september instrument sale increase instal base end unit highthroughput cobas systems diabetes care regional sale change sale sale chf chf cer europe middle east africa emea north america rest world total sale sale decrease line continue contract blood glucose monitoring market patient switch continuous glucose monitoring system covid pandemic impact decrease reflect mainly emea region decline notably germany italy uk tissue diagnostic regional sale change sale sale chf chf cer europe middle east africa emea north america rest world total sale sale increase growth advance stain instrument sale recovery manufacturing delay prior year north america increase sale companion diagnostic sale partially offset low testing volume covid pandemic north america regionally asiapacific grow high reagent salesfinance report financial review roche group diagnostic division sale region change sale sale chf chf cer europe middle east africa emea north america asiapacific latin america japan total sale molecular diagnostic global driver sale growth mainly north america emea offset reduction routine testing business rest portfolio furthermore sale emea positively impact centralised point care solution business sale sarscov rapid antigen test allow fast triage decision point care sale decrease asiapacific drive china decrease routine testing follow covid pandemic restriction diagnostic division continue reduce channel inventory china diagnostic division sale e lead emerge market change sale sale chf chf cer brazil china india mexico russia south korea turkey total sale operating result diagnostic division royalty operating income change chf chf cer royalty income income outlicense agreement income disposal product total ifrs core basis core royalty operating income decrease cer drive base effect settlement royalty dispute low royalty income follow low immunodiagnostic sale partner company roche group financial review finance report diagnostic division cost sale change chf chf cer manufacturing cost good sell period cost royalty expense impairment property plant equipment cost sale core basis global restructuring plan amortisation intangible asset impairment intangible asset total ifrs basis core cost increase cer high sale increase cost global supply chain additional product volume high shipping rate increase sale growth favourable product mix core costofsale ratio decrease percentage point global restructuring cost relate strategy plan impairment charge relate intangible asset molecular diagnostic sequence business diagnostic division marketing distribution change chf chf cer marketing distribution core basis global restructuring plan amortisation intangible asset total ifrs basis core cost remain stable cer low spending congress travel follow covid restriction cost containment measure offset high personnel expense inventory writeoff core basis marketing distribution cost percentage sale decrease compare global restructuring cost decrease significant project relate sale force prior year diagnostic division research development change chf chf cer research development core basis global restructuring plan amortisation intangible asset total ifrs basis core cost increase cer spend covid product development project cardiac disease centralised point care solution portfolio increase spend digital solution percentage sale research development core cost stable global restructuring cost decrease cost strategy plan previous yearfinance report financial review roche group diagnostic division general administration change chf chf cer administration pension past service cost gain loss disposal property plant equipment rightofuse asset gain loss disposal divestment subsidiary business taxis capital taxis general item general administration core basis global restructuring plan impairment goodwill intangible asset merger acquisition alliance transaction legal environmental case total ifrs basis core cost increase cer percentage sale core cost decrease administration cost high legal expense global restructuring plan cost relate mainly employee expense strategy plan impairment charge chf million goodwill impairment relate avl medical instrument geneweave acquisition merger acquisition alliance transaction include income reversal contingent consideration provision legal environmental cost include litigation cost meso case financial position diagnostic division net operating asset movement movement change change transaction cta chf chf chf cer chf chf trade receivables inventory trade payable net trade work capital receivables payable net work capital property plant equipment rightofuse asset goodwill intangible asset provision longterm asset net longterm net operating asset net operating asset absolute movement consolidated balance report swiss franc split actual transaction translate average rate currency translation adjustment cta arise consolidation transaction include noncash movement movement table amount show operate free cash flow include cash movement consolidated balance sheet give annual financial statement reconciliation balance sheet information give roche group financial review finance report currency translation effect balance sheet amount compare start year swiss franc appreciate currency dollar strong effect additionally brazilian real turkish lira significant effect net operating asset diagnostic division result negative translation impact exchange rate give net work capital net working capital increase high inventory trade receivable partially offset high net liability receivablespayable inventory increase ongoing rollout covidrelated product include recently launch sarscov rapid antigen test increase trade receivable sale growth increase net liability receivablespayable come high product accrual employeerelate accrual longterm net operating asset overall longterm net operating asset increase cer mainly attributable increase property plant equipment site investment germany switzerland include covidrelated manufacture expansion chf million intangible asset low goodwill impairment relate avl medical instrument geneweave acquisition partly offset intangible asset addition inlicense transaction asset acquisition diagnostic division chf billion mainly stratos genomic asset acquisition free cash flow diagnostic division operate free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provision equity compensation plan operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment principal portion lease liability pay investment intangible asset operate free cash flow sale definition free cash flow detailed breakdown page operate free cash flow diagnostic division chf billion increase compare cash generation business measure operating profit net operating cash adjustment increase chf million sale growth positive impact operate free cash flow net work capital increase absorb chf million cash attributable increase inventory receivables offset high payable accrual reason describe financial position section capital expenditure slightly high site investment decline investment intangible asset relate inlicense transaction appreciation swiss franc significant negative impact free cash flow measure express chf termsfinance report financial review roche group corporate operating result corporate operating result summary change chf chf cer administration business taxis capital taxis general item general administration cost core basis global restructuring plan legal environmental case total cost ifrs basis financial position net work capital longterm net operating asset net operating asset free cash flow b operate free cash flow page definition core result b page definition free cash flow detailed breakdown general administration cost increase cer core basis administration cost high increase buildup share service centre network provide service division total cost ifrs basis affect low level restructuring activity corporate function corporate operating free cash flow show high outflow high administration cost settlement payable roche group financial review finance report foreign exchange impact operating result group exposure movement foreign currency affect operating result express swiss franc summarise follow key figure comment growth report cer chf change cer change chf pharmaceutical division sale core operate profit diagnostic division sale core operating profit group sale core operating profit exchange rate swiss franc december average december average usd eur jpy result express swiss franc negatively impact appreciation swiss franc currency impact express swiss franc compare constant exchange rate percentage point sale percentage point core operating profit percentage point core ep sensitivity group sale core operating profit change average foreign currency exchange rate swiss franc show table currency sensitivity impact increase average exchange rate sale core operating profit versus swiss franc chf chf dollar euro japanese yen currency group revenue primarily generate sale product customer revenue mainly receive local currency customer home market certain emerge market invoicing major international currency dollar euro cost sale marketing administration cost follow currency pattern sale majority research development activity incur group global research facility cost mainly concentrate dollar swiss francs euros general administration cost tend incur mainly central location switzerland germany chugais revenues cost denominate japanese yenfinance report financial review roche group treasury taxation result treasury taxation result change change chf chf chf cer ifrs result operate profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core result operate profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest financial position net debt lease liability pension income taxis c equity investment derivative net collateral net interest payable nonoperate asset net total net asset liability c free cash flow b treasury activity taxis pay total page definition core result b page definition free cash flow c provisional balance sheet amount restate final accounting spark therapeutic acquisition note annual financial statement financing cost core financing cost chf million decrease cer compare interest expense debt decrease cer chf million mainly early repayment debt second half loss early debt redemption chf million net interest cost define benefit pension plan decrease cer low discount rate germany end analysis financing cost give note annual financial statement roche group financial review finance report financial income expense core financial income expense net expense chf million compare net income chf million income equity security predominantly reflect fair value change realise gain loss roche venture fund investment notably investment allakos report net gain chf million compare net gain chf million net interest income decrease cer chf million low liquid fund level available investment low interest rate compare net foreign exchange result reflect hedging cost loss unhedged position loss chf million compare net loss chf million analysis financial income expense give note annual financial statement income taxis group effective core tax rate increase percentage point mainly impact resolution tax dispute reduce group effective core tax rate percentage point percentage point ifrs result see effective tax rate increase percentage point addition core impact mention noncore impact swiss tax reform impairment goodwill tax deductible impact ifrs tax rate ifrs result include release contingent consideration provision taxable net effect merger acquisition alliance transaction line table detail group income tax expense relate balance sheet position give note annual financial statement analysis group effective tax rate profit income profit income tax taxis tax rate tax taxis tax rate chf chf chf chf group effective tax rate core basis global restructuring plan goodwill intangible asset merger acquisition alliance transaction legal environmental case pension plan settlement transitional effect swiss tax reform normalisation equity compensation plan tax benefit group effective tax rate ifrs basis financial position decrease net debt drive free cash flow chf billion offset annual dividend payment chf billion outflow transaction equity instrument chf billion net pension liability high decrease discount rate region net tax asset increase mainly taxis pay exceed income tax expense defer tax effect pension plan december group hold equity investment market value chf billion consist holding biotechnology pharmaceutical company acquire licensing transaction scientific collaboration investment roche venture fund free cash flow net cash outflow treasury activity remain stable chf billion low interest payment offset investment financial longterm asset notably chf billion equity sarepta total taxis pay decrease chf billion line low pretax profitsfinance report financial review roche group cash flow net debt operate free cash flow billion chf free cash flow billion chf free cash flow millions chf pharmaceutical diagnostic corporate group operate profit ifrs basis operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment principal portion lease liability pay investment intangible asset operate free cash flow treasury activity taxis pay free cash flow operating profit ifrs basis operate profit cash adjustment operate profit net operating cash adjustment increase decrease net working capital investment property plant equipment principal portion lease liability pay investment intangible asset operate free cash flow treasury activity taxis pay free cash flow definition free cash flow detailed breakdown page operate free cash flow decrease cer chf billion low chf term increase net work capital delivery covidrelate test lead certain buildup inventory december high investment inlicense alliance arrangement pharmaceutical division low sale increase research development spend negative impact operate free cash flow partly offset low spending marketing distribution diagnostic division sale growth positive impact operate free cash flow free cash flow chf billion low cer low chf result low operating free cash flow high financial longterm investment partly offset low interest pay low taxis pay appreciation swiss franc significant negative impact free cash flow measure express chf term roche group financial review finance report net debt millions chf january cash cash equivalent marketable security longterm debt shortterm debt net debt begin period change net debt free cash flow dividend payment transaction equity instrument merger acquisition net divestment subsidiary hedge collateral arrangement currency translation fair value movement change net debt december cash cash equivalent marketable security longterm debt shortterm debt net debt end period definition net debt net debt currency profile millions chf cash marketable security debt dollar euro swiss franc japanese yen pound sterling total dollardenominate debt include bond note denominate euro swap dollar consolidated result economic characteristic equivalent dollardenominate bond note net debt position group december chf billion decrease chf billion december drive free cash flow chf billion offset annual dividend payment chf billion outflow transaction equity instrument chf billion transaction equity instrument relate purchase connection group equity compensation plansfinance report financial review roche group contractual obligation commitment group obligation commitment set table carry value show consolidated balance sheet potential obligation show discount riskadjuste note amount denominate foreign currency translate swiss franc december exchange rate provision legal environmental matter include timing cash outflow uncertain contingent development matter question contractual obligation commitment december millions chf potential obligation undiscounte carry year year year year total value onbalance sheet debt bond note debt contingent consideration account payable noncurrent liability lease liability current liability lease liability unfunded define benefit plan total onbalance sheet commitment offbalance sheet capital commitment property plant equipment leasing commitment contract manufacturing commitment alliance collaboration commitment total offbalance sheet commitment total contractual commitment reference note annual financial statement debt consist mainly bond note include principal interest group debt instrument debt mainly commercial paper carry value discount base interest rate inherent instrument contingent consideration potential payment arise merger acquisition carry value riskadjuste discount lease liability future obligation noncancellable lease contract unfunde define benefit plan mainly pension plan group german affiliate fully reserve pension obligation selffinance local affiliate operation carry value discount future company contribution group fund plan show table capital commitment property plant equipment noncancellable commitment purchase construction mainly roche site basel switzerland south san francisco mannheim germany chugai research development site yokohama japan leasing commitment major noncancellable commitment sign lease agreement lease term started mainly relate foundation medicine site boston roche group financial review finance report contract manufacturing commitment future minimum takeorpay commitment purchase inventory arise group major longterm agreement external contract manufacturing organisation cmos alliance collaboration commitment potential upfront milestone payment group inlicense alliance arrangement intangible asset purchase agreement include asset acquisition potential payment alliance partner asset purchase agreement year include assume project currently development successful potential payment year include asset purchase agreement pension postemployment benefit postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution expense group define contribution plan chf million chf million plan classify define benefit plan group potential obligation minor relatively remote possibility arise plan usually establish trust independent group fund payment group employee case plan unfunded group pay pension retire employee directly financial resource expense group define benefit plan chf million chf million define benefit plan fund status balance sheet position chf chf fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation total funding status limit asset recognition reimbursement right net recognise asset liability overall funding status ifrs basis group fund define benefit plan increase compare start year came increase fair value plan asset partly offset higher define benefit obligation decrease discount rate region fund status pension fund monitor local pension fund governance body closely review group level total cash outflow group define benefit plan chf billion compare chf billion high additional contribution pay group pension plan japan unfunded plan mainly group german affiliate fully reserve pension obligation invest local affiliate operation unfunded liability plan increase decrease eurozone discount rate detail group pension postemployment benefit give note annual financial statementsfinance report financial review roche group roche share share price market capitalisation december change chf share price chf nonvoting equity security genussschein price chf market capitalisation billion chf roche rank number peer group consist roche healthcare company total shareholder return tsr define share price growth plus dividend measure swiss franc actual exchange rate constant exchange rate cer roche rank number yearend return roche share roche nonvoting equity security combine performance share nonvoting equity security compare weight average return peer group chf term cer year high volatility stock market equity market recover heavy loss quarter swiss market index smi stay stable outperform european index trail major indice global healthcare sector grow roche outperform peer chf term strong sale growth diagnostic launch new product peer group abbott abbvie amgen astellas astrazeneca bayer bristolmyers squibb glaxosmithkline johnson johnson lilly merck co novartis pfizer roche sanofi takeda total shareholder return development dec mar june sept dec roche share roche nonvoting equity security peer set index source refinitiv eikon datum roche peer index rebase january peer index convert swiss franc daily actual exchange rate currency fluctuation influence representation relative performance roche versus peer index roche group financial review finance report propose dividend board director propose increase dividend chf share nonvoting equity security chf approval annual general meeting th consecutive increase dividend dividend proposal approve shareholder dividend payment total share nonvoting equity security chf billion chf billion result payout ratio base core net income base price yearend dividend yield roche share yield nonvoting equity security information roche security give page information share nonvoting equity security change chf chf chf eps basic eps diluted core ep basic core ep diluted equity attributable roche shareholder share dividend share detail refer note annual financial statement payout ratio calculate dividend share divide core earning sharefinance report financial review roche group debt schedule debt repayment debt redemption new debt issue maturity schedule group bond note outstanding december show table bond note nominal amount december contractual maturity dollar euro pound sterling swiss franc total total usd eur gbp chf usd chf b total total translate december exchange rate b proceed bond note eur million swap dollar consolidated result bond note economic characteristic equivalent dollardenominate bond note group plan meet debt obligation exist liquid fund cash generate business operation year free cash flow chf billion include cash generate operation payment interest tax shortterm financing requirement group commercial paper program issue usd billion unsecured commercial paper note commit credit line usd billion available backstop line december commercial paper note total usd billion outstanding usd billion longerterm financing group maintain strong longterm investmentgrade credit rating aa standard poor aa moodys facilitate efficient access international capital market information group debt give note annual financial statement roche group financial review finance report financial risk december group net debt position chf billion chf billion financial asset group manage conservative way objective meet group financial obligation times asset allocation considerable portion cash marketable security group currently hold debt repayment liquid fund hold cash invest highquality investmentgrade fix income security investment horizon meet liquidity requirement cash marketable security chf total chf total cash cash equivalent money market instrument debt security equity security total cash marketable security credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group rating profile group chf billion cash fix income marketable security remain strong invest aaaa range group sign net collateral agreement counterpartie order mitigate counterparty risk derivative position group trade receivables chf billion begin financial difficulty southern european country notably spain italy greece portugal group lead supplier healthcare sector country december trade receivables eur billion chf billion public customer country decrease compare december euro term group use different measure improve collection country include intense communication customer factor negotiation payment plan charge interest late payment legal action group trade receivable balance southern europe decrease euro term liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time addition current liquidity position group strong cash generation ability future cash flow repay debt instrument come year roche enjoy strong longterm investmentgrade credit rating aa standard poor aa moodys time roche rate high available shortterm rating agency event financing requirement rating strong credit roche permit efficient access international capital market include commercial paper market group commit credit line financial institution total usd billion available backstop line commercial paper program december debt draw credit line market risk market risk arise change market price group financial asset financial liability exposure predominantly relate change interest rate foreign exchange rate equity price group use valueatrisk var assess impact market risk financial instrument var data indicate value range give financial instrument fluctuate preset probability result movement market price group var decrease december reflect reduction interest rate interest rate risk interest rate risk arise movement interest rate affect group financial result value group equity group use interest rate derivative manage interest raterelate exposure financial result information financial risk management financial risk var methodology include note annual financial statementsfinance report financial review roche group international financial reporting standard roche group international financial reporting standard ifrs report consolidated result new revise standard apply group implement minor amendment exist standard interpretation material impact group overall result financial position amendment ifrs business combination definition business mandatorily applicable early adopt group roche group roche group consolidated financial statement finance report roche group consolidate financial statement roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income revenue cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf finance report roche group consolidate financial statement roche group roche group consolidated income statement year end december millions chf pharmaceutical diagnostic corporate group sale royalty operating income revenue cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest earning share nonvoting equity security basic chf diluted chf roche group roche group consolidated financial statement finance report roche group consolidated statement comprehensive income million chf year end december net income recognise income statement comprehensive income oci remeasurement define benefit plan fair value change equity investment fair value oci item reclassify income statement fair value change debt security fair value oci cash flow hedge currency translation foreign operation item reclassified income statement comprehensive income net tax total comprehensive income attributable roche shareholder noncontrolle interest total finance report roche group consolidate financial statement roche group roche group consolidate balance sheet million chf december december december noncurrent asset property plant equipment rightofuse asset goodwill intangible asset defer tax asset define benefit plan asset noncurrent asset total noncurrent asset current asset inventory account receivable current income tax asset current asset marketable security cash cash equivalent total current asset total asset noncurrent liability longterm debt defer tax liability define benefit plan liability provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable current liability total current liability total liability total net asset equity capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity disclose note balance sheet december restate follow finalisation valuation net asset acquire related spark therapeutic acquisition reconciliation previously publish balance sheet provide note disclose note group change accounting policy lease follow implementation ifrs lease effective january group apply cumulative catchup method transition mean comparative balance sheet december restate roche group roche group consolidated financial statement finance report roche group consolidate statement cash flow million chf year end december cash flow operating activity cash generate operation increase decrease net work capital payment define benefit plan utilisation provision disposal product income taxis pay total cash flow operating activity cash flow invest activity purchase property plant equipment purchase intangible asset disposal property plant equipment disposal intangible asset business combination asset acquisition divestment subsidiary interest dividend receive sale equity security debt security purchase equity security debt security sale purchase money market instrument time account month net invest cash flow total cash flow invest activity cash flow financing activity proceed issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt hedge collateral arrangement change ownership interest subsidiary equity contribution noncontrolle interest interest pay principal portion lease liability pay dividend pay equitysettle equity compensation plan net transaction equity financing cash flow total cash flow financing activity net effect currency translation cash cash equivalent increase decrease cash cash equivalent cash cash equivalent january cash cash equivalent december finance report roche group consolidate financial statement roche group roche group consolidate statement change equity millions chf non share retain fair value hedge translation control total capital earning reserve reserve reserve total interest equity year end december january implementation ifrs lease january revise net income recognise income statement net change fair value financial asset fair value oci cash flow hedge currency translation foreign operation remeasurement define benefit plan total comprehensive income dividend equity compensation plan net transaction equity change ownership interest subsidiary change noncontrolle interest equity contribution noncontrolle interest december year end december january net income recognise income statement net change fair value financial asset fair value oci cash flow hedge currency translation foreign operation remeasurement define benefit plan total comprehensive income dividend equity compensation plan net transaction equity change ownership interest subsidiary change noncontrolle interest equity contribution noncontrolle interest december disclose note group change accounting policy lease follow implementation ifrs lease effective january detail additional asset liability report effective january provide note roche group note roche group consolidated financial statement finance report note roche group consolidate financial statement general accounting principle basis preparation consolidate financial statement annual financial statement roche group prepare accordance international financial reporting standard ifrs comply swiss law prepare historical cost convention item require account fair value approve issue board director february subject approval annual general meeting shareholder march financial statement annual financial statement roche holding ltd company register switzerland subsidiary group group significant accounting policy change accounting policy disclose note key accounting judgement estimate assumption preparation annual financial statement require management judgement estimate assumption affect report amount revenue expense asset liability contingent amount actual outcome differ management estimate estimate underlying assumption review ongoing basis base historical experience factor revision estimate recognise period estimate revise follow consider key accounting judgement estimate assumption believe appropriate base currently available information revenue nature group business sale transaction simple structure consist performance obligation satisfy different time contract enter diagnostic division typically include performance obligation instrument include provide leasing arrangement reagent consumable service instrument sell cash sale transaction discount price instrument provide operating lease arrangement entire lease revenue variable subject subsequent reagent sale sale net discount base estimate relate obligation include standalone selling price require judgement determine different obligation satisfied include enforceable purchase commitment obligation exist arise outlicense agreement entered obligation include commitment conduct research latestage development regulatory approval comarketing manufacturing settle combination upfront payment milestone payment license fee reimbursement service provide consider commitment single performance obligation separate one scope ifrs revenue contract customer straightforward require judgement depend conclusion result revenue calculate inception recognise spread term long performance obligation sale record net allowance estimate rebate chargeback cash discount estimate product return establish time sale product sale allowance base estimate amount earn claim relate sale december group chf million provision accrual expect sale return chargeback rebate include medicaid similar rebate country provision accrual relate pharmaceutical business amount chf million chf million associate expect sale return estimate consideration historical experience current contractual statutory requirement specific know market event trend competitive pricing new product introduction estimate inventory level shelf life product actual future result vary estimate need adjust effect sale earning period adjustmentfinance report note roche group consolidate financial statement roche group business combination group initially recognise fair value identifiable asset acquire liability assume noncontrolle interest consideration transfer business combination management judgement particularly involve assessment net asset acquire constitute business recognition fair value measurement intellectual property inventory contingent liability contingent consideration make assessment management consider underlie economic substance item concern addition contractual term management apply consider appropriate optional concentration test set ifrs business combination aid assessment transaction represent business combination simply substance purchase single asset group similar asset impairment property plant equipment rightofuse asset goodwill intangible asset december group chf million property plant equipment note chf million rightofuse asset note chf million goodwill note chf million intangible asset note goodwill intangible asset available use review annually impairment property plant equipment rightofuse asset intangible asset use assess impairment trigger event provide evidence asset impair assess impairment exist estimate expect future cash flow actual outcome vary significantly estimate factor change discount rate plan use building machinery equipment closure facility presence competition technical obsolescence lowerthananticipate product sale lead short useful life impairment impairment financial asset december group chf million allowance doubtful account trade lease receivable note allowance doubtful account base assumption risk default expect loss rate group use judgement make assumption select input calculation allowance doubtful account base company past experience exist market condition forwardlooke estimate end reporting period pension postemployment benefit group operate number define benefit plan fair value recognise plan asset liability base statistical actuarial calculation measurement net define benefit obligation particularly sensitive change discount rate inflation rate expect mortality medical cost trend rate assumption december present value group define benefit obligation chf million note actuarial assumption differ materially actual result change market economic condition long short lifespan participant change factor assess difference impact define benefit plan asset liability recognise balance sheet future period legal provision group provide anticipated legal settlement cost probable outflow resource reliably estimate reliable estimate provision record contingent liability disclose material december group chf million legal provision status significant legal case disclose note estimate consider specific circumstance legal case relevant legal advice inherently judgemental highly complex nature legal case estimate change substantially time new fact emerge legal case progress environmental provision group provide anticipate environmental remediation cost probable outflow resource reasonably estimate december group chf million environmental provision note environmental provision consist primarily cost fully clean refurbish contaminate site include landfill treat contain contamination certain site estimate inherently judgemental uncertainty relate detection previously unknown contamination method extent remediation percentage problematic material attributable group remediation site financial capability potentially responsible party estimate change substantially time new fact emerge environmental remediation progress contingent consideration provision group make provision estimate fair value contingent consideration arrangement arise business combination december group chf million contingent consideration provision note total potential payment contingent consideration arrangement business combination chf million note estimate amount provide expect payment determine consider possible scenario forecast sale performance criterion pay scenario probability scenario discount net present value estimate change substantially time new fact emerge scenario develop roche group note roche group consolidated financial statement finance report income taxis december group current income tax net liability chf million defer tax net asset chf million note significant estimate require determine current defer tax asset liability estimate base interpretation exist tax law regulation tax position uncertain accrual record income tax liability management well estimate ultimate liability expect arise base specific circumstance group historical experience factor impact current defer taxis include change tax law regulation rate change interpretation exist tax law regulation future level research development spending change pretax earning lease group lessee key judgement include assess arrangement contain lease determine lease term assess contract contain lease require judgement depend specify asset group obtain substantially economic benefit use asset group right direct use asset order determine lease term judgement require extension termination option assess fact circumstance create economic incentive exercise extension option exercise termination option estimate include calculate discount rate base incremental borrowing rate december group chf million rightofuse asset chf million lease liability note group lessor treatment leasing transaction mainly determine lease consider operating finance lease making assessment management look substance lease legal form make judgement substantially risk reward ownership transfer arrangement legal form lease convey right use asset cover assessment consolidation group periodically undertake transaction involve obtain control significant influence company transaction include equity acquisition asset purchase alliance agreement case management make assessment group control significant influence company consolidated subsidiary account associate company make assessment management consider underlie economic substance transaction addition contractual term impact covid pandemic group assess certain accounting matter generally require consideration forecast financial information take account potential future impact covid pandemic accounting matter assess include limited group provision product return allowance doubtful account trade lease receivables inventory allowance carry value goodwill intangible asset property plant equipment define benefit pension plan asset liability continue negative impact pandemic impact matter bad debt expense overdue receivable remain relatively low level significant cost idle manufacturing capacity inventory writeoff directly attribute covid factor minor additional covidrelated cost incur construction project intangible asset impairment charge chf million incur result delay clinical trial partly cause covid spark therapeutic haemophilia programme note impairment issue note goodwill intangible asset directly attribute pandemic impairment issue directly attribute pandemic note financial asset volatility global market correspond impact carry value equity investment hold fair value similarly certain volatility fair value pension asset discount rate half situation largely stabilise end year exceptional funding payment group pension plan currently foresee significant impact area assess group annual financial statement group continue monitor area increase judgement risk material changesfinance report note roche group consolidate financial statement roche group operating segment information group division pharmaceutical diagnostic revenue primarily generate sale prescription pharmaceutical product diagnostic instrument reagent consumable respectively division derive revenue sale licensing product technology party residual operating activity divest business certain global activity report corporate include corporate executive committee global group function communication human resource finance include treasury taxis legal safety environmental service subdivisional information present roche pharmaceutical chugai operate segment pharmaceutical division divisional information millions chf pharmaceutical diagnostic corporate group revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination interdivisional revenue total segment result operate profit capital expenditure business combination asset acquisition addition property plant equipment addition rightofuse asset addition intangible asset total research development research development cost segment information depreciation property plant equipment depreciation rightofuse asset amortisation intangible asset impairment reversal property plant equipment impairment reversal rightofuse asset impairment goodwill impairment intangible asset equity compensation plan expense roche group note roche group consolidated financial statement finance report pharmaceutical subdivisional information millions chf roche pharmaceutical chugai pharmaceutical division revenue external customer sale royalty operating income total revenue operate segment sale royalty operate income elimination income division total segment result operate profit elimination result division operate profit capital expenditure business combination asset acquisition addition property plant equipment addition rightofuse asset addition intangible asset total research development research development cost elimination cost division total segment information depreciation property plant equipment depreciation rightofuse asset amortisation intangible asset impairment reversal property plant equipment impairment reversal rightofuse asset impairment goodwill impairment intangible asset equity compensation plan expense finance report note roche group consolidate financial statement roche group net asset millions chf asset liability net asset december net operating asset pharmaceutical diagnostic corporate total current income tax net asset liability defer tax net asset liability define benefit plan net asset liability lease liability marketable security cash cash equivalent debt net asset liability total net asset disclose note net operating asset pharmaceutical division defer tax net asset liability group december restate follow finalisation valuation net asset acquire related spark therapeutic acquisition reconciliation previously publish balance sheet provide note net operating asset pharmaceutical subdivisional information million chf asset liability net asset december roche pharmaceutical chugai elimination division pharmaceutical division disclose note net operating asset roche pharmaceutical december restate follow finalisation valuation net asset acquire related spark therapeutic acquisition reconciliation previously publish balance sheet provide note roche group note roche group consolidated financial statement finance report information geographical area millions chf revenue external customer noncurrent asset royaltie property plant goodwill sale operate income equipment rightofuse asset ntangible asset switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total sale allocate geographical area destination accord location customer royalty operating income allocate accord location group company receive revenuefinance report note roche group consolidate financial statement roche group disclose note group change accounting policy lease follow implementation ifrs lease effective january group apply cumulative catchup method transition mean comparative balance sheet december restate detail additional segment net operating asset report total chf million give transition impact ifrs segment net operating asset millions chf january assets liabilitie net asset roche pharmaceutical chugai pharmaceutical division diagnostic division corporate total operating lease liability group major customer total national wholesale distributor represent approximately group revenue national wholesale distributor mckesson corp chf billion chf billion amerisourcebergen corp chf billion chf billion cardinal health inc chf billion chf billion approximately revenue roche pharmaceutical operating segment residual diagnostic operating segment roche group note roche group consolidated financial statement finance report revenue disaggregate revenue information disaggregation revenue millions chf revenue revenue contract revenue contract revenue customer source total customer source total pharmaceutical division sale therapeutic area oncology immunology neuroscience haemophilia ophthalmology infectious disease therapeutic area sale royalty income income outlicense agreement income disposal product royalty operate income diagnostic division sale business area centralise point care solution molecular diagnostic diabete care tissue diagnostic sale royalty income income outlicense agreement income disposal product royalty operating income total revenue source primarily relate lease revenue collaboration income counterparty consider customer income profitshare arrangementsfinance report note roche group consolidate financial statement roche group grosstonet sale reconciliation pharmaceutical division grosstonet sale reconciliation pharmaceutical division show table company diagnostic division similar reconciling item low amount pharmaceutical division sale grosstonet reconciliation million chf gross sale government regulatory mandatory price reduction contractual price reduction cash discount customer return reserve net sale government regulatory mandatory price reduction consist mandatory price reduction major element b drug discount program medicaid plan total usd billion equivalent chf billion usd billion equivalent chf billion contractual price reduction include rebate chargeback result contractual agreement primarily volume base performance base cash discount include credit offer wholesaler remit payment purchase contractually define incentive period customer return reserve allowance establish expect product return sale reduction expect withhold customer settlement contractual price reduction cash discount record balance sheet deduction trade receivable note sale reduction separately payable customer governmental health authority healthcare regulatory authority record balance sheet accrue liability note provision sale return record balance sheet provision note contract balance receivables millions chf account receivable current receivables contract customer noncurrent receivables contract customer total receivable current receivable mainly include royalty licensing receivable december total receivable include lease receivables consider receivables contract customer contract asset millions chf accrue income total contract asset roche group note roche group consolidated financial statement finance report contract liability millions chf defer income noncurrent defer income current total contract liability movement contract liability millions chf january business combination revenue recognise include contract liability balance begin year increase cash receive receivable exclude amount recognise revenue year currency translation effect december revenue recognise relation performance obligation satisfy previous year increase revenue recognise chf million increase chf million relate performance obligation satisfy previous period mainly adjustment sale deduction provision accrual expect sale return chargeback allowance respect previous year remain performance obligation partially unsatisfie longterm contract remain performance obligation partially unsatisfie longterm contract include defer income relate amount group expect receive good service transfer customer exist noncancellable enforceable contract mainly associate contract diagnostic division minimum purchase commitment related reagent consumable previously sell instrument monitor maintenance service contract original duration year group elect practical expedient disclose transaction price remain performance obligation end report period point time group expect recognise sale transaction price allocate contract partially unsatisfie performance obligation millions chf contract liability hold contract liability hold total thereof expect recognise revenue year year year total finance report note roche group consolidate financial statement roche group net financial expense financing cost millions chf interest expense amortisation debt discount net gain loss redemption repurchase bond note discount unwind net interest cost define benefit plan interest expense lease liability total financing cost financial income expense millions chf net gain loss equity investment security fair value profit loss dividend income equity investment security fair value profit loss dividend income equity investment security fair value oci net income equity investment security interest income debt security fair value oci amortise cost net gain loss sale debt security fair value oci net interest income income debt security net foreign exchange gain loss net gain loss foreign currency derivative foreign exchange gain loss gain loss net monetary position hyperinflationary economy net financial income expense associate total financial income expense net financial expense million chf financing cost financial income expense net financial expense financial result treasury management financial result pension management associate net financial expense roche group note roche group consolidated financial statement finance report hyperinflationary economy july group consider argentina hyperinflationary economy context ias financial report hyperinflationary economy cumulative inflation index year exceed measure national wholesaler price index sistema de ndice de precios mayorista accordingly group review reporting affiliate argentina necessary restate line ia potential adjustment result application ias significant impact group operate result balance sheet adjustment record gain loss net monetary position loss chf million result loss purchasing power positive net monetary position group argentinian affiliate loss chf million income taxis income tax expense millions chf current income taxis defer taxis total income tax expense group operate internationally subject income taxis different tax jurisdiction group calculate average expect tax rate weight average tax rate tax jurisdiction group operate rate change year year change mix group taxable income change local tax rate group average expect tax rate stable significant change local tax rate tax jurisdiction group operate group effective tax rate increase mainly low effect resolution tax dispute compare transitional effect swiss tax reform impairment goodwill tax deductible impact effective tax rate group effective tax rate reconcile group average expect tax rate follow reconciliation group effective tax rate average expect tax rate tax effect nontaxable incomenondeductible expense equity compensation plan research development tax credit deduction state tax impact tax unremitted earning transitional effect swiss tax reform resolution tax dispute prior year difference group effective tax rate finance report note roche group consolidate financial statement roche group income tax benefit record respect equity compensation plan vary accord price underlie equity chf million chf million income tax benefit record solely basis ifrs expense multiply applicable tax rate benefit approximately chf million chf million record tax effect comprehensive income millions chf pretax aftertax pretax aftertax tax tax remeasurement define benefit plan equity investment fair value oci debt security fair value oci cash flow hedge currency translation foreign operation comprehensive income income tax asset liability millions chf current income taxis asset liability net current income tax asset liability defer taxis asset liability net defer tax asset liability disclose note defer tax asset december restate follow finalisation valuation net asset acquire related spark therapeutic acquisition reconciliation previously publish deferred tax asset provide note current income tax liability include accrual uncertain tax position current income taxis movement recognise net asset liability millions chf net current income tax asset liability january income taxis pay business combination charge credit income statement charge credit equity equity compensation plan transaction shareholder currency translation effect movement net current income tax asset liability december roche group note roche group consolidated financial statement finance report defer taxis movement recognise net asset liability millions chf property plant equipment rightofuse intangible define temporary asset asset benefit plan ifference total year end december january business combination asset acquisition charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect movement december year end december january business combination asset acquisition charge credit income statement charge credit comprehensive income charge credit equity equity compensation plan transaction shareholder currency translation effect movement december disclose note net defer tax asset liability december restate follow finalisation valuation net asset acquire related spark therapeutic acquisition reconciliation previously publish net defer tax asset liability provide note defer tax net asset temporary difference mainly relate accrue liability include lease liability provision unrealise profit inventory defer tax asset recognise tax loss carry forward extent realisation relate tax benefit probable group unrecognised tax loss include valuation allowance follow unrecognised tax loss expiry applicable applicable chf tax rate chf tax rate year year year total unrecognised tax loss year category include loss state income tax purpose state permit tax report separate entity basis defer tax liability establish withholding tax taxis payable remittance earning foreign subsidiary amount currently regard permanently reinveste purpose financial statement total unremitted earning group regard permanently reinveste purpose financial statement chf billion december chf billionfinance report note roche group consolidate financial statement roche group merger acquisition note include transaction account business combination asset acquisition asset acquisition acquisition legal entity qualify business combination ifrs include acquisition value acquire company largely consist right single product technology cash consideration pay asset acquisition transaction date subsequent additional contingent payment achievement performancerelate development milestone present line asset acquisition disclose separately subsequent consideration performancerelate development milestone transaction treat asset acquisition recognise intangible asset specific milestone achieve business combination group complete business combination business combination spark therapeutics inc december group acquire control interest spark therapeutics inc spark therapeutic publicly own company base philadelphia pennsylvania list nasdaq spark therapeutic fully integrate commercial company commit discover develop deliver gene therapy spark therapeutic report pharmaceutical division roche pharmaceutical operating segment total consideration usd million pay cash annual financial statement accounting spark therapeutic acquisition provisional base preliminary information transaction close shortly december identification valuation intangible asset asset liability finalise identifiable asset acquire liability assume set table business combination net asset acquire millions chf spark therapeutic property plant equipment rightofuse asset intangible asset product intangible use product intangible available use defer tax asset cash cash equivalent marketable security defer tax liability noncurrent liability defer income lease liability longterm liability net asset liability net identifiable asset goodwill total consideration cash total consideration roche group note roche group consolidated financial statement finance report intangible asset include spark therapeutic lead clinical asset spk novel gene therapy treatment haemophilia luxturna spark therapeutic market gene therapy treatment patient confirm biallelic rpe mutationassociate retinal dystrophy inherit retinal disease luxturna gene therapy receive fda approval european commission grant marketing authorisation luxturna intangible asset include spark therapeutic clinical preclinical asset fair value intangible asset determine excess earning method base management forecast observable market datum discount rate tax rate foreign exchange rate present value calculate riskadjusted discount rate valuation perform independent valuer goodwill represent spark therapeutic technological capability gene therapy gene therapy manufacturing adenoassociate viral vector engineering immunology furthermore goodwill represent control premium acquire work force expect synergy notably area research development commercialisation gene therapy goodwill expect deductible income tax purpose spark therapeutic account receivable comprise gross contractual amount chf million expect collectable date acquisition directly attributable transaction cost chf million report roche pharmaceutical operating segment general administration expense impact acquisition result pharmaceutical division group material acquisition occur january management estimate spark therapeutic contributed revenue approximately chf million net loss tax approximately chf million information provide illustrative purpose necessarily indicative result combine group occur spark therapeutic actually acquire beginning year indicative future result combine group cash flow business combination business combination net cash outflow millions chf pharmaceutical diagnostic total pharmaceutical diagnostic total cash consideration pay deferred consideration pay contingent consideration pay cash acquire company total net cash outflow asset acquisition promedior inc february group acquire control interest promedior inc promedior privately own company base lexington massachusetts acquisition group obtain right promedior entire portfolio include phase iiiready asset prm recombinant human pentraxin molecule treatment idiopathic pulmonary fibrosis promedior report pharmaceutical division cash consideration pay acquisition date usd million additional contingent payment base achievement performancerelate milestone stratos genomics inc group acquire control interest stratos genomics inc stratos genomics privately own company base seattle washington stratos genomic earlystage sequence technology company group acquire advance development group nanopore sequencer acquisition provide group access stratos genomic unique chemistry sequence expansion stratos genomic report diagnostic division cash consideration pay acquisition date usd million additional contingent payment base achievement performancerelate milestonesfinance report note roche group consolidate financial statement roche group lexent bio inc june group acquire control interest lexent bio inc lexent bio privately own company base san francisco san diego california acquisition provide group access lexent bio novel multiomics liquid biopsy platform lexent bio report pharmaceutical division cash consideration pay acquisition date usd million additional contingent payment base achievement performancerelate milestone inflazome ltd september group acquire control interest inflazome ltd inflazome privately own company base dublin ireland acquisition group obtain right inflazome portfolio clinical preclinical orally available small molecule nlrp inhibitors inflazome report pharmaceutical division cash consideration pay acquisition date eur million additional contingent payment base achievement performancerelate milestone tmema ltd october group acquire control interest tmema ltd tmema privately own company base brighton united kingdom tmema spin enterprise therapeutic ltd immediately transaction acquisition group gain access portfolio tmema potentiator include lead compound phase clinical trial tmema report pharmaceutical division cash consideration pay acquisition date gbp million additional contingent payment base achievement performancerelate milestone asset acquisition previously close group record addition product intangible asset relate achievement performancerelate milestone chf million nil chf million pay nil asset acquisition net asset acquire million chf strato promedior g enomics lexent bio inflazome tmema total intangible asset product intangible available use defer tax asset cash cash equivalent net asset liability net identifiable asset fair value previously hold equity interest total consideration cash defer consideration total cash consideration asset acquisition group complete asset acquisition cash flow asset acquisition asset acquisition net cash outflow millions chf pharmaceutical diagnostic total pharmaceutical diagnostic total cash consideration pay cash acquire company contingent payment relate previous acquisition total net cash outflow roche group note roche group consolidated financial statement finance report restate balance sheet december annual financial statement accounting spark therapeutic acquisition provisional base preliminary information transaction close shortly december identification valuation intangible asset asset liability finalise result comparative balance sheet information december restate reconciliation balance sheet net asset acquire publish previously provisional acquisition accounting restate amount report comparative final acquisition accounting require ifrs business combination present restate roche group consolidate balance sheet select item millions chf december originally measurement publish adjustment restate goodwill intangible asset defer tax asset net asset net asset measurement adjustment table closing exchange rate december restate spark therapeutic acquisition net asset acquire select item millions chf spark therapeutic originally measurement publish djustment restate intangible asset product intangible use product intangible available use defer tax asset defer tax liability net asset liability net identifiable asset goodwill total consideration measurement adjustment table exchange rate date control spark therapeutic acquisition december finance report note roche group consolidate financial statement roche group global restructuring plan group continue implementation global restructuring plan initiate prior year global restructuring plan cost incur millions chf diagnostic site consolidation plan total year end december global restructuring cost employeerelate cost site closure cost divestment product business reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental case total cost year end december global restructuring cost employeerelate cost site closure cost divestment product business reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental case total cost diagnostic division strategy plan diagnostic division incur cost chf million mainly employeerelate cost site consolidation employeerelate cost mainly optimisation enable function drug product network site closure cost include impairment reversal chf million roche group note roche group consolidated financial statement finance report global restructuring plan major item include employeerelate cost chf million mainly outsource operational activity global share service centre external provider drive business transformation efficiency gain global restructuring plan summary cost incur millions chf employeerelate cost termination cost define benefit plan employeerelate cost total employeerelate cost site closure cost impairment reversal property plant equipment rightofuse asset accelerate depreciation property plant equipment rightofuse asset gain loss disposal property plant equipment rightofuse asset site closure cost total site closure cost divestment product business gain loss divestment subsidiary gain loss divestment product business total cost divestment product business reorganisation expense total global restructuring cost additional cost impairment goodwill impairment intangible asset legal environmental case total cost finance report note roche group consolidate financial statement roche group global restructuring plan classification cost millions chf depreciation depreciation amortisation amortisation impairment cost total impairment cost total cost sale pharmaceutical diagnostic marketing distribution pharmaceutical diagnostic research development pharmaceutical diagnostic general administration pharmaceutical diagnostic corporate total total operating segment roche pharmaceutical chugai diagnostic corporate total roche group note roche group consolidated financial statement finance report property plant equipment property plant equipment movement carry value asset millions chf building land machinery construction land improvement equipment progress total january cost accumulate depreciation impairment net book value year end december january reclassification rightofuse asset previously report finance lease implementation ifrs lease january revise business combination addition disposal transfer depreciation charge impairment reversal charge currency translation effect december cost accumulate depreciation impairment net book value year end december january asset acquisition addition disposal transfer depreciation charge impairment reversal charge currency translation effect december cost accumulate depreciation impairment net book value finance report note roche group consolidate financial statement roche group classification impairment property plant equipment million chf cost sale marketing distribution research development general administration total impairment reversal charge impairment reversal property plant equipment mainly relate global restructuring plan note impairment property plant equipment record mainly idle plant reimbursement receive insurance company respect impairment property plant equipment borrowing cost capitalise property plant equipment december machinery equipment original cost chf billion chf billion net book value chf billion chf billion lease party note capital commitment group noncancellable capital commitment purchase construction property plant equipment totalling chf billion chf billion roche group note roche group consolidated financial statement finance report goodwill goodwill movement carry value asset millions chf january cost accumulate impairment net book value year end december january business combination impairment charge record general administration currency translation effect december cost accumulate impairment net book value allocate follow cashgenerating unit roche pharmaceutical roche pharmaceutical product transaction chugai total pharmaceutical division diagnostic customer area diabetes care customer area divisional goodwill total diagnostic division disclose note goodwill december restate follow finalisation valuation net asset acquire related spark therapeutic acquisition reconciliation previously publish goodwill provide note cashgenerating unit allocate goodwill pharmaceutical division basis use cashgenerating unit allocate goodwill pharmaceutical division follow roche pharmaceutical operating segment goodwill arise broad type transaction strategic transaction transformative effect division technology transaction acquire technology range area application product transaction acquire product typically limited synergistic benefit outside immediate product therapeutic area cashgenerating unit goodwill arise strategic transaction roche pharmaceutical operating segment cashgenerating unit goodwill arise technology transaction roche pharmaceutical operating segment acquire technology permanently cease operate treat disposal business case goodwill deem dispose fully impair cashgenerating unit goodwill arise product transaction small identifiable group asset relate revenue relate cost arise development commercialisation product question synergistic benefit product therapeutic area revenue cost correspond asset product take account acquire product permanently cease generate economic benefit treat disposal business case goodwill deem dispose fully impair chugai separate operating segment group financial report separate cashgenerating unit goodwill allocatedfinance report note roche group consolidate financial statement roche group group allocate goodwill roche pharmaceutical operating segment list strategic transaction consist genentech foundation medicine flatiron health spark therapeutic technology transaction consist therapeutic human polyclonal dutalys santaris product transaction consist glycart tanox diagnostic division group comprehensive reassessment cashgenerating unit allocate goodwill diagnostic division reassessment light follow factor business transformation diagnostic division notably organisation change announce second half business development activity diagnostic information solution area ongoing reprioritisation business activity light covid pandemic development wide diagnostic business conclusion reassessment follow diagnostic division goodwill arise broad type transaction strategic transaction transformative effect division technology transaction acquire technology range area application product transaction acquire product synergistic benefit wide business limit synergistic benefit outside immediate product therapeutic area cashgenerating unit goodwill arise strategic transaction diagnostic division cashgenerating unit goodwill arise technology transaction diagnostic customer area diabetes care customer area acquire technology permanently cease operate treat disposal business case goodwill deem dispose fully impair cashgenerating unit goodwill arise product transaction small identifiable group asset relate revenue relate cost arise development commercialisation product question synergistic benefit product business revenue cost correspond asset product take account cashgenerating unit diagnostic customer area diabete care customer area acquire product permanently cease generate economic benefit treat disposal business case goodwill deem dispose fully impair base reassessment group allocate remain goodwill roche diagnostic operating segment list basis reallocation historical amount goodwill arise individual transaction strategic transaction consist corangeboehringer mannheim technology transaction consist viewic diagnostic customer area mysugr diabetes care customer area product transaction diagnostic customer area consist avl medical instruments igen bioveris ventana pvt iquum geneweave bioscience product transaction diabetes care customer area consist disetronic medingo impairment charge diagnostic division assessment potential impairment goodwill diagnostic division carry cash generating unit set impairment charge total chf million record diagnostic division avl medical instruments acquisition charge chf million record writeoff goodwill avl medical instrument acquisition acquire avl medical instrument lead supplier blood gas electrolyte analyser pointofcare test blood gas currently lossmake expect continue lossmake accord late business plan diagnostic customer area business develop replacement product plan substantial research development investment area knowledge bloodgas business synergy gain avl medical instrument acquisition reflect current goodwill play minor incidental role future diagnostic customer area strategy development nextgeneration product accordingly goodwill deem dispose fully impair intangible asset relate acquisition fully amortise previous year roche group note roche group consolidated financial statement finance report geneweave bioscience acquisition charge chf million record writeoff goodwill geneweave bioscience acquisition acquire geneweave bioscience focus advance clinical microbiology diagnostic solution support healthcare provider fight drugresistant bacteria acquisition date product intangible asset available use totalling chf million record impairment charge record fully write intangible asset factor lead impairment decrease forecast cash flow follow change timeline future product development pricing penetration rate update market size assumption update assumption timeline research development expense production cost timeline delay reprioritisation resource covidrelate project currently unclear future revenue support carry value goodwill synergistic benefit product business incidental accordingly goodwill deem dispose fully impair impairment charge charge chf million record diagnostic division partial writeoff goodwill relate diabetes care business impairment result revise market assumption relate blood glucose monitoring area slow expect growth part business value use value use calculate discount expect cash flow approach posttax discount rate apply project riskadjuste posttax cash flow terminal value discount rate group weight average cost capital cashgenerating unit integrate operation large part group derive capital asset pricing model data capital market include government twentyyear bond assess value use cash flow projection base recent longterm forecast approve management longterm forecast include management late estimate sale volume pricing production operating cost assume significant change organisation key assumption calculation period cash flow projection include longterm forecast terminal value growth rate discount rate key assumption valueinuse calculation period terminal period terminal cash flow value discount rate cash flow value discount rate p rojection growth rate tax p rojection growth rate tax pharmaceutical division year na year na diagnostic division year year cashgenerating unit terminal value growth respective rate exceed longterm project growth rate relevant market fair value cost disposal goodwill arise chugai acquisition fair value cost disposal determined reference publicly quote price chugai share sensitivity analysis management perform sensitivity analyse roche pharmaceutical diagnostic division increase discount rate combine decrease forecast cash flow chugai decrease publicly quote share price result sensitivity analysis demonstrate change key assumption cause carry value goodwill exceed recoverable amount december finance report note roche group consolidate financial statement roche group intangible asset intangible asset movement carry value asset millions chf product product intangible intangible use available use intangible total january cost accumulate amortisation impairment net book value year end december january business combination asset acquisition addition disposal transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocate operating segment roche pharmaceutical chugai diagnostic total group year end december january business combination asset acquisition addition disposal transfer amortisation charge impairment charge currency translation effect december cost accumulate amortisation impairment net book value allocate operating segment roche pharmaceutical chugai diagnostic total group disclose note intangible asset december restate follow finalisation valuation net asset acquire related spark therapeutic acquisition reconciliation previously publish intangible asset provide note marketing intangible technology intangible previously present separately aggregate intangible comparative information adjust roche group note roche group consolidated financial statement finance report significant intangible asset december millions chf remain operating segment net book value amortisation period product intangible use rozlytrek ignyta acquisition roche pharmaceutical year esbriet intermune acquisition roche pharmaceutical year xofluza shionogi licence transaction roche pharmaceutical year flatiron health acquisition roche pharmaceutical year gavreto blueprint medicine licence transaction roche pharmaceutical year luxturna spark therapeutic acquisition roche pharmaceutical year foundation medicine acquisition roche pharmaceutical year brahms licence transaction diagnostic year kapa acquisition diagnostic year product intangible available use spk haemophilia gene therapy spark therapeutic acquisition roche pharmaceutical na sarepta licence transaction roche pharmaceutical na inflazome acquisition roche pharmaceutical na promedior acquisition roche pharmaceutical na atea licence transaction roche pharmaceutical na spk haemophilia b gene therapy spark therapeutic acquisition roche pharmaceutical na stratos genomic acquisition diagnostic na gavreto blueprint medicine licence transaction roche pharmaceutical na biontech licence transaction roche pharmaceutical na dicerna licence transaction roche pharmaceutical na intangible technology intangible use adaptive licence transaction roche pharmaceutical year classification intangible asset amortisation impairment expense millions chf amortisation impairment cost sale pharmaceutical diagnostic marketing distribution pharmaceutical diagnostic research development pharmaceutical diagnostic total finance report note roche group consolidate financial statement roche group internally generate intangible asset december commercial software intangible asset amount chf million nil include intangible group internally generate intangible asset development criterion recognition asset meet intangible asset indefinite useful life group currently intangible asset indefinite useful live intangible asset available use represent inprocess research development asset acquire inlicense arrangement business combination asset acquisition separate purchase december approximately project pharmaceutical division know decision point month certain circumstance lead impairment inherent uncertainty research development process intangible asset available use particularly risk impairment project expect result commercialise product intangible asset impairment impairment charge arise change estimate future cash flow expect result use asset eventual disposal factor presence absence competition technical obsolescence lowerthananticipate sale product capitalise right result shorten useful life impairment impairment charge pharmaceutical division impairment charge total chf million record major item relate charge chf million partial impairment intangible asset spk novel gene therapy treatment haemophilia acquire spark therapeutic acquisition impairment result delay clinical trial partly impact covid pandemic leading reduce sale expectation asset concern amortise write estimate recoverable chf million charge chf million partial impairment intangible asset luxturna market gene therapy treatment patient inherit retinal disease mutation copy rpe gene acquire spark therapeutic acquisition impairment result reduce sale expectation asset concern write estimate recoverable chf million intangible asset continue amortise remain estimate useful life year impairment charge pharmaceutical division impairment charge total chf million record major item relate charge chf million impairment compound purchase separately drive change development plan asset concern amortise fully write charge chf million follow clinical datum assessment compound asset concern amortise fully write charge chf million decision stop development compound alliance partner asset concern amortise fully write charge chf million partial impairment compound develop alliance partner mainly drive reduce revenue forecast asset concern amortise partially write charge chf million decision stop development compound relate collaboration activity alliance partner asset concern amortise fully write charge chf million decision stop development compound purchase separately asset concern amortise fully write roche group note roche group consolidated financial statement finance report diagnostic division impairment charge total chf million record relate charge chf million impairment molecular diagnostic product intangible use acquire geneweave acquisition main factor lead update assumption timeline research development expense production cost asset concern amortise fully write charge chf million impairment sequence business product intangible use acquire ariosa acquisition mainly change timeline launch related sequence product asset concern amortise fully write potential commitment alliance collaboration purchase agreement year group party inlicense similar arrangement alliance partner intangible asset purchase agreement party include asset acquisition arrangement purchase agreement require group certain milestone similar payment dependent achievement agree objective performance target define collaboration purchase agreement group current estimate future thirdparty commitment payment year set table figure undiscounte riskadjuste meaning include potential payment arise assume project currently development successful timing base group current good estimate figure include potential commitment group arise roche chugai business potential future thirdparty collaboration purchase payment december millions chf pharmaceutical diagnostic group year year year total inventory inventory million chf raw material supply work process intermediate finish good provision slowmove obsolete inventory total inventory inventory expense cost sale total chf billion chf billion inventory writedown year result expense chf million chf millionfinance report note roche group consolidate financial statement roche group account receivable account receivable millions chf trade receivables note receivable receivables allowance doubtful account chargeback allowance withhold settlement total account receivable allowance doubtful account movement recognise allowance millions chf january additional allowance create unused amount reverse utilise year currency translation effect december bad debt expense record marketing distribution cost total chf million expense chf million marketable security marketable security millions chf equity security fair value profit loss debt security fair value oci money market instrument fair value oci time account month amortise cost total marketable security marketable security hold fund management purpose primarily denominate dollar euro swiss franc money market instrument contract mature year december debt security contract maturity million chf year year year total debt security roche group note roche group consolidated financial statement finance report cash cash equivalent cash cash equivalent millions chf cash cash hand current account cash equivalent time account maturity month total cash cash equivalent noncurrent asset noncurrent asset millions chf equity investment fair value oci equity investment fair value profit loss loan receivable restrict cash receivables contract customer receivables total financial noncurrent asset longterm employee benefit asset total nonfinancial noncurrent asset associate total noncurrent asset equity investment designate fair value oci mainly investment private company pharmaceutical sector hold group strategic alliance effortsfinance report note roche group consolidate financial statement roche group current asset current asset millions chf accrue interest income derivative financial instrument restrict cash cash collateral receivables receivables contract customer receivables total financial current asset prepaid expense accrue income taxis recoverable asset total nonfinancial current asset total current asset account payable account payable million chf trade payable taxis payable dividend payable payable total account payable noncurrent liability noncurrent liability millions chf defer income lease liability longterm liability total noncurrent liability longterm liability mainly relate accrued employee benefit follow implementation ifrs lease note noncurrent lease liability chf million record mainly lease classify operating lease group lessee effective january roche group note roche group consolidated financial statement finance report current liability current liability millions chf defer income lease liability accrue payroll relate item interest payable derivative financial instrument cash collateral payable accrue chargeback allowance separately payable accrue royalty commission accrue liability total current liability follow implementation ifrs lease note current lease liability chf million record mainly lease classify operating lease group lessee effective january finance report note roche group consolidate financial statement roche group provision contingent liability provision movement recognise liability millions chf contingent legal environmental restructuring consideration p rovision provision provision provision p rovision total year end december january reclassification lease liability implementation ifrs lease january revise additional provision create unused amount reverse utilise discount unwind business combination acquire company defer consideration contingent consideration asset acquisition currency translation effect december current noncurrent december year end december january additional provision create unused amount reverse utilise discount unwind business combination acquire company defer consideration contingent consideration asset acquisition currency translation effect december current noncurrent december expect outflow resource year year year year december chf million provision utilise chf million chf million chf million include cash flow operating activity chf million chf million include cash flow business combination payment deferred contingent consideration arrangement note roche group note roche group consolidated financial statement finance report legal provision legal provision consist number separate legal matter include claim arise trade group company nature amount timing outflow difficult predict regular review litigation matter management reassess provision record certain litigation matter base development litigation notably accutane case provision previously hold release resulted income chf million major element expense legal case net income chf million include general administration net expense chf million detail major legal case outstanding disclose environmental provision provision environmental matter include separate environmental issue number country nature amount timing outflow difficult predict significant provision discount time value money material significant provision relate site nutley new jersey divest september estimate remediation cost landfill site near grenzach germany manufacturing operation close year ago estimate remediation cost manufacturing site clarecastle ireland net environmental expense nil net expense chf million group procedure environmental protection include annual report page include action take group regard climate change notably group commitment reduce greenhouse gas emission restructuring provision arise plan programme materially change scope business undertaken group manner business conduct provision include cost necessarily entail restructuring associate recur activity group timing cash outflow reasonably certain provision discount time value money material matter pharmaceutical division significant provision relate resource flexibility plan redesign strategic realignment manufacturing network diagnostic division significant provision associate programme address longterm strategy corporate relate initiative outsource operational activity global share service centre external provider detail give note contingent consideration provision group party certain contingent consideration arrangement arise business combination significant provision discount average discount rate time value money material additional detail measurement total potential payment arrangement provide note provision provision relate item show table exception employee provision time cash outflow nature uncertain provision million chf sale return employee provision item total provision december item include provision previously record estimate potential obligation past royalty relate pdl inhibitor litigation describe november settlement agreement reach dispute agree cash settlement record provisionsfinance report note roche group consolidate financial statement roche group contingent liability operation earning group continue time time vary degree affect political legislative fiscal regulatory development include relate environmental protection country operate industry group operate subject risk kind nature frequency development event cover insurance effect future operation earning predictable group enter strategic alliance company order gain access potential new product utilise company help develop group potential new product potential future payment certain collaboration partner achieve certain milestone define collaboration agreement group good estimate future commitment payment give note legal case december provision legal case chf million chf million mainly relate legal case pharmaceutical division chf million chf million diagnostic division chf million chf million provision record case settled mainly relate meso diagnostic legal case pharmaceutical legal matter list accutane hoffmannla roche inc hlr roche affiliate name defendant numerous legal action relate acne medication accutane litigation allege accutane cause certain condition include limited inflammatory bowel disease ibd birth defect psychiatric disorder hlr announce follow reevaluation portfolio medicine available generic manufacturer rapidly decline brand sale high cost personalinjury lawsuit continue defend vigorously decide immediately discontinue manufacture distribution product action pende federal court allege ibd consolidated pretrial proceeding multidistrict litigation mdl district court middle district florida tampa division august mdl closed pendency mdl district court grant summary judgment favour hlr federal ibd case proceed affirm court appeal eleventh circuit action pende state court new jersey allege ibd consolidated pretrial proceeding superior court new jersey law division atlantic county february superior court new jersey law division atlantic county hold eightday evidentiary hearing plaintiff expert testify accutane cause crohns disease february superior court bar plaintiff expert method meet requirement scientific reliability superior court enter order dismiss prejudice agreedupon list crohns disease case subject superior court february order july new jersey appellate division reverse order exclude plaintiff expert testify accutane cause crohns disease reinstate dismiss case find trial court wrongfully bar plaintiff expert witness hlr file petition review new jersey supreme court grant december august supreme court issue decision plaintiff expert testify accutane cause crohns disease supreme court reverse judgment new jersey appellate division conclude trial court properly exclude expert dismiss case allege accutane cause plaintiff crohns disease plaintiff appeal crohns disease case permanently dismiss superior court enter order grant summary judgment dismiss case file new jersey resident basis drug label adequate matter law july superior court grant hlrs motion summary judgment adequacy label post ingestion case jurisdiction superior court apply new jersey law jurisdiction grant hlrs motion dismiss approximately case alternative superior court apply home state law grant summary judgment jurisdiction deny jurisdiction resulted case dismiss july new jersey appellate division affirm dismissal case reinstate judgment case base strength hlrs warning hlr dismiss plaintiff file petition review new jersey supreme court grant december october supreme court issue decision case reverse judgment new jersey appellate division reinstate case basis drug label adequate matter law plaintiff appeal case permanently dismiss roche group note roche group consolidated financial statement finance report january october superior court enter order grant summary judgment dismiss case failure prove accutane proximately cause ulcerative colitis plaintiff appeal decision february march superior court hold evidentiary hearing plaintiff expert testify accutane cause ulcerative colitis april superior court bar plaintiff expert method meet requirement scientific reliability superior court enter order dismiss ulcerative colitis case subject superior court april order plaintiff appeal decision december hlr defend pende action approximately case appeal hear january january new jersey appellate division issue decision plaintiff expert testify accutane cause ulcerative colitis affirm trial court ruling conclude trial court properly exclude expert dismiss case allege accutane cause plaintiff ulcerative colitis plaintiff file petition appeal new jersey supreme court supreme court enter order deny petition plaintiff appeal remain case permanently dismiss supreme court dismiss previously case matter conclude avastinlucentis investigation february italian antitrust authority agcm announce investigation determine roche genentech novartis enter agreement restrict competition italian market drug reference particular avastin market roche lucentis market novartis avastin lucentis different drug develop approve different therapeutic purpose contain different active pharmaceutical ingredient march agcm issue verdict allege roche novartis collude artificially differentiate avastin lucentis order foster sale lucentis italy agcm fine roche eur million novartis eur million roche appeal agcm verdict tribunale amministrativo regionale del lazio tar december tar uphold decision agcm roche appeal verdict tar consiglio di stato july roche pay eur million fine protest avoid additional penalty fee record expense general administration january european court justice render decision question refer european court justice consiglio di stato july consiglio di stato issue final verdict case uphold verdict agcm tar respect fine agcm matter conclude italian ministry health italian region notify group intention seek damage relate matter january french competition authority fca issue statement objection roche genentech novartis anticompetitive practice concern commercialisation avastin lucentis france fca allege roche genentech novartis abuse collective dominant position french market treatment wet agerelate macular degeneration september fca issue decision find roche genentech novartis infringe competition law impose fine eur million roche genentech roche genentech appeal decision december liability hold fine include account payable line item payable note fine pay protest avoid additional penalty fee later february addition group challenge policy regulation allow offlabelunlicense use reimbursement economic reason country group vigorously defend matter outcome matter determined timefinance report note roche group consolidate financial statement roche group pdl inhibitor litigation july bristolmyers squibb co bms file lawsuit genentech inc genentech delaware bms allege genentech sale tecentriq infringe patent bms seek judgment favour find wilfulness monetary damage october genentech file answer counterclaim seek declaratory judgment invalidity patent bms genentech agree drop lawsuit prejudice case refile later date november bms genentech reach settlement agreement dispute term agreement party conclude royalty agreement future worldwide sale tecentriq genentech cash settlement past royalty provision previously record estimate potential obligation past royalty agree cash settlement record provision matter conclude average wholesale price litigation hlr roche laboratories inc rli approximately brand generic pharmaceutical company name defendant legal action relate price pharmaceutical drug state medicaid reimbursement primary allegation litigation pharmaceutical company misrepresent report inaccurate average wholesale price awp andor wholesale acquisition cost wac drug price allegedly rely state calculate medicaid reimbursement entity retail pharmacy state respective attorney general seek repayment amount claim overreimburse time period associate case december hlr rli defend awp action file state new jersey hlr rli vigorously defend trial date set outcome matter determine time boniva litigation hlr genentech roche affiliate collectively roche name defendant numerous legal action dismiss case canada relate postmenopausal osteoporosis medication boniva litigation plaintiffs allege boniva cause osteonecrosis jaw atypical femoral fracture december roche defend approximately action involve approximately plaintiff bring federal state court personal injury allegedly result use boniva case early discovery stage litigation individual trial result depend variety factor include unique particular case roche vigorously defend matter outcome matter determine time meso litigation february roche diagnostic corporation roche file lawsuit district court district delaware meso scale diagnostic llc meso patent infringement case involve certain patent own bioveris corporation bioveris company acquire group meso hold limited exclusive licence use certain aspect electrochemiluminescence ecl detection technology roche meso disagree scope licence lawsuit seek declaratory judgment judicial clarification roche infringe mesos licence november jury find roche use patent infringe scope meso licence injunction grant jury award meso usd million damage posttrial motion file party meso move enhancement prejudgment interest postjudgment royalty court hearing take place december district court issue final order judgment jury award confirm meso request enhance damage deny group appeal decision addition pharmaceutical legal case list currently provision record potential future obligation confirm occurrence nonoccurrence uncertain future event obligation measure sufficient reliability roche group note roche group consolidated financial statement finance report hemlibra litigation baxalta inc baxalta gmbh baxalta subsidiary takeda pharmaceutical company limit file patent infringement declaratory judgment patent infringement suit district court district delaware allege genentech chugai pharmaceutical co ltd chugai currently imminently manufacture use sell offer sale import hemlibra infringe baxalta patent baxalta seek judgment infringement injunctive monetary relief attorney fee cost expense genentech serve complaint genentech response counterclaim complaint file june june chugai waive service september chugai file motion dismiss complaint lack personal jurisdiction december baxalta file request preliminary injunction genentech inhibitor patient subject injunction hearing hold district court district delaware june hearing baxalta withdraw request preliminary injunction inhibitor patient june baxalta submit new propose preliminary injunction order genentech permit sell hemlibra inhibitor patient noninhibitor patient currently hemlibra clinical trial select noninhibitor patient additional medically diagnose condition render factor viii therapy impracticable august district court rule baxalta deny request injunction september chugai dismiss case february district court issue final judgment favour genentech state hemlibra infringe baxalta patent base court definition key term relate patent february baxalta appeal decision august appeal court reverse claim construction rule district court favour genentech remand case district court group vigorously defend matter outcome matter determined time march case bring baxalta chugai japan tokyo district court rule favour chugai notably hemlibra infringe baxalta patent baxalta appeal decision october japanese intellectual property high court issue ruling uphold tokyo district court decision baxalta file appeal japanese supreme court august japanese supreme court decide accept baxalta final appeal decision japanese intellectual property high court final baxalta patent japan valid infringe hemlibra pende legal action japan terminate matter japan conclude iraqi ministry health october f hoffmannla roche ltd fhlr hoffmannla roche inc hlr genentech certain pharmaceutical andor medical device company name defendant complaint file federal district court district columbia behalf servicemember relative allege kill injure iraq iraq lawsuit complaint allege defendant violate antiterrorism act state law provide fund terrorist organisation sale practice pursuant pharmaceutical andor medical device contract iraqi ministry health addition fhlr receive inquiry july department justice connection anticorruption investigation relate activity iraq include interaction iraqi government certain matter allege iraq lawsuit october department justice close inquiry fhlr july federal district court grant defendant motion dismiss plaintiff appeal decision group vigorously defend matter outcome matter determined time tamiflu qui tam litigation roche holding ltd roche hold hoffmannla roche inc hlr genentech inc genentech serve lawsuit file relator district court district maryland qui tam whistleblower provision false claim act lawsuit originally file seal year early behalf government state government lawsuit allege certain improper conduct group respect sale tamiflu government state government department justice decline intervene lawsuit january group file motion dismiss september plaintiff dismiss complaint roche hold genentech district court deny hlrs motion summary judgment group vigorously defend matter outcome matter determined timefinance report note roche group consolidate financial statement roche group debt debt movement carry value recognise liability millions chf january reclassification lease liability implementation ifrs lease na january revise proceed issue bond note redemption repurchase bond note increase decrease commercial paper increase decrease debt change finance cash flow net gain loss redemption repurchase bond note amortisation debt discount financing cost business combination asset acquisition net foreign currency transaction gain loss currency translation effect change foreign exchange rate change fair value hedge instrument change december bond note commercial paper amount bank financial institution borrowing total debt longterm debt shortterm debt total debt pledge group asset connection debt roche group note roche group consolidated financial statement finance report bond note recognise liability effective interest rate bond note million chf effective interest rate underlie include instrument hedge dollar note fix rate note september principal usd billion isin usba note september principal usd billion outstanding usd billion isin usbb note january principal usd billion isin usbm note september principal usd billion outstanding usd billion isin usbn na note september principal usd billion outstanding usd billion isin usbe na note november principal usd billion outstanding usd billion isin usbj na note principal usd billion isin usbk na note january principal usd billion isin usbl na note september principal usd billion isin usbp na note march principal usd billion outstanding usd billion isin usuan usau note november principal usd billion isin usbh na dollar note float rate note september principal usd billion isin usaz na euro medium term note programme fix rate note march principal usd billion isin xs note march principal eur billion outstanding eur billion isin xs note february principal eur billion isin xs na note august principal gbp billion outstanding gbp billion isin xs na note february principal eur billion isin xs swiss franc bond fix rate bond september principal chf billion isin ch bond september principal chf billion isin ch bond september principal chf billion isin ch na bond march principal chf billion isin ch na bond september principal chf billion isin ch na genentech senior note senior note july principal usd billion outstanding usd billion isin usac na total bond note finance report note roche group consolidate financial statement roche group bond note maturity millions chf year year year year year year total bond note unamortised discount include carry value bond note millions chf dollar note euro note swiss franc bond pound sterling note total unamortised discount issuance bond note group issue bond note issuance bond note group issue bond note redemption repurchase bond note group repay bond note redemption repurchase bond note redemption dollar note date september group repay fix rate note principal usd billion cash outflow chf million plus accrue interest effective interest rate note date september group repay float rate note principal usd billion cash outflow chf million plus accrue interest effective interest rate note december group resolve exercise option early redemption fix rate note principal usd billion par month schedule date march cash outflow chf million plus accrue interest effective interest rate note december group complete tender offer redeem follow instrument usd million fix rate note september effective interest rate usd million fix rate note september effective interest rate usd million fix rate note september effective interest rate usd million fix rate note november effective interest rate usd million fix rate note july effective interest rate usd million fix rate note march effective interest rate cash outflow chf million plus accrue interest loss redemption chf million include chf million pay bank fee roche group note roche group consolidated financial statement finance report cash flow redemption repurchase bond note cash outflow redemption repurchase bond note millions chf euro medium term note programme dollar note dollar note total cash outflow redemption repurchase bond note commercial paper roche holdings inc commercial paper program roche holdings inc establish commercial paper program issue usd billion unsecured commercial paper note guarantee roche holding ltd commit credit line available backstop support commercial paper program usd billion december july previously exist committed credit line refinance new committed credit line initial maturity year maturity note program exceed day date issuance december unsecured commercial paper note principal usd billion average interest rate outstanding movement commercial paper obligation millions chf january net cash proceed payment currency translation effect december amount bank financial institution amount denominate currency average interest rate december amount outstanding chf million chf million yearfinance report note roche group consolidate financial statement roche group equity attributable roche shareholder change equity attributable roche shareholder millions chf share retain fair value hedge translation c apital earning reserve reserve reserve total year end december january net income recognise income statement financial asset fair value oci fair value gain loss equity investment fair value oci fair value gain loss take retain earning disposal equity investment fair value oci fair value gain loss debt security fair value oci fair value gain loss transfer income statement debt security fair value oci income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statement income taxis noncontrolle interest currency translation foreign operation exchange difference accumulate difference transfer income statement divestment subsidiary noncontrolle interest define benefit plan remeasurement gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend equity compensation plan net transaction equity change ownership interest subsidiary change noncontrolle interest december b entire transfer income statement report financial income expense b cost hedging reserve relate eurusd crosscurrency swap include hedging reserve amount chf million net tax roche group note roche group consolidated financial statement finance report change equity attributable roche shareholder millions chf share retain fair value hedge translation c apital earning reserve reserve reserve total year end december january net income recognise income statement financial asset fair value oci fair value gain loss equity investment fair value oci fair value gain loss take retain earning disposal equity investment fair value oci fair value gain loss debt security fair value oci fair value gain loss transfer income statement debt security fair value oci income taxis noncontrolle interest cash flow hedge gain loss take equity transfer income statement income taxis noncontrolle interest currency translation foreign operation exchange difference accumulate difference transfer income statement divestment subsidiary noncontrolle interest define benefit plan remeasurement gain loss limit asset recognition income taxis noncontrolle interest comprehensive income net tax total comprehensive income dividend equity compensation plan net transaction equity change ownership interest subsidiary change noncontrolle interest december b entire transfer income statement report financial income expense b cost hedging reserve relate eurusd crosscurrency swap include hedging reserve amount chf million net tax genentech transaction group complete purchase noncontrolle interest genentech effective march base international accounting standard separate financial statement ias consistent international financial reporting standard consolidated financial statement ifrs adopt group transaction account equity transaction consequence carrying consolidate equity group time reduce chf billion chf billion allocate eliminate book value genentech noncontrolle interest accounting effect significantly impact group net equity effect group business dividend policyfinance report note roche group consolidate financial statement roche group share capital december authorise issue share capital roche holding ltd group parent company consist million share nominal value chf precede year share bearer share group maintain register shareholder base information supply group shareholder group pool voting right owns issue share december shareholder group announce continue shareholder pooling agreement exist modify shareholder composition duration pool extend indefinite period shareholder group pool voting right hold share correspond share issue figure include share pooled voting right hold outside group individual member group ms maja oeri member pool hold share represent voting right independently pool describe note base information supply group novartis hold ag basel own participation issue share nonvoting equity security genussscheine december nonvoting equity security authorise issue precede year swiss company law nonvoting equity security nominal value share capital issue contribution show asset balance sheet roche holding ltd nonvoting equity security confer right share participate net profit remain proceed liquidation follow repayment nominal value share participation certificate accordance law article incorporation roche holding ltd company entitle times exchange nonvoting equity security share participation certificate dividend march shareholder approve distribution dividend chf share nonvoting equity security chf respect business year distribution holder outstanding share nonvoting equity security total chf million chf million record retain earning board director propose dividend business year chf share nonvoting equity security approve result total distribution shareholder chf million subject approval annual general meeting march equity instrument holding equity instrument equivalent number nonvoting equity security million million share nonvoting equity security total equity instrument record equity original purchase cost december fair value share chf million fair value nonvoting equity security chf billion equity instrument hold group potential conversion obligation arise group equity compensation plan note reserve fair value reserve december fair value reserve represent cumulative net change fair value financial asset fair value oci asset sell impair dispose hedging reserve hedging reserve represent effective portion cumulative net change fair value cash flow hedge instrument relate hedged transaction occur translation reserve translation reserve represent cumulative currency translation difference relate consolidation group company use functional currency swiss franc roche group note roche group consolidated financial statement finance report subsidiary chugai effective october roche group chugai complete alliance create lead researchdriven japanese pharmaceutical company form merger chugai roche japanese pharmaceuticals subsidiary nippon roche merged company know chugai consolidated subsidiary chugai fully consolidated subsidiary group base group interest chugai december roche relationship chugai found basic alliance licensing research collaboration agreement common stock chugai publicly trade list tokyo stock exchange stock code tse january chugai announce split common stock effective july number issue share increase threeforone split chugai prepare financial statement accordance international financial reporting standard ifrs file quarterly basis tokyo stock exchange certain consolidation entry minor difference chugais standalone ifrs result result chugai consolidated roche group accordance ifrs chugai summarise financial information millions chf income statement sale royalty operating income total revenue operate profit balance sheet noncurrent asset current asset noncurrent liabilitie current liability total net asset cash flow cash flow operating activity cash flow invest activity cash flow financing activity dividend dividend distribute party hold chugai share total chf million chf million record noncontrolle interest note dividend pay chugai roche eliminate consolidation intercompany itemsfinance report note roche group consolidate financial statement roche group roche relationship chugai chugai enter certain agreement roche discuss basic alliance agreement basic alliance agreement sign december roche chugai enter certain arrangement cover future operation governance chugai matter cover follow area structure alliance roche right shareholder roche right nominate members chugais board director certain limitation roche ability buy sell chugais common stock chugai issue additional share common stock connection convertible debt equity compensation plan issue additional share purpose affect roche percentage ownership interest basic alliance agreement provide matter chugai guarantee roche right maintain shareholde percentage chugai licensing agreement japan umbrella right agreement sign december chugai exclusive right market roche pharmaceutical product japan chugai right refusal development marketing japan development compound advanced roche rest world umbrella right agreement exclude japan south korea sign revise amend restate rest world umbrella right agreement exclude japan south korea taiwan sign august agreement chugai shall offer roche right refusal development marketing chugais development compound market outside japan exclude south korea taiwan agreement roche chugai sign series separate agreement certain specific product depend specific circumstance term agreement result payment arm length basis roche chugai follow matter upfront payment right refusal license product exercise milestone payment dependent achievement agree performance target royalty future product sale specific product agreement cover manufacture supply respective product meet party clinical andor commercial requirement arm length basis research collaboration agreement roche chugai enter research collaboration agreement area smallmolecule synthetic drug research biotechnologybase drug discovery roche group note roche group consolidated financial statement finance report noncontrolle interest change equity attributable noncontrolle interest millions chf january net income recognise income statement chugai noncontrolle interest total net income recognise income statement equity investment fair value oci debt security fair value oci cash flow hedge currency translation foreign operation remeasurement define benefit plan comprehensive income net tax total comprehensive income business combination dividend noncontrolle shareholder chugai noncontrolle interest equity compensation plan net transaction equity change ownership interest subsidiary change noncontrolle interest equity contribution noncontrolle interest december chugai noncontrolle interest total noncontrolle interest finance report note roche group consolidate financial statement roche group employee benefit employee remuneration million chf wage salary social security cost define contribution plan operating expense define benefit plan equity compensation plan termination cost employee benefit employee remuneration include operating result net interest cost define benefit plan total employee remuneration employee benefit consist mainly life insurance scheme certain insurance scheme provide medical coverage longterm shortterm disability benefit pension postemployment benefit group objective provide attractive competitive postemployment benefit employee time ensure plan appropriately finance manage potential impact group longterm financial position employee cover pension plan sponsor group company nature plan vary accord legal regulation fiscal requirement market practice country employee employ postemployment benefit plan classify ifrs define contribution plan group pay fix contribution separate fund thirdparty financial institution legal constructive obligation pay contribution plan classify define benefit plan define contribution plan define contribution plan fund payment employee group fund administer party group expense plan chf million chf million asset liability recognise group balance sheet respect plan apart regular prepayment accrual contribution withhold employee wage salary group contribution group major define contribution plan roche k saving plan define benefit plan plan usually establish trust independent group fund payment group company employee case notably major define benefit plan germany plans unfunded group pay pension retire employee directly financial resource plan usually govern senior governing body board trustee typically compose employee employer representative funding plan determine local regulation independent actuarial valuation separate independent actuarial valuation prepare accordance requirement ias use group financial statement group major pension plan locate switzerland germany total account group define benefit obligation roche group note roche group consolidated financial statement finance report pension plan switzerland current pension arrangement employee switzerland plan govern swiss federal occupational old age survivor disability pension act bvg group pension plan administer separate legal foundation fund regular employee company contribution final benefit contribution base certain minimum guarantee minimum guarantee swiss plan treat define benefit plan purpose ifrs financial statement characteristic define contribution plan underfunding remedie measure increase employee company contribution lower interest rate retirement account balance reduce prospective benefit suspension early withdrawal facility pension plan group major define benefit plan close new member new employee join define contribution plan large remain define benefit plan fund pension plan small unfunded supplementary retirement plan benefit base high average annual rate earning specify period length employment plan noncontributory employee group make periodic payment plan underfunding normally remedie additional company contribution payment group pension plan germany group major pension arrangement germany govern occupational pension act betravg plan unfunded group pay pension retire employee directly financial resource plan noncontributory employee benefit base final salary length employment plan close new member replace new plan fund regular employee company contribution administer contractual trust agreement final benefit contribution base minimum guarantee minimum guarantee plan treat define benefit plan purpose ifrs financial statement characteristic define contribution plan pension plan rest world represent approximately group define benefit obligation consist number small plan country large pension plan chugai independently manage chugai main pension plan united kingdom chugai additional voluntary contribution jpy billion pension plan jpy billion chugai plan fully describe chugais ifrs financial statement uk pension plan fund regular employee company contribution benefit base final salary length employment plan close new member replace define contribution plan postemployment benefit opeb plan represent approximately group define benefit obligation consist postemployment healthcare life insurance scheme mainly plan mainly unfunde andor contributory employee group reimburse retire employee directly financial resource group major opeb plan close new member cost plan reimbursable medicare prescription drug improvement modernization act statutory funding requirement plan group funding plan extent tax efficient payment group plan december ifrs funding status include reimbursement right fund opeb plan define benefit plan income statement millions chf post post pension employment total pension employment total plan benefit plan expense plan benefit plan expense current service cost past service income cost settlement gain loss total operating expense net interest cost define benefit plan total expense recognise income statement finance report note roche group consolidate financial statement roche group funding status fund group define benefit plan responsibility respective senior governing body board trustee sponsor employer manage base local statutory valuation follow legislation requirement respective jurisdiction plan establish qualified independent actuary carry statutory actuarial valuation regular basis actuarial assumption determine funding status statutory basis regularly assess local senior governing body funding status closely monitor corporate level unfunded plan mainly group german affiliate fully reserve pension obligation selffinance local affiliate operation ifrs funding status fund define benefit plan increase reimbursement right link postemployment medical plan represent expect reimbursement medical expenditure provide medicare prescription drug improvement modernization act define benefit plan fund status millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total fund plan fair value plan asset define benefit obligation fund unfunded plan define benefit obligation total funding status limit asset recognition reimbursement right net recognise asset liability report balance sheet define benefit plan asset define benefit plan liability plan asset responsibility investment strategy fund plan respective senior governance body board trustee assetliability study perform regularly major pension plan study examine obligation postemployment benefit plan evaluate investment strategy respect key financial measure expect return expect risk expect contribution expect funded status plan interdependent way goal assetliability study select appropriate asset allocation fund hold plan investment strategy develop optimise expect return manage risk contain fluctuation statutory fund status assetliability study include strategy match cash flow asset plan obligation group currently use longevity swap manage longevity risk plan asset manage internal external asset manager actual performance continually monitor pension fund governance body closely monitor corporate level financial statement difference interest income actual return plan asset remeasurement record directly comprehensive income actual return plan asset gain chf million gain chf million exclude actual return reimbursement right recognition plan asset limit present value economic benefit available refund plan reduction future contribution plan roche group note roche group consolidated financial statement finance report define benefit plan fair value plan asset reimbursement right millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january interest income plan asset reimbursement right remeasurement plan asset reimbursement right currency translation effect employer contribution employee contribution benefit pay fund plan benefit pay settlement administration cost december define benefit plan composition plan asset millions chf equity security debt security property cash money market instrument investment december asset invest variety different class order maintain balance risk return follow equity debt security mainly quote market price level fair value hierarchy property primarily private commercial property fund mainly observable input level fair value hierarchy cash money market instrument mainly invest financial institution credit rating low investment mainly consist alternative mortgage commodity insurance contract risk management purpose mainly observable input level fair value hierarchy unobservable input level fair value hierarchy include fair value plan asset group share nonvoting security fair value chf million chf million debt instrument issue group fair value chf million chf millionfinance report note roche group consolidate financial statement roche group define benefit obligation define benefit obligation calculate project unit credit method reflect service render employee date valuation incorporate actuarial assumption primarily discount rate determine present value benefit project rate remuneration growth mortality rate present value define benefit obligation determine discount estimate future cash outflow interest rate highquality corporate bond government bond countrie deep market corporate bond corporate government bond denominate currency benefit pay maturity term approximate term relate pension obligation group final salarybase define benefit pension plan germany united kingdom close new participant active employee member pension plan time close new participant continue accrue benefit final salarybase define benefit pension plan new employee uk join group define contribution plan new employee germany join contributionbase plan minimum guarantee result proportion define benefit obligation relate closed plan expect decrease future define benefit pension plan switzerland final benefit contribution base minimum guarantee remain open new employee define benefit plan define benefit obligation millions chf post post pension employment pension employment plan benefit plan total plan benefit plan total january current service cost interest cost remeasurement demographic assumption financial assumption experience adjustment currency translation effect employee contribution benefit pay fund plan benefit pay unfunded plan benefit pay settlement past service income cost settlement gain loss december composition plan active member defer vested member retire member december plan geography switzerland united states germany rest world december duration year roche group note roche group consolidated financial statement finance report actuarial assumption actuarial assumption financial statement base requirement set ias employee benefit unbiased mutually compatible estimate variable determine ultimate cost provide postemployment benefit set annual basis local management base advice actuary subject approval corporate management group actuarie actuarial assumption consist demographic assumption matter mortality employee turnover financial assumption matter interest rate salary benefit level inflation rate cost medical benefit actuarial assumption vary base local economic social condition actuarial assumption statutory valuation differ base local legal regulatory requirement demographic assumption significant demographic assumption relate mortality rate group actuary use mortality table account historic pattern expect change increase longevity rate employee turnover disability early retirement base historical behaviour average life expectancy assume individual age follow define benefit plan average life expectancy age major scheme year male female country mortality table switzerland bvg projected cmi model united states pri project mp germany heubeck table g project cmi model mortality assumption pension plan switzerland base bvg apply continuous mortality investigation cmi model longterm rate longevity improvement group mortality assumption pension plan germany heubeck table g apply cmi model longterm rate longevity improvement financial assumption base market expectation period obligation settle assumption actuarial valuation show define benefit plan financial actuarial assumption weighted weight average range average range discount rate expect rate salary increase expect rate pension increase expect inflation rate immediate medical cost trend rate ultimate medical cost trend rate discount rate determine reference interest rate highquality corporate bond government bond countrie deep market corporate bond expect rate salary increase base expected inflation rate adjustment reflect group late expectation longterm real salary increase take account expect inflation rate factor expect rate pension increase generally link expected inflation rate funding status plan expect inflation rate derive look level inflation imply financial market conjunction economist price inflation forecast historic price inflation economic variable circumstance medical cost trend rate account benefit set plan term expect future change medical cost group major postemployment medical plan employee rate drive development usfinance report note roche group consolidate financial statement roche group sensitivity analysis measurement net define benefit obligation particularly sensitive change discount rate inflation rate expect mortality medical cost trend rate assumption follow table summarise impact change assumption present value define benefit obligation define benefit plan sensitivity define benefit obligation actuarial assumption millions chf increase decrease define benefit obligation life expectancy year increase discount rate increase decrease expect inflation rate increase decrease immediate medical cost trend rate increase decrease sensitivity analysis consider change assumption time leave assumption unchanged approach show isolated effect change individual assumption account assumption relate method carry sensitivity analysis prior year cash flow group incur cash flow define benefit plan show table define benefit plan cash flow million chf employer contribution net reimbursement fund plan benefit pay unfunded plan total cash inflow outflow base recent actuarial valuation group expect employer contribution fund plan approximately chf million include estimate chf million additional voluntary contribution relate chugai benefit plan benefit pay unfunded plan estimate approximately chf million relate german define benefit plan roche group note roche group consolidated financial statement finance report equity compensation plan group operate equity compensation plan include separate plan chugai ifrs sharebase payment require fair value equity compensation plan award grant employee estimate grant date record expense vest period expense equity compensation plan millions chf cost sale marketing distribution research development general administration total operating expense equity compensation plan roche stocksettle stock appreciation right roche restrict stock unit plan roche performance share plan roche connect roche option plan bonus stock award chugai plan total operating expense equitysettle cashsettle cash inflow outflow equity compensation plan millions chf roche option plan exercise chugai plan exercise roche connect cost transaction equity total cash inflow outflow equitysettle equity compensation plan net transaction equity net cash outflow transaction equity mainly arise sale purchase equity instrument hold group potential conversion obligation arise group equity compensation plan note equity compensation plan roche stocksettle stock appreciation right group issue stocksettle stock appreciation right ssar certain director management employee select discretion group ssar employee right receive nonvoting equity security reflect value appreciation market price nonvoting equity security grant date exercise date roche ssar plan million ssar available issuance tenyear period start right nontradable equitysettle award tenyear duration vest phase basis year right grant sevenyear duration vest phase basis yearsfinance report note roche group consolidate financial statement roche group roche ssar movement number right outstanding weighted average weight average number right exercise price number right exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable roche ssar term right outstanding december right outstanding right exercisable weighted average weighted average weight average number outstanding year remain exercise price number exercisable exercise price year grant thousand c ontractual life chf thousand chf total roche restrict stock unit plan group issue restrict stock unit rsus award certain director management employee select discretion group rsus nontradable represent right receive nonvoting equity security rsus vest phase basis year subject performance condition rsus grant vest threeyear period currently performance condition outstanding rsus december roche rsu plan million nonvoting equity security available issuance tenyear period start roche rsu plan include value adjustment equivalent sum shareholder distribution group vest period attributable number nonvoting equity security individual award grant roche rsus movement number awards outstanding number award number award thousand thousand outstanding january grant forfeit transfer participant outstanding december vest transferable roche group note roche group consolidated financial statement finance report roche performance share plan group offer future share nonvoting equity security awards discretion board director cash equivalent certain director key senior manager nontradable equitysettle award programme remain annual threeyear cycle roche performance share plan psp include value adjustment equivalent sum shareholder distribution group vest period attributable number share nonvoting equity security individual award grant share nonvoting equity security allocate depend individual salary level achievement performance target link group total shareholder return share nonvoting equity security combine relative group peer threeyear period date grant discretion board director award grant result zero share nonvoting equity security value adjustment depend achievement performance target new psp award grant roche performance share plan term outstanding award december number award outstanding thousand vest period year allocate recipient feb fair value unit grant chf total fair value grant chf million roche connect programme enable employee worldwide certain country regular deduction salary purchase nonvoting equity security administer independent party group contribute programme allow employee purchase nonvoting equity security discount usually administrator purchase necessary nonvoting equity security directly market december administrator hold million nonvoting equity security million cost plan chf million chf million roche option plan programme country ssar award plan employee right purchase nonvoting equity security exercise price specify grant date option nontradable equitysettle award tenyear duration vest phase basis year option grant sevenyear duration vest phase basis year roche option plan movement number option outstanding weight average weight average number option exercise price number option exercise price thousand chf thousand chf outstanding january grant forfeit exercise expired outstanding december exercisable finance report note roche group consolidate financial statement roche group roche option plan term option outstanding december option outstanding option exercisable weighted average weighted average weight average number outstanding year remain exercise price number exercisable exercise price year grant thousand c ontractual life chf thousand chf total weighted average share price roche nonvoting equity securities year chf chf bonus stock awards chairman board directors chief executive officer grant bonus stock award lieu cashsettle bonus financial year subject approval annual general meeting march issue march number award fair value award calculate grant date fair value measurement input measurement fair value grant date equity compensation plan follow fair value measurement roche roche stocksettle stock restrict stock roche appreciation right unit plan option plan progressively progressively progressively vest period year year year contractual life year na year number grant year thousand weight average fair value chf model binomial market pricea binomial input option pricing model share price grant date chf exercise price chf expect volatility b na expect dividend yield na early exercise factor c na expect exit rate na fair value roche rsus equivalent share price date grant b volatility determine primarily reference historically observe price underlie equity riskfree interest rate derive zero coupon swap rate grant date take datastream c early exercise factor describe ratio expect market price exercise date exercise price early exercise expect base historically observe behaviour roche group note roche group consolidated financial statement finance report lease implementation ifrs lease effective january group implement ifrs lease ifrs replace exist lease guidance include ias lease set principle recognition measurement lease main effect group lessee ifrs introduce single onbalance sheet lease accounting model require lessee recognise asset liability leases lease liability reflect present value remain lease payment rightofuse asset correspond lease liability adjust payment lease commencement date lease incentive item relate lease agreement result rightofuse asset total chf million lease liability total chf million record balance sheet effective january transition impact balance sheet show table transition impact ifrs roche group consolidate balance sheet select item millions chf originally publish application revise december ifrs january property plant equipment rightofuse asset current asset longterm debt noncurrent provision noncurrent liability shortterm debt current provision current liability total net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity weight average incremental borrowing rate apply lease liability recognise transition operating lease commitment finance lease liability report annual financial statement apply previous leasing standard ias reconcile lease liability recognise transition ifrs show table reconciliation lease liability recognise transition january millions chf operating lease commitment undiscounte report december apply ias finance lease liability report december apply ias recognition exemption shortterm lease lease lowvalue asset lease arrangement commencement date december discount lease liability recognise transition january apply ifrs thereof noncurrent liability current liability total group lessor application new standard material effectsfinance report note roche group consolidate financial statement roche group transition approach use practical expedient group apply cumulative catchup method transition cumulative effect adopt ifrs recognise adjustment opening balance retain earning january restatement comparative information rightofuse asset generally measure equal lease liability adjust payment lease commencement date lease incentive item relate lease agreement recognise balance sheet immediately date initial application rightofuse asset measure carrying ifrs apply lease commencement date discount group incremental borrowing rate january practical expedient permit standard notably reassess transition existing contract contain lease definition lease ifrs apply contract enter change january recognition exemption shortterm lease lease lowvalue asset motor vehicle separate nonlease component instead account lease nonlease component single lease component apply ias onerous lease instead perform impairment review group lessee group enter lease transaction lessee mainly reason convenience flexibility group good cash generation ability enjoy strong longterm investment grade credit rating typically enter leasing arrangement finance consideration main area lease group enter property office apartment small number lease represent value car sale representative office equipment photocopier similar roche group note roche group consolidated financial statement finance report rightofuse asset report group lease show table rightofuse asset movement carry value asset millions chf building land improve machinery land ment equipment total year end december january cumulative catchup previously report operating lease implementation ifrs reclassification property plant equipment previously report finance lease implementation ifrs january revise business combination addition disposal depreciation impairment reversal charge currency translation effect december cost accumulate depreciation impairment net book value year end december january business combination asset acquisition addition disposal depreciation impairment reversal charge currency translation effect december cost accumulate depreciation impairment net book value classification impairment reversal charge rightofuse asset millions chf cost sale marketing distribution research development general administration total impairment reversal charge impairment charge rightofuse asset mainly relate global restructuring plan note income chf million recognise related impairment reversal rightofuse asset lease arrangement assess onerous contract finance report note roche group consolidate financial statement roche group liability report group lease show table lease movement carry value recognise liability millions chf january cumulative catchup previously report operating lease implementation ifrs na reclassification debt previously report finance lease obligation implementation ifrs na january revise increase new lease arrangement repayment lease liability business combination asset acquisition disposal interest expense lease liability currency translation effect december noncurrent lease liability current lease liability total lease liability maturity analysis lease liability give note liquidity risk section shortterm lease lease lowvalue asset account recognition exemption permit ifrs expense shortterm lease recognise straightline basis mainly include shortterm property lease employee apartment report chf million chf million expense lease lowvalue asset recognise straightline basis mainly include certain office equipment report chf million chf million expense variable lease payment include measurement lease liability chf million chf million income subleasing rightofuse asset chf million chf million group enter sale leaseback transaction major cash flow respect lease group lessee show table lease cash flow millions chf include cash flow operating activity include cash flow financing activity total lease payment cash flow operating activity include cash flow shortterm lease lease lowvalue asset variable lease payment cash flow financing activity include payment interest principal portion lease liability prepayment lease commencement date lease commit commence july foundation medicine inc fmi enter bind lease agreement party lease laboratory office space building boston construct landlord location currently know boston seaport accord agreement fmi commit lease building year commencement date lease currently expect second half initial rightofuse asset lease liability relate agreement estimate approximately usd million base current assumption roche group note roche group consolidated financial statement finance report group lessor diagnostic division group enter certain contract include placement diagnostic instrument supply reagent consumable service arrangement depend term agreement instrument placement result finance lease operating lease group perform thorough customer assessment new leasing agreement sign usually group retain right terminate modify contract certain condition meet finance lease certain asset mainly diagnostic instrument lease party finance lease arrangement asset report receivables equal net investment lease income finance lease recognise revenue amount represent fair value instrument approximate present value minimum lease payment arrangement finance income finance lease arrangement long month defer subsequently recognise base pattern approximate use effective interest method record royalty operating income follow amount record income respect finance lease finance lease select item income million chf sell profit difference sale cost sale finance income net investment lease currently group income variable lease payment finance lease carry net investment finance lease report receivables chf million chf million finance lease future minimum lease receipt noncancellable lease millions chf present value minimum gross investment lease lease receipt year year year year year year total unearned finance income na na unguaranteed residual value na na net investment lease operating lease certain asset mainly diagnostic instrument lease party operate lease arrangement income operating lease recognise revenue straightline basis lease term lease revenue entirely base variable lease payment subject subsequent reagent sale performance obligation reagent satisfied lease income chf million chf million include sale chf million chf million relate variable lease payment depend index ratefinance report note roche group consolidate financial statement roche group lease asset report property plant equipment show table machinery equipment subject operating lease movement carry value asset millions chf lease use total lease use total january cost accumulate depreciation impairment net book value year end december january reclassification rightofuse asset implementation ifrs lease na na na january revise business combination asset acquisition addition disposal transfer depreciation charge impairment reversal charge currency translation effect december cost accumulate depreciation impairment net book value undiscounte amount expect receive noncancellable operating lease show table operating lease future minimum lease receipt noncancellable lease millions chf year year year year year year total minimum receipt roche group note roche group consolidated financial statement finance report earning share nonvoting equity security basic earning share nonvoting equity security net income attributable roche shareholder chf million number share million number nonvoting equity security millions weight average number share nonvoting equity security hold million weight average number share nonvoting equity security issue calculate basic earning share millions basic earning share nonvoting equity security chf dilute earning share nonvoting equity security net income attributable roche shareholder chf million increase noncontrolle interest share group net income assume outstanding chugai stock option exercise chf million net income calculate diluted earning share chf million weight average number share nonvoting equity security issue million adjustment assume exercise equity compensation plan dilutive million weight average number share nonvoting equity security issue calculate diluted earning share millions diluted earning share nonvoting equity security chf finance report note roche group consolidate financial statement roche group statement cash flow cash flow operating activity cash flow operating activity arise group primary activity pharmaceutical diagnostic division calculate indirect method adjust group operate profit operating income expense cash flow example depreciation amortisation impairment order derive cash generate operation operate cash flow show statement cash flow operate cash flow include income taxis pay activity cash generate operation million chf net income add nonoperate income expense financing cost financial income expense income taxis operate profit depreciation property plant equipment depreciation rightofuse asset amortisation intangible asset impairment goodwill impairment intangible asset impairment reversal property plant equipment impairment reversal rightofuse asset operating income expense define benefit plan operate expense equitysettle equity compensation plan net income expense provision bad debt reversal expense inventory writedown net gain loss disposal product adjustment cash generate operation cash flow invest activity cash flow invest activity principally arise group investment property plant equipment intangible asset acquisition divestment subsidiary associate business cash flow connected group portfolio marketable security investment include interest dividend payment receive respect security investment cash flow indicate group net reinvestment operate asset cash flow effect business combination divestment cash generate group investment interest dividend receive millions chf interest receive dividend receive total roche group note roche group consolidated financial statement finance report cash flow financing activity cash flow financing activity primarily proceed issue repayment group equity debt instrument include interest payment dividend payment instrument cash flow shortterm financing include cash flow indicate group transaction provider equity debt financing cash flow lease payment include financing activity cash flow shortterm borrowing show net movement consist large number transaction short maturity dividend pay millions chf dividend roche group shareholder dividend noncontrolle shareholder chugai noncontrolle interest dividend withholding tax total liability arise financing activity movement carry value recognise asset liability millions chf cash principal derivative collateral p ortion financial receivables interest lease nstrument payable debt p ayable l iabilitie net net total year end december january cash flow outflow inflow noncash change finance cost business combination fair value foreign exchange rate december year end december january cash flow outflow inflow noncash change finance cost business combination asset acquisition fair value foreign exchange rate december significant noncash transaction significant noncash transaction leasing transaction group lessee note finance report note roche group consolidate financial statement roche group risk management group risk management risk management fundamental element group business practice level encompass different type risk group level risk management integral longterm forecasting controlling process material risk monitor regularly discuss corporate executive committee audit committee board director financial risk management group expose financial risk arise underlie operation corporate finance activity group financial risk exposure predominantly relate change foreign exchange rate interest rate equity price creditworthiness solvency group counterpartie financial risk management group govern policy review board director roche chugai appropriate area statutory responsibility policy cover credit risk liquidity risk market risk policy provide guidance risk limit type authorise financial instrument monitor procedure general principle policy prohibit use derivative financial instrument speculative trading purpose policy implementation daytoday risk management carry relevant treasury function regular reporting risk perform relevant accounting controlling function roche chugai credit risk credit risk arise possibility counterpartie transaction default obligation cause financial loss group objective manage counterparty credit risk prevent loss liquid fund deposit invest counterpartie maximum exposure credit risk result financial activity consider net agreement take account collateral hold credit enhancement equal carrying value group financial asset group consider financial asset default counterparty unlikely pay obligation group assess counterparty default group consider qualitative quantitative indicator eg overdue status base datum develop internally certain financial asset obtain external source major group receivables past day relate public customer risk default public customer consider low group reasonable supportable information demonstrate lag default criterion appropriate particular customer segment account receivable december group trade receivables chf billion chf billion subject policy active credit risk management focus assessment country risk credit availability ongoing credit evaluation account monitor procedure objective trade receivables management maximise collection unpaid amount group use allowance matrix estimate allowance doubtful account trade receivable expect credit loss ecl rate base group historical experience group expectation economic condition period receivables expect pay roche group note roche group consolidated financial statement finance report customer credit risk exposure base account receivable day overdue millions chf overdue overdue overdue credit total current month month year impair december gross carrying group expect credit loss rate allowance doubtful account december gross carrying group expect credit loss rate allowance doubtful account december group combine trade receivable balance national wholesale distributor mckesson corp amerisourcebergen corp cardinal health inc equivalent chf billion represent group consolidated trade receivables chf billion represent significant concentration counterparty credit risk group large number customer wide geographical spread risk limit exposure continuously monitor country nature counterpartie group obtain credit insurance similar enhancement appropriate protect collection trade receivables december collateral consider measure expect credit loss trade receivable financial difficulty southern european country notably spain italy greece portugal group lead supplier healthcare sector country trade receivable chf billion chf billion public private customer country group use different measure improve collection country include intense communication customer factor negotiation payment plan charge interest late payment legal action nature geographic location counterpartie account receivable overdue impair show table include balance national wholesalers southern europe public customer describe account receivable overdue net allowance doubtful account allowance nature geographical location counterpartie millions chf saler saler region total public distributor private total public distributor private switzerland europe north america latin america japan asia australia oceania rest world total finance report note roche group consolidate financial statement roche group cash marketable security exclude equity security december group cash marketable security exclude equity security chf billion chf billion subject policy restricting exposure highquality counterpartie set define limit individual counterpartie limit counterparty credit rating review regularly cash cash equivalent hold bank financial institution predominantly rate investment grade base moodys standard poor rating cash shortterm time deposit subject rule limit group exposure individual financial institution impairment cash cash equivalent measure month expect credit loss ecl basis reference external credit rating counterpartie reflect short maturity exposure group consider cash cash equivalent low credit risk base external credit rating investment marketable security exclude equity security enter basis guideline regard liquidity quality maximum general rule group invest highquality security adequate liquidity counterpartie credit rating baa moodys bbb standard poor credit risk counterpartie external rating investment grade rating closely monitor review individual basis rating analysis cash marketable security exclude equity security market value millions chf fair value fair value oci amortise cost oci amortise cost total month ecl month ecl total month ecl month ecl aaa range aa range range bbb range total investment grade bbb range investment grade unrated total gross carrying amount loss allowance loss allowance relate fair value oci affect carry marketable security exclude equity security book correspond oci reserve instead debt security amortise cost fair value oci investment grade consider low risk impairment allowance determine month expect credit loss ecl reference external credit rating counterpartie debt security group observe significant increase credit risk require application lifetime expect credit loss impairment model addition material movement loss allowance respectively master netting agreement group enter derivative transaction collateral agreement international swap derivative association isda master netting agreement respective counterpartie order mitigate counterparty risk agreement amount owe counterparty single day respect transaction outstanding currency aggregate single net payable party isda agreement meet criterion offset balance sheet group currently enforceable right offset recognise amount right offset enforceable occurrence future event default credit event contract term december significant financial asset term renegotiate impairment losse financial asset exclude equity investmentssecuritie impairment loss roche group note roche group consolidated financial statement finance report liquidity risk liquidity risk arise surplus financial obligation available financial asset point time group approach liquidity risk maintain sufficient readily available reserve order meet liquidity requirement point time roche chugai enjoy strong credit quality rate major credit rating agency rating permit efficient access international capital market event major financing requirement december group unused committed credit line financial institution total chf billion chf billion chf billion chf billion serve backstop line commercial paper program july previously exist committed credit line refinance new committed credit line initial maturity year remain undiscounted cash flow contractual maturity financial liability include estimate interest payment show table contractual maturity financial liability millions chf carrying value total year year year year december debt bond note debt contingent consideration account payable noncurrent liability lease liability current liability lease liability derivative financial instrument total financial liability december debt bond note debt contingent consideration account payable noncurrent liability lease liability current liability lease liability derivative financial instrument total financial liability takeorpay commitments group enter contract manufacturing agreement company develop manufacturing capacity flexibility mainly pharmaceutical division future minimum takeorpay commitment agreement total potential commitment group chf billion december chf billion market risk market risk arise change market price mainly foreign exchange rate interest rate group financial asset financial liability affect group financial result equityfinance report note roche group consolidate financial statement roche group valueatrisk group use valueatrisk var measure impact market risk financial instrument var indicate value range give financial instrument fluctuate preset probability result movement market price var calculate historical simulation approach scenario financial instrument fully value total change value earning determine var calculation base confidence level hold period trading day past year hold period reflect time require change correspond risk exposure deem appropriate actual future gain loss associate treasury activity differ materially var analysis inherent limitation associate predict timing change interest rate foreign exchange rate equity investment price particularly period high market volatility furthermore var include effect change credit spread market risk financial instrument millions chf var interest rate component var foreign exchange component var price component diversification var total market risk interest rate component decrease reduction underlie interest rate major currency foreign exchange component decrease favourable exposure mix price component increase mainly high price equity investment equity securities foreign exchange risk group use swiss franc report currency result expose movement foreign currency mainly dollar japanese yen euro group foreign exchange risk management strategy preserve economic value current future asset minimise volatility group financial result primary focus group foreign exchange risk management activity hedge transaction exposure arise foreign currency flow monetary position hold foreign currency group use forward contract foreign exchange option crosscurrency swap hedge transaction exposure application instrument intends continuously immunise unfavourable development foreign exchange rate interest rate risk group mainly raise debt fix rate basis bond note group expose movement interest rate mainly dollar swiss franc euro float rate financial instrument shortterm debt group interest rate risk management strategy optimise net interest result group use forward contract option interest rate swap hedge interest rate exposure depend interest rate environment major currency group use instrument generate appropriate mix fix float rate exposure price risk price risk arise mainly movement price equity security group manage price risk place limit individual total equity investment limit define percentage total liquid fund absolute number individual equity investment capital management group define capital manage group total capitalisation sum debt plus equity include noncontrolle interest group objective manage capital safeguard group ability continue go concern continue provide benefit patient return investor provide adequate return investor base level risk undertake available necessary financial resource allow group invest area deliver future benefit patient return investor maintain sufficient financial resource mitigate risk unforeseen event roche group note roche group consolidated financial statement finance report capitalisation report senior management group regular internal management reporting show table capital millions chf capital reserve attributable roche shareholder equity attributable noncontrolle interest total equity total debt capitalisation group net equity significantly impact genentech transaction note group subject regulatory capital adequacy requirement know financial service industry group majority shareholding chugai note chugai public company objective policy process manage capital determine chugai management financial instrument accounting classification fair value fair value financial asset liability carry value show consolidated balance sheet follow carry value fair value financial instrument millions chf financial instrument mandatorily financial financial fair value instrument fair value asset total profit fair value hedging amortise financial carrying loss oci instrument cost l iabilitie value fair value december noncurrent asset equity investment financial noncurrent asset account receivable marketable security equity security debt security money market instrument time account month cash cash equivalent current asset derivative financial instrument financial current asset total financial asset debt bond note debt contingent consideration account payable noncurrent liability current liability total financial liability finance report note roche group consolidate financial statement roche group carry value fair value financial instrument millions chf financial instrument mandatorily financial financial fair value instrument fair value asset total profit fair value hedging amortise financial carrying loss oci instrument cost l iabilitie value fair value december noncurrent asset equity investment financial noncurrent asset account receivable marketable security equity security debt security money market instrument time account month cash cash equivalent current asset derivative financial instrument financial current asset total financial asset debt bond note debt contingent consideration account payable noncurrent liability current liability total financial liability fair value bond note level calculate base observable market price debt instrument present value future cash flow instrument discount market rate interest instrument similar credit status cash flow maturity period roche group note roche group consolidated financial statement finance report fair value hierarchy table analyse financial instrument carry fair value valuation method different level define follow level quote price unadjuste active market identical asset liability level observable input quote price active market identical asset liability level unobservable input fair value hierarchy financial instrument millions chf level level level total december marketable security equity security fair value profit loss debt security fair value oci money market instrument fair value oci derivative financial instrument equity investment fair value oci equity investment fair value profit loss financial asset recognise fair value derivative financial instrument contingent consideration financial liability recognise fair value december marketable security equity security fair value profit loss debt security fair value oci money market instrument fair value oci derivative financial instrument equity investment fair value oci equity investment fair value profit loss financial asset recognise fair value derivative financial instrument contingent consideration financial liability recognise fair value level financial asset consist treasury bill bond quote share level financial asset consist primarily commercial paper certificate deposit derivative financial instrument group determine level fair value follow valuation technique marketable security derivative financial instrument base valuation model use observable market datum interest rate yield curve foreign exchange rate imply volatility similar instrument measurement date equity investment fair value oci fair value profit loss base valuation model use recently publish observable market datum group recognise transfer level fair value hierarchy end report period transfer occur significant transfer level level vice versa year nonefinance report note roche group consolidate financial statement roche group level fair value detail determination level fair value measurement set contingent consideration arrangement millions chf january arise business combination utilise settlement total gain loss include income statement unused amount reverse record general administration additional create record general administration discount unwind include financing cost total gain loss include comprehensive income currency translation effect december contingent consideration arrangement group party certain contingent consideration arrangement include business combination fair value contingent consideration business combination determine consider expect payment discount present value riskadjusted average discount rate expect payment determine consider possible scenario forecast sale performance criterion pay scenario probability scenario significant unobservable input forecast sale performance criterion riskadjuste discount rate estimate fair value increase forecast sale performance criterion rate higher riskadjuste discount rate low december total potential payment contingent consideration arrangement arise business combination chf billion chf billion follow potential payment contingent consideration arrangement millions chf acquisition year acquire operating segment dutalys roche pharmaceutical santaris roche pharmaceutical genia diagnostic diagnostic december roche group note roche group consolidated financial statement finance report derivative financial instrument group enter currency swap certain nonus dollar debt instrument cash collateral agreement enter counterpartie currency swap mitigate counterparty risk follow table set carry value derivative financial instrument amount subject master netting agreement derivative financial instrument millions chf asset liability foreign currency derivative forward exchange contract crosscurrency swap interest rate derivative swap derivative carry value derivative financial instrument derivative subject master netting agreement collateral arrangement net collateral arrangement movements cash collateral receivable accrue liability millions chf january net cash deliver group fair value currency translation effect december hedge accounting describe group risk management strategy hedge transaction exposure arise foreign currency flow monetary position hold foreign currency generate appropriate mix fix float rate exposure level hedging depend market condition business requirement group group designate specific interest rate risk management objective ensure predetermine level interest rate risk exposure float rate hedge effectiveness determined inception hedge relationship periodic prospective effectiveness assessment report date ensure economic relationship exist hedge item hedging instrument group perform qualitative assessment hedge effectiveness critical term match method critical term hedge item hedge instrument match group conclude risk hedge hedged item hedge instrument sufficiently align inherent mismatch hedge relationship hedge ratio apply actual quantity hedge hedge accountingfinance report note roche group consolidate financial statement roche group accounting treatment source ineffectiveness prospective effectiveness assessment method risk category prospective effectiveness accounting treatment potential source ineffectiveness assessment method interest rate foreign exchange rate fluctuation cash flow hedge counterparty credit risk critical term match foreign exchange rate fluctuation cash flow hedge low volume hedge item critical term match counterparty credit risk interest rate fluctuation fair value hedge counterparty credit risk critical term match ineffective portion hedge accounting recognise income statement include financial income expense measure hypothetical derivative method cash flow hedge cumulative dollar offset method fair value hedge december december respectively potential source ineffectiveness individually collectively result material amount actual ineffectiveness report hedge accounting relationship table show fair value nominal amount derivative financial instrument include range maturity nominal hedge instrument designate hedge instrument cash flow hedge fair value hedge december respectively group follow cash flow hedge fair value hedge designate qualifying hedge relationship fair value nominal amount derivative hedge accounting december fair value asset fair value liability nominal million chf million chf maturity range cash flow hedge risk hedge interest rate foreign exchange rate fluctuation crosscurrency swap eur million fix usd risk hedge foreign exchange rate fluctuation forward exchange contract jpy billion total fair value hedge risk hedge interest rate fluctuation interest rate swap usd million interest rate swap eur million interest rate swap chf million total fair value nominal amount derivative hedge accounting december fair value asset fair value liability nominal million chf million chf maturity range cash flow hedge risk hedge interest rate foreign exchange rate fluctuation crosscurrency swap eur million fix usd risk hedge foreign exchange rate fluctuation forward exchange contract jpy billion total fair value hedge risk hedge interest rate fluctuation interest rate swap usd million interest rate swap eur million interest rate swap chf million total roche group note roche group consolidated financial statement finance report fair value derivative financial instrument hedge accounting include current asset note current liability note group approach manage market risk include interest rate risk foreign currency risk discuss market risk section note cash flow hedge group enter crosscurrency swap hedge foreign exchange interest rate risk bond note issue group denominate euro december instrument record net fair value liability chf million net fair value liability chf million ineffective portion chugai enter forward exchange contract hedge foreign translation exposure swiss franc dollar december instrument record fair value asset chf million fair value liability chf million fair value asset chf million fair value liability chf million ineffective portion hedge instrument currently hold apply hedge accounting affect interbank offer rate ibor reform carrying item designate hedge item cash flow hedging relationship million chf asset liability asset liability december bond note risk hedge crosscurrency swap interest rate foreign exchange rate fluctuation bond note inventory risk hedge forward exchange contract foreign exchange rate fluctuation inventory hedge reserve continue hedge relationship millions chf forward cross forward crosscur exchange currency exchange total rency swap contract total swap contract january gain loss take equity transfer income statement income taxis noncontrolle interest currency translation effect december entire transfer income statement report financial income expense hedging relationship hedge accounting long apply change hedge reserve equity show note finance report note roche group consolidate financial statement roche group expect undiscounted cash flow qualify cash flow hedge include interest payment duration derivative contract final settlement maturity show table expect cash flow qualify cash flow hedge millions chf total year year total year year cash inflow cash outflow total cash inflow outflow undiscounte cash flow table affect profit loss show include interest payment duration derivative contract include final settlement maturity expect cash flow qualify cash flow hedge impact profit loss million chf total year year total year year cash inflow cash outflow total cash inflow outflow fair value hedge group enter interest rate swap hedge exposure change fair value fixedterm debt instrument respect benchmark interest rate december instrument record fair value asset chf million fair value asset chf million fair value adjustment chf million record interest rate swap chf million interest rate swap currently hold apply hedge accounting reference benchmark rate london interbank offer rate libor hedge instrument hedging portion eur million note march fair value hedge highly effective inception result interest rate swap largely offset change fair value hedge debt instrument group approach manage market risk include interest rate risk discuss market risk section note carry item designate hedge item fair value hedge relationship million chf fair value fair value adjustment adjustment liability cumulative current year december bond note risk hedged interest rate swap interest rate fluctuation bond note december bond note risk hedged interest rate swap interest rate fluctuation bond note december group resolve exercise option early redemption fix rate note principal usd billion par month schedule date march note result termination fair value hedge accounting apply interest rate swap nominal value usd million fair value chf million date termination net investment hedge group net investment hedge roche group note roche group consolidated financial statement finance report relate party control shareholder share capital roche holding ltd group parent company consist bearer share december base information supply group shareholder group pool voting right own share represent issue share december shareholder group announce continue shareholder pool agreement modify shareholder composition group consist mr andr hoffmann ms marieanne hoffmann ms vera michalski mr alexander hoffmann mr frederic hoffmann ms isabel hoffmann mr lucas hoffmann ms marina hoffmann ms kasia barbotinlarrieu ms tatiana fabre mr andreas oeri ms catherine oeri ms sabine duschmal mr jrg duschmal mr lukas duschmal charitable foundation wolf artuma holding ltd shareholder pooling agreement exist duration pool extend indefinite period figure include share pooled voting right hold outside group individual member group ms maja oeri member pool hold share represent voting right independently pool mr andr hoffmann dr jrg duschmal member board director roche holding ltd dr andreas oeri previously member board director roche holding ltd stand reelection annual general meeting mr hoffmann receive remuneration totalling chf chf dr duschmal receive remuneration totalling chf nil dr oeri receive remuneration totalling chf chf transaction group individual member shareholder group subsidiary associate list group subsidiary associate include note list exclude chugais subsidiary company material notably company inactive dormant liquidation transaction parent company subsidiary subsidiary eliminate consolidation significant transaction group associatesfinance report note roche group consolidate financial statement roche group key management personnel total remuneration key management personnel chf million chf million member board director roche holding ltd receive annual remuneration payment time expense relate membership board committee chairman board director member corporate executive committee cec roche holding ltd receive remuneration consist annual salary bonus expense allowance group pay social insurance contribution respect remuneration pay contribution pension postemployment benefit plan chairman board director member cec members cec participate certain equity compensation plan describe term vest condition fair value award disclose note new member cec include table calendar year join cec similarly member cec retire partway year include calendar year leave cec remuneration member board director corporate executive committee millions chf salary include cashsettle bonus bonus stock award social security cost pension postemployment benefit equity compensation plans board fee employee benefit total purpose remuneration disclosure value equity compensation plan include bonus stock award calculate base fair value note represent cost group award grant date reflect matter observe exercise behaviour exit rate population receive award initial simulation performance condition detailed disclosure executive remuneration require swiss law include remuneration report disclose annual report page disclosure value equity compensation plan include bonus stock award represent fair value employee receive take account preliminary assessment complete performance condition fair value show table reconcile disclosure require swiss law relate party disclosure key management personnel reconciliation executive remuneration disclosure require swiss law millions chf total remuneration member board director corporate executive committee ifrs basis table deduct bonus stock award ifrs basis equity compensation plan ifrs basis add bonus stock award swiss legal basis equity compensation plan swiss legal basis total remuneration member board director corporate executive committee swiss legal basis include social security cost board director annual report corporate executive committee annual report roche group note roche group consolidated financial statement finance report bonus stock awards chairman board directors chief executive officer grant bonus stock award lieu cashsettle bonus financial year subject approval annual general meeting march issue march number award fair value award calculate grant date equity compensation plan member corporate executive committee receive equity compensation show follow table number right option award grant member corporate executive committee roche stocksettle stock appreciation right roche restrict stock unit plan contribution pay member corporate executive committee millions chf roche connect define benefit plan transaction group define benefit plan employee group describe note finance report note roche group consolidate financial statement roche group list subsidiary associate follow list group subsidiary associate excludes chugais subsidiary company material notably company inactive dormant liquidation list company share capital equity interest location company city millions switzerland roche holding ltd basel chf stock exchange swiss exchange zurich stock code share ro valor stock code genussschein rog valor isin share ch isin genussschein ch market capitalisation chf million japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo stock code tse isin jp market capitalisation jpy million nonliste company share capital equity interest location company city millions algeria roche algrie spa hydra dzd argentina productos roche sa qumica e industrial tigre ar roche diabetes care argentina sa tigre ar australia roche diabetes care australia pty limited north ryde aud roche diagnostic australia pty limited north ryde aud roche product pty limited sydney aud austria mysugr gmbh vienna eur roche austria gmbh vienna eur roche diabetes care austria gmbh vienna eur roche diagnostic gmbh vienna eur bangladesh roche bangladesh limited dhaka bdt belarus fllc roche product limit minsk usd belgium nv roche sa brussels eur roche diagnostic belgium nv diegem eur bermuda chemical manufacturing trading company limited hamilton usd hoffmannla roche product limit hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd sapac corporation ltd hamilton cad bolivia roche bolivia srl santa cruz bob bosnia herzegovina roche doo farmaceutsko drustvo roche ltd pharmaceutical company sarajevo bam brazil produto roche qumico e farmacuticos sa paulo brl roche diabete care brasil ltda paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn cameroon roche cameroun sarl douala xaf canada hoffmannla roche limited mississauga cad chile roche chile limitada santiago de chile clp roche group note roche group consolidated financial statement finance report share capital equity interest location company city millions china roche china holding ltd shanghai usd roche shanghai pharmaceuticals consulting co ltd shanghai cny roche shanghai pharmaceuticals trading co ltd shanghai usd roche diagnostic hong kong limited hong kong hkd roche diagnostic shanghai ltd shanghai usd roche diagnostic suzhou limited suzhou usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia producto roche sa bogot cop costa rica roche services america sociedad de responsabilidad limitada san jose crc roche servicios sa heredia usd cte roche cte sarl abidjan xof croatia roche doo zagreb hrk czech republic roche sro prague czk denmark obi aps hadsund dkk roche medicinalvarer og kemikalier hvidovre dkk roche diagnostic hvidovre dkk roche innovation center copenhagen hoersholm dkk dominican republic producto roche dominicana srl santo domingo dop ecuador roche ecuador sa quito usd egypt roche diagnostic egypt trading sae giza egp roche egypt manufacturing trading sae cairo egp roche egypt llc cairo egp el salvador productos roche el salvador sa de cv antiguo cuscatlan svc estonia roche eesti tallinn eur finland roche diagnostic oy espoo eur roche oy espoo eur france institut roche sas boulognebillancourt eur roche diabetes care france sas meylan eur roche diagnostic france sas meylan eur roche sas boulognebillancourt eur timkl sas montbonnotsaintmartin eur trophos sa marseille eur georgia roche georgia llc tbilisi gel germany ascur versicherungsvermittlung gmbh grenzachwyhlen eur foundation medicine gmbh penzberg eur galenus mannheim pharma gmbh mannheim eur roche beteiligung gmbh grenzachwyhlen eur roche deutschland hold gmbh grenzachwyhlen eur roche diabete care deutschland gmbh mannheim eur roche diabetes care gmbh mannheim eur roche diagnostic automation solution gmbh ludwigsburg eur roche diagnostic deutschland gmbh mannheim eur roche diagnostic gmbh mannheim eur roche mtm laboratories ag mannheim eur roche pharma ag grenzachwyhlen eur roche privacy gmbh grenzachwyhlen eur roche real estate service mannheim gmbh mannheim eur roche registration gmbh grenzachwyhlen eur rox health gmbh berlin eur signature diagnostic gmbh potsdam eur ghana roche product ghana limit accra ghs greece roche hellas sa marousi eur roche diagnostic hellas sa marousi eur guatemala producto roche guatemala sociedad annima guatemala gtq honduras producto roche honduras sa tegucigalpa hnl hungary roche hungary ltd budaor huf roche services europe ltd budapest huf india roche diabetes care india private limited mumbai inr roche diagnostic india private limited mumbai inr roche product india private limited mumbai inr viewics india private limit pune inr finance report note roche group consolidate financial statement roche group share capital equity interest location company city million indonesia pt roche indonesia jakarta idr iran roche par co ltd tehran irr ireland inflazome limited dublin eur roche ireland limited clarecastle eur roche products ireland limited dublin eur spark therapeutics ireland limited dublin eur israel medingo ltd yoqneam illit il roche pharmaceutical israel ltd hod hasharon il italy roche diabetes care italy spa monza eur roche diagnostic spa monza eur roche spa monza eur japan roche dc japan k k tokyo jpy roche diagnostic kk tokyo jpy jordan f hoffmannla roche ltd jordan psc amman jod kazakhstan roche kazakhstan llp almaty kzt kenya roche kenya limited nairobi kes kuwait roche trading medicine equipment device medical supply spc salmiya kwd latvia roche latvija sia riga eur lebanon roche lebanon sarl beirut lbp lithuania uab roche lietuva vilnius eur malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostic malaysia sdn bhd petale jaya myr roche services asia pacific sdn bhd kuala lumpur myr mauritius roche products mauritius ltd moka mur mexico producto roche sa de cv mexico city mxn roche dc mxico sa de cv mexico city mxn morocco roche sa casablanca mad myanmar roche myanmar company limited yangon usd netherland roche diabete care nederland bv almere eur roche diagnostic nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholde bv woerden eur new zealand roche diagnostic nz limited mount wellington nzd roche product new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio nigeria roche product limited lagos ngn north macedonia roche makedonija dooel skopje eur norway roche diagnostic norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr panama productos roche panama sa panama city pab producto roche interamericana sa prisa panama city usd peru producto roche qumica farmacutica sa lima pen roche farma peru sa lima pen philippine roche philippines inc taguig city php poland roche diabetes care polska sp z oo warsaw pln roche diagnostic polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda amadora eur puerto rico genentech pr inc san juan usd roche products inc ponce usd syntex puerto rico inc ponce usd romania roche romania srl bucharest ron russian federation rochemoscow jsc moscow rub limited liability company roche diabetes care rus moscow rub limited liability company roche diagnostic rus moscow rub saudi arabia roche diagnostic saudi arabia llc riyadh sar roche product saudi arabia llc jeddah sar serbia roche doo beograd belgrade eur roche group note roche group consolidated financial statement finance report share capital equity interest location company city millions singapore roche diabetes care asia pacific pte ltd singapore sgd roche diagnostic asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche farmacevtska druba doo ljubljana eur south africa kapa biosystem pty ltd cape town zar roche diabetes care south africa proprietary limited midrand zar roche diagnostic proprietary limited midrand zar roche product proprietary limited illovo zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain roche diabetes care spain sl sant cugat del valls eur roche diagnostic sl sant cugat del valls eur roche farma sa madrid eur sweden roche ab solna sek roche diagnostic scandinavia ab solna sek switzerland biopharm ag basel chf f hoffmannla roche ltd basel chf hoffmann la roche ltd basel chf intermune international ag basel chf museum tinguely ag basel chf phaor ag basel chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche chemische unternehmungen ag basel chf roche diabete care switzerland ltd rotkreuz chf roche diagnostic switzerland ltd rotkreuz chf roche diagnostic international ltd rotkreuz chf roche finance ltd basel chf roche forum buonas ltd buonas chf roche glycart ltd schlieren chf roche long term foundation basel chf roche pharma switzerland ltd basel chf syntex pharm ag rotkreuz chf tavero ag basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostic thailand limited bangkok thb roche thailand limited bangkok thb tunisia roche tunisie sa tunis tnd turkey infogenetik molekler bilgi hizmetleri anonim irketi istanbul try roche diagnostic turkey anonim irketi istanbul try roche mstahzarlari sanayi anonim irketi istanbul try ukraine roche ukraine llc kiev uah united arab emirate roche diabetes care middle east fzco dubai ae roche diagnostic middle east fzco dubai ae roche pharmaceutical middle east fzco dubai ae united kingdom flatiron health uk ltd st albans gbp intermune holding limit welwyn garden city gbp roche diabetes care limited burgess hill gbp roche diagnostic limited burgess hill gbp roche hold uk limited welwyn garden city gbp roche product limit welwyn garden city gbp roche registration limited welwyn garden city gbp spark therapeutic uk ltd london gbp tmema limited welwyn garden city gbp tusk therapeutics limit welwyn garden city gbp finance report note roche group consolidate financial statement roche group share capital equity interest location company city millions united states adheron therapeutics inc south san francisco usd anadys pharmaceuticals inc south san francisco usd ariosa diagnostics inc san jose usd bina technologies inc pleasanton usd bioveris corporation indianapoli usd flatiron health inc new york usd forsight vision inc south san francisco usd foundation medicine security corporation cambridge usd foundation medicine inc cambridge usd genentech usa inc south san francisco usd genentech inc south san francisco usd hoffmannla roche inc little fall usd survive corp south san francisco usd igen international inc pleasanton usd igen ls llc pleasanton usd ignyta inc south san francisco usd intermune inc south san francisco usd iquum inc marlborough usd jecure therapeutics inc south san francisco usd kapa biosystem inc wilmington usd lexent bio inc south san francisco usd memory pharmaceutical corp little falls usd promedior inc south san francisco usd roche diabetes care inc indianapoli usd roche diagnostic corporation indianapoli usd roche diagnostic hematology inc westborough usd roche diagnostic operation inc indianapoli usd roche diagnostic seattle inc seattle usd roche holdings inc south san francisco usd roche laboratory inc little fall usd roche molecular systems inc pleasanton usd roche palo alto llc south san francisco usd roche sequence solutions inc pleasanton usd roche tcrc inc little fall usd seragon pharmaceuticals inc south san francisco usd spark therapeutic international holdings inc philadelphia usd spark therapeutics inc philadelphia usd tanox inc south san francisco usd tensha therapeutics inc south san francisco usd therapeutic human polyclonals inc south san francisco usd ventana medical systems inc tucson usd viewics inc santa clara usd uruguay roche international ltd montevideo branch montevideo uyu venezuela producto roche sa caracas vef vietnam roche pharma vietnam company limited ho chi minh city vnd roche vietnam company limit ho chi minh city usd share capital local currency unit roche group note roche group consolidated financial statement finance report significant accounting policy consolidation policy subsidiary company group control group control entity group expose right variable return involvement entity ability affect return power entity company acquire year consolidated date control transfer group subsidiary divest include date control pass group intercompany balance transaction result unrealised income eliminate change ownership interest subsidiary account equity transaction occur control obtain result loss control associate company group exercise power exercise significant influence control account equity method segment report purpose segment report group corporate executive committee cec consider group chief operating decision maker determination group operate segment base organisation unit information report cec regular basis information provide basis segment revenue profit disclosure report note geographic analysis base location customer select segment balance sheet information routinely provide cec transfer price operate segment set arm length basis operate asset liability consist property plant equipment goodwill intangible asset trade receivablespayable inventory asset liability provision reasonably attribute report operating segment nonoperate asset liability mainly include current defer income tax balance postemployment benefit assetsliabilitie financial assetsliabilitie cash marketable security investment debt foreign currency translation annual financial statement present swiss franc group company use local currency functional currency certain group company use currency dollar swiss franc euro functional currency currency primary economic environment entity operate local transaction currency initially report exchange rate date transaction gain loss settlement transaction gain loss translation monetary asset liability denominate currency include income qualify cash flow hedge arise monetary item substance form group net investment foreign entity case gain loss defer comprehensive income consolidation asset liability group company functional currency swiss franc translate swiss franc yearend rate exchange income statement statement cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average yearend exchange rate take directly comprehensive income revenue sale revenue sale good supply product sale service render recode sale sale recognise promise customer contract performance obligation satisfied transferring control promise good service customer control promise good service refer ability direct use obtain substantially remain benefit good service control usually transfer shipment delivery receipt good customer service render accordance delivery acceptance term agree customer good subject installation instrument sell diagnostic division sale generally recognise completion installation customer site customer acceptance sale recognise transaction price base consideration group expect receive exchange good service exclude amount collect behalf party value add taxis taxis directly link sale contract contain performance obligation transaction price allocate performance obligation base relative standalone selling pricesfinance report note roche group consolidate financial statement roche group instrument diagnostic division sell good reagent consumable service single contract contract combine revenue recognition purpose sale recognise satisfaction performance obligation contract instrument sell cash instalment sale transaction available customer finance lease operating lease transaction finance lease arrangement group transfer substantially risk reward ownership customer treat finance lease arrangement income finance lease recognise revenue amount represent fair value instrument approximate present value minimum lease payment arrangement interest rate embed finance lease arrangement approximately market rate income finance lease comparable revenue outright sale finance income finance lease arrangement long month defer subsequently recognise base pattern approximate use effective interest rate method record royalty operating income operating lease income operating lease recognise revenue straightline basis lease term lease revenue entirely variable subject subsequent reagent sale performance obligation deliver reagent satisfied sale net discount base estimate relate obligation include standalone selling price fair value require judgement determine different obligation satisfied include enforceable purchase commitment obligation exist arise contract distributor sale recognise good physically transfer distributor consignment arrangement distributor act agent case sale recognise control good transfer endcustomer distributor commission present marketing distribution commission similar payment distributor act principal deduct sale payment exchange distinct service consideration receive group exchange good service fix variable variable consideration recognise consider highly probable significant revenue reversal occur underlie uncertainty relate variable consideration subsequently resolve common element variable consideration pharmaceutical division list government regulatory mandatory price reduction consist mandatory price reduction major element b drug discount program medicaid plan contractual price reduction include rebate chargeback result contractual agreement primarily volume base performance base cash discount include credit offer wholesaler remit payment purchase contractually define incentive period customer return reserve allowance establish expect product return revenue product sale record net allowance estimate rebate chargeback cash discount estimate product return establish time sale product sale allowance base estimate amount earn claim related sale estimate consideration historical experience current contractual statutory requirement specific know market event trend competitive pricing new product introduction estimate inventory level shelf life product actual future result vary estimate need adjust effect sale earning period adjustment sale reduction expect withhold customer settlement contractual price reduction cash discount record balance sheet deduction trade receivables sale reduction separately payable customer governmental health authority healthcare regulatory authority record balance sheet accrue liability provision sale return record balance sheet provision group recognise defer income contract liability consideration receive receivable group transfer promise good service customer defer income mainly relate remain performance obligation good free charge certain patient access similar programme reagent consumable service remain performance obligation partially unsatisfie longterm contract include defer income relate amount group expect receive good service transfer customer exist noncancellable enforceable contract mainly associate contract minimum purchase commitment related reagent consumable previously sell instrument monitor maintenance service contract original duration year group elect practical expedient disclose transaction price remain performance obligation end report period point time group expect recognise sale roche group note roche group consolidated financial statement finance report royalty operating income royalty operating income include royalty income income outlicense agreement income disposal product item royalty income earn licence recognise underlie sale record licensee income outlicense agreement typically arise receipt upfront milestone similar payment party grant licence product technologyrelate intellectual property ip outlicense agreement entered obligation include commitment conduct research latestage development regulatory approval comarkete manufacturing licence grant usually right use ip generally unique basis allocate revenue performance obligation make use residual approach upfront payment licensing fee usually recognise grant licence income shall defer performance obligation residual approach defer income release recognise revenue performance obligation satisfy milestone payment typically receive reach specific scientific milestone development milestone achieve certain annual sale milestone commercial milestone development milestone income recognise point time highly probable respective milestone event criterion achieve risk revenue reversal consider remote commercial milestone income accrue recognise revenue highly probable annual sale milestone reach period payment receive disposal product similar right recognise revenue transfer control right extent payment relate performance obligation portion defer residual approach recognise revenue activity manufacturing service render income profitshare arrangement collaboration partner recognise underlie sale cost sale record collaboration partner include income service render usually group primary business activity extent revenue record sale recognise control transfer performance obligation satisfy cost sale cost sale include correspond direct production cost relate production overhead good sell service render royalty alliance collaboration expense include collaboration profitshare arrangement report cost sale startup cost validation achievement normal production capacity expense incur research development internal research development activity expense incur follow internal research cost incur purpose gain new scientific technical knowledge understand internal development cost incur application research finding knowledge plan develop new product commercial production development project undertake group subject technical regulatory uncertainty opinion management criterion capitalisation intangible asset meet prior obtain marketing approval regulatory authority major market postmarkete study regulatory approval phase iv cost pharmaceutical business generally involve safety surveillance ongoing technical support drug receive marketing approval sell require regulatory authority undertaken safety commercial reason cost postmarkete study capitalise intangible asset opinion management generate separately identifiable incremental future economic benefit reliably measure acquire inprocess research development resource obtain inlicense arrangement business combination separate asset purchase capitalise intangible asset acquire asset control group separately identifiable expect generate future economic benefit uncertainty exist research development ultimately result marketable product consequently upfront milestone payment party pharmaceutical product compound regulatory marketing approval recognise intangible asset asset acquire arrangement measure basis set intangible asset policy subsequent internal research development cost incur postacquisition treat way internal research development cost research development embed contract strategic alliance group carefully assess upfront milestone payment constitute funding research development work acquisition assetfinance report note roche group consolidate financial statement roche group employee benefit shortterm employee benefit include wage salary social security contribution pay annual leave sick leave profit share bonus nonmonetary benefit current employee cost recognise operating result employee render associate service group recognise liability profit share bonus contractually oblige past practice create constructive obligation longterm employee benefit include longservice sabbatical leave longservice benefit longterm disability benefit expect cost benefit accrue period employment change carry value longterm employee benefit liability recognise operating result termination benefit payable employment terminate group normal retirement date employee accept voluntary redundancy exchange benefit termination cost recognise early group long withdraw offer benefit group recognise related restructuring cost pension postemployment benefit define contribution plan group contribution recognise operating result employee render associated service prepay contribution recognise asset extent cash refund reduction future payment available define benefit plan liability recognise balance sheet present value define benefit obligation fair value plan asset change net define benefit liability recognise occur follows recognise income statement current service cost charge appropriate income statement head operating result past service cost include curtailment gain loss recognise immediately general administration operating result settlement gain loss recognise general administration operating result net interest net define benefit liability recognise financing cost recognise comprehensive income actuarial gain loss arise experience adjustment difference previous assumption actually occur change actuarial assumption return plan asset exclude amount include net interest net define benefit liability change limit recognition plan asset exclude amount include net interest net define benefit liability net interest net define benefit liability comprise interest income plan asset interest cost define benefit obligation interest effect limit recognition pension asset net interest calculate discount rate calculate define benefit obligation apply net define liability start period take account change contribution benefit payment pension asset liability different define benefit plan offset group legally enforceable right use surplus plan settle obligation plan equity compensation plan fair value equity compensation award grant employee estimate grant date record expense vest period expense charge appropriate income statement head operating result equitysettle plan increase equity record expense subsequent cash flow exercise vested award record change equity roche group note roche group consolidated financial statement finance report property plant equipment property plant equipment initially record cost purchase construction include cost directly attributable bring asset location condition necessary capable operating manner intend management include item cost site preparation installation assembly cost professional fee net cost test asset function properly include validation cost include initially record cost construction interest borrowing cost incur respect qualify asset capitalise include carry value asset property plant equipment depreciate straightline basis land depreciate estimate useful life major class depreciable asset follow land improvement year building year machinery equipment year diagnostic instrument year office equipment year motor vehicle year part item property plant equipment different useful life account separate component estimate useful life asset regularly review necessary future depreciation charge accelerate repair maintenance cost expense incur lease group lessee policy applicable january inception contract group assess contract contain lease contract contain lease contract convey right control use identify asset period time exchange consideration group recognise rightofuse asset correspond lease liability contract contain lease lease commencement date shortterm lease lease lowvalue asset payment shortterm lease lease lowvalue asset recognise expense straightline basis term respective lease lease liability initially measure present value future lease payment pay lease commencement date lease payment discount interest rate implicit lease readily determinable group incremental borrowing rate respective market lease payment include fix payment variable payment depend index rate know lease commencement date payment exercise extension purchase option group reasonably certain exercise lease liability subsequently measure amortise cost effective interest method remeasure correspond adjustment relate rightofuse asset change future lease payment follow contract renegotiation change index rate reassessment option rightofuse asset initially measure cost comprise initial lease liability adjust payment lease commencement date include initial direct cost incur expect cost obligation dismantle remove refurbish underlie asset incentive receive rightofuse asset depreciate straightline basis lease commencement date short lease term useful life underlie asset rightofuse asset assess impairment indication impairment group lessee policy applicable january group classify lease substantially transfer risk reward ownership finance lease finance lease capitalise property plant equipment start lease fair value present value minimum lease payment low rental obligation net finance charge report debt finance lease asset depreciate short lease term useful life interest element lease payment charge income lease term base effective interest rate method lease classify operating lease operating lease exist substantially risk reward ownership transfer group payment operating lease charge income straightline basis period leasefinance report note roche group consolidate financial statement roche group group lessor certain asset mainly diagnostic instrument lease thirdparty customer finance operating lease arrangement transaction enter separate contract combine contract include reagent consumable service treatment leasing transaction mainly determine lease consider operating finance lease making assessment management look substance lease legal form make judgement substantially risk reward ownership transfer case lease finance lease operating lease arrangement legal form lease convey right use asset cover assessment finance lease finance lease asset report receivables equal net investment lease income finance lease recognise revenue amount represent standalone selling price instrument approximate present value minimum lease payment arrangement minimum lease payment exclude variable lease payment contingent rent finance income finance lease arrangement long month defer subsequently recognise base pattern approximate use effective interest method record royalty operating income operating lease income operating lease recognise revenue straightline basis lease term amount represent standalone selling price instrument approximate present value minimum lease payment arrangement minimum lease payment exclude variable lease payment contingent rent lease revenue entirely base variable lease payment subject subsequent reagent sale recognise performance obligation reagent satisfy sale net discount base estimate relate obligation include standalone selling price require judgement determine different obligation satisfied include enforceable purchase commitment obligation exist arise merger acquisition business combination business combination account acquisition method accounting date acquisition group initially recognise fair value identifiable asset acquire liability assume noncontrolle interest acquire business consideration transfer measure fair value date acquisition group acquire ownership acquire business noncontrolle interest record fair value proportion fair value acquire net asset attributable noncontrolle interest directly attributable acquisitionrelated cost expense incur general administration expense asset acquisition asset acquisition acquisition legal entity qualify business combination date acquisition group initially recognise individual identifiable asset acquire liability assume cost group date acquisition allocate individual identifiable asset liability basis relative fair value date acquisition subsequent consideration performancerelate development milestone recognise intangible asset specific milestone achieve transaction rise goodwill material directly attributable acquisitionrelated cost include cost acquire asset goodwill goodwill arise business combination excess consideration transfer acquire business underlie fair value net identify asset acquire goodwill amortise test impairment annually occurrence indication impairment intangible asset purchase patent licence trademark intangible asset initially record cost asset acquire business combination initially record fair value commercial software development cost capitalise certain recognition criterion technical feasibility commercial viability meet available use intangible asset amortise straightline basis useful life intangible asset review impairment reporting date estimate useful life low legal duration economic useful life estimate useful life intangible asset regularly review estimate useful life major class amortisable intangible asset follow product intangible use year marketing intangible use year technology intangible use year roche group note roche group consolidated financial statement finance report impairment property plant equipment rightofuse asset intangible asset impairment assessment carry evidence asset impair addition intangible asset available use test impairment annually recoverable asset high fair value cost disposal value use carrying value carry value reduce recoverable reduction report income statement impairment loss value use calculate estimate cash flow generally fiveyear period extrapolate projection subsequent year discount appropriate longterm interest rate impairment loss arise useful life asset review necessary future depreciationamortisation charge accelerate impairment loss subsequently decrease decrease relate objectively event occurring impairment recognise previously recognise impairment loss reverse income statement impairment reversal impairment goodwill goodwill assess impairment reporting date additionally test annually impairment goodwill allocate cashgenerating unit recoverable cashgenerate unit high fair value cost disposal value use carrying value carry value goodwill reduce recoverable reduction report income statement impairment loss acquire business include cashgenerating unit permanently cease operate treat disposal business separately identifiable goodwill generate initial acquisition business factor goodwill entirely unrelated continue operation cashgenerating unit goodwill deem dispose fully impair impairment testing methodology describe note inventory inventory state low cost net realisable value cost finish good work process intermediate include raw material direct labour directly attributable cost overhead base normal capacity production facility cost determine weighted average method net realisable value estimate selling price cost completion selling expense receivables include account receivable receivables carry original invoice allowance doubtful account trade discount cash discount volume rebate similar allowance receivable represent right consideration unconditional exclude contract asset allowance doubtful account record expect credit loss term receivables estimate base specific indicator age customer balance specific credit circumstance group historical loss rate category customer adjust forwardlooke macroeconomic datum expense doubtful trade receivables recognise marketing distribution expense trade discount cash discount volume rebate similar allowance record accrual basis consistent recognition relate sale estimate base exist contractual obligation historical trend group experience receivable write partly reasonable expectation recovery receivable write group continue engage enforcement activity attempt recover receivable recovery recognise profit loss trade lease receivables group apply simplified approach prescribe ifrs requirespermit use lifetime expect loss provision initial recognition receivables group measure allowance doubtful account equal credit loss expect lifetime trade lease receivables cash cash equivalent cash cash equivalent include cash hand time current balance bank similar institution balance report cash equivalent readily convertible know amount cash subject insignificant risk change fair value maturity month date acquisitionfinance report note roche group consolidate financial statement roche group provision contingency provision recognise legal constructive obligation incur probably lead outflow resource reliably estimate particular restructuring provision recognise group detailed formal plan commence implementation announce provision record estimate ultimate liability expect arise discount time value money material contingent liability disclose existence obligation confirm future event obligation measure reasonable reliability contingent asset recognise disclose inflow economic benefit probable fair value fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date determine reference quote market price use establish valuation technique option pricing model discount cash flow method quote price active market available financial instrument group classify financial instrument follow measurement category disclose note amortise cost fair value oci fair value oci equity investment fair value profit loss include hedging instrument classification depend group business model manage financial asset contractual term cash flow group reclassifie debt security financial asset amortise cost business model manage asset change initial recognition group measure financial asset fair value plus case financial asset fair value profit loss transaction cost directly attributable acquisition financial asset transaction cost financial asset carry fair value profit loss expense profit loss amortise cost asset hold collection contractual cash flow cash flow represent solely payment principal interest measure amortise cost provision impairment gain loss debt security subsequently measure amortise cost hedge relationship recognise profit loss asset derecognise impair interest income financial asset include financial income effective interest rate method asset amortise cost mainly comprise account receivable cash cash equivalent time account month fair value comprehensive income fair value oci financial asset hold collection contractual cash flow sell financial asset asset cash flow represent solely payment principal interest initially record subsequently carry fair value change fair value record comprehensive income recognition impairment gain loss interest revenue foreign exchange gain loss recognise profit loss financial asset derecognise cumulative gain loss previously recognise oci reclassify equity profit loss interest income financial asset include financial income effective interest rate method fair value comprehensive income asset mainly comprise money market instrument debt security equity investment fair value comprehensive income fair value oci equity investment private biotechnology company keep group strategic alliance effort asset subsequently measure fair value dividend recognise financial income profit loss dividend clearly represent recovery cost investment net gain loss recognise oci include fair value reserve asset derecognise cumulative gain loss previously recognise oci reclassify equity fair value reserve retain earning profit loss roche group note roche group consolidated financial statement finance report fair value profit loss financial asset performance evaluate fair value basis gain loss financial asset subsequently measure fair value profit loss hedge relationship recognise profit loss present financial income expense period arise fair value profit loss asset mainly comprise equity investmentssecuritie contingent consideration liability initially record subsequently carry fair value change fair value record general administration operating result income statement fair value profit loss hedge instrument derivative financial instrument manage exposure foreign currency interest rate equity market credit risk instrument initially record subsequently carry fair value apart derivative designate qualify cash flow hedge instrument change fair value record financial income expense financial liability nonderivative financial liability financial liability initially record fair value transaction cost subsequently carry amortise cost effective interest rate method financial liability mainly comprise debt trade payable debt debt instrument initially record cost proceed receive net transaction cost subsequently report amortise cost discount net proceed receive principal value redemption amortise duration debt instrument recognise finance cost effective interest rate method derecognition financial asset derecognise contractual cash flow asset expire group transfer right receive contractual cash flow financial asset transaction substantially risk reward ownership financial asset transfer financial liability derecognise contractual obligation discharge cancel expire impairment financial asset group recognise loss allowance expect credit loss ecl financial asset measure amortise cost debt security measure fair value oci trade lease receivables group measure allowance doubtful account equal lifetime ecl debt security carry fair value oci debt security financial asset amortise cost determine low credit risk base external credit rating counterpartie group measure loss allowance equal month ecl group consider debt security low credit risk credit risk rating equivalent globally understand definition investment grade group consider baa moodys bbb standard poor credit risk debt security carry fair value oci debt security financial asset amortise cost increase significantly initial recognition group measure loss allowance equal lifetime ecl group assume credit risk instrument increase significantly day past financial asset write partially realistic prospect recovery generally case group determine customer asset source income generate sufficient cash flow repay amount subject writeoff financial asset write subject enforcement activity order comply group policy recovery amount hedge accounting group use derivative manage exposure foreign currency interest rate equity market credit risk instrument include interest rate swap crosscurrency swap forwards contract option group generally limit use hedge account certain significant transaction qualify hedge accounting hedging relationship meet strict condition eligibility hedge hedge instrument formal designation documentation hedge effectiveness reliability measurement transaction consider hedge economic term require condition meet relationship qualify hedge accounting case hedge instrument hedge item report independently hedge relationship mean derivative report fair value change fair value include financial income expensefinance report note roche group consolidate financial statement roche group cash flow hedge hedge exposure variability cash flow attributable particular risk associate recognise asset liability highly probable forecast transaction affect profit loss hedge instrument record fair value effective portion hedge include comprehensive income ineffective portion report financial income expense hedge relationship hedge foreign currency risk firm commitment highly probable forecast transaction result recognition nonfinancial item cumulative change fair value hedge instrument record comprehensive income include initial carrying value nonfinancial item date recognition cash flow hedge cumulative change fair value hedge instrument record comprehensive income include financial income expense forecast transaction affect net income fair value hedge hedge exposure change fair value recognise asset liability unrecognised firm commitment identify portion asset liability firm commitment attributable particular risk affect profit loss hedge instrument record fair value hedge item record previous carrying value adjust change fair value attributable hedged risk change fair value report financial income expense taxation income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base income property capital taxis include general administration expense liability income taxis mainly withhold taxis arise remittance retain earning principally relate subsidiary recognise probable earning remit foreseeable future tax liability uncertain accrual record income tax liability management well estimate ultimate liability expect arise base specific circumstance group historical experience defer tax asset liability recognise temporary difference tax basis asset liability carry value defer tax asset recognise extent probable future taxable profit available unused tax loss utilise current defer tax asset liability offset income taxis levy taxation authority legally enforceable right offset defer taxis determine base currently enact tax rate applicable tax jurisdiction group operate equity instrument group holding equity instrument record deduction equity original purchase cost consideration receive subsequent resale equity instrument movement report change equity instrument hold group potential conversion obligation arise group equity compensation plan change accounting policy group implement minor amendment exist standard interpretation material impact group overall result financial position amendment ifrs business combination definition business mandatorily applicable early adopt group future new revise standard group currently assess potential impact new revise standard interpretation mandatory january group apply base analysis date group anticipate material impact group overall result financial position group assess new revise standard mandatory roche group report roche management internal control financial reporting finance report report roche management internal control financial reporting report roche management internal control financial reporting board director management roche holding ltd responsible establish maintain adequate control financial report internal control system design provide reasonable assurance reliability financial reporting preparation fair presentation consolidate financial statement accordance international financial reporting standard internal control system matter design inherent limitation system determine effective prevent detect misstatement provide reasonable assurance respect financial statement preparation presentation projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate management assess effectiveness system internal control financial reporting december base criterion effective internal control financial reporting describe internal control integrate framework issue committee sponsor organization treadway commission coso base assessment management conclude system internal control financial reporting effective december statutory auditor kpmg ag audit consolidated financial statement roche holding ltd year end december accordance swiss auditing standard international standard audit isa christoph franz alan hippe chairman board directors chief financial officer basel february finance report statutory auditor report roche group statutory auditor report general meeting roche holding ltd basel report audit consolidated financial statement opinion audit consolidated financial statement roche holding ltd subsidiary group comprise consolidated balance sheet december consolidated income statement consolidate statement comprehensive income consolidate statement change equity consolidate statement cash flow year end note consolidate financial statement include summary significant accounting policy opinion consolidated financial statement page true fair view consolidate financial position group december consolidated financial performance consolidated cash flow year end accordance international financial reporting standard ifrs comply swiss law basis opinion conduct audit accordance swiss law international standard auditing isa swiss auditing standard responsibility provision standard describe auditor responsibility audit consolidated financial statement section report independent group accordance provision swiss law requirement swiss audit profession international ethic standard board accountant international code ethic professional accountant include international independence standard iesba code fulfil ethical responsibility accordance requirement believe audit evidence obtain sufficient appropriate provide basis opinion key audit matter chargeback rebate sale return pharmaceutical business carrying value product intangible asset income tax uncertain tax position acquisition spark therapeutics inc key audit matter matter professional judgement significance audit consolidated financial statement current period matter address context audit consolidated financial statement form opinion thereon provide separate opinion matter roche group statutory auditor report finance report chargeback rebate sale return pharmaceuticals business key audit matter response group pharmaceutical business make sale audit procedure include sample customer fall certain commercial basis obtain management calculation accrue governmentmandate contract purchasing liability provision account receivable deduction reimbursement arrangement significant testing accuracy calculation assess medicaid b drug discount program appropriateness key input assumption group provide right return customer estimate perform assessment reference certain product return period case internal external source information include extend year future arrangement term applicable contract government pricing result deduction gross amount invoice arrive information historical rate chargeback rebate revenue create obligation group provide historical rate sale return consideration current customer credit chargeback rebate payment trend estimate amount deduct gross sale record accrue liability rebate provision evaluate accuracy management estimate sale return deduction account receivable compare rate historical estimate rate chargeback estimate base analyse actual rebate payment chargeback assess exist contractual legislatively mandate obligation change accrual rate estimate recent trend historical experience compare accrual rate current chargeback rebate payment sale return trend management determine accrue liability deduction account receivable expect evaluate appropriateness group chargeback rebate predominantly medicaid revenue recognition accounting policy include chf million necessary december recognition measurement deduction gross sale additionally provision sale return mainly relate relate chargeback rebate sale return product near loss exclusivity chf million relate disclosure record december focus area arrangement complex establish appropriate yearend position require significant judgement estimation management assumption require estimate provision sale return complicated give recent loss exclusivity group pharmaceutical product information chargeback rebate sale return pharmaceutical business refer follow significant accounting policy note general accounting principle key accounting judgement estimate assumption note page financial disclosure note revenue note account receivable note current liability note provision contingent liabilitiesfinance report statutory auditor report roche group carry value product intangible asset key audit matter response group significant product intangible asset audit procedure include challenge december chf million acquire robustness key assumption determine business combination asset acquisition inlicense recoverable amount include forecast revenue arrangement comprise product intangible use useful life discount rate challenge base chf million amortise product intangible understand commercial prospect available use chf million amortise individual product relevant business area impairment assessment carry product market operate valuation intangible evidence asset specialist assist evaluate assumption impair intangible asset available methodology management relation use test impairment annually discount rate assess key input project pricing volume product project share product intangible use chf million predominantly therapeutic area vitro diagnostic market compare relate acquire product launch relevant assumption industry forecast review key risk ability successfully commercialise analyst commentary retrospective assessment product concern key estimate assumption include accuracy previous projection compare revenue growth timing impact loss exclusivity management assumption external datum discount rate development commercialisation available perform sensitivity analysis individual compete product driver revenue growth include intangible asset impairment model assess level persistence rate treatment rate market share sensitivity key assumption focus work area assess management allowance risk product intangible available use chf million represent inprocess research development addition product intangible available asset inherent uncertainty research use audit include assess reasonableness development process intangible asset available management assumption probability use particularly risk impairment impairment obtain regulatory approval comparison industry assessment require management key assumption practice past history consideration group judgement clinical technical commercial internal governance approval process viability new product accordingly focus audit work area risk include inability achieve successful trial result obtain require clinical regulatory approval highly competitive business environment therapeutic area group significant asset research development information carry value product intangible asset refer follow significant accounting policy note general accounting principle key accounting judgement estimate assumption note page financial disclosure note intangible asset roche group statutory auditor report finance report income tax uncertain tax position key audit matter response group operate wide range different tax audit procedure include obtain jurisdiction world tax treatment understand uncertain tax position inquiry tax filing subject challenge local tax authority employee tax department management respect crossborder transfer pricing arrangement affiliate inspect documentation relation tax good service finance transactionrelated tax exposure item include correspondence tax authority matter connection integration investment report issue tax advisor verify uncertain divestment license contract tax treatment tax position consider provide involve uncertainty include agreement transfer pricing necessary arrangement affiliate involve group global manufacturing supply chain significant item challenge management judgement eventual resolution probable tax authority accept uncertainty assistance local country tax treatment tax liability recognise financial specialist reperforme calculation estimate statement reflect management good estimate exposure inspect thirdparty transfer pricing study outcome base fact know relevant evaluate applicable past experience jurisdiction group open tax transfer pricing management interaction tax authority matter tax authority range respective jurisdiction additionally tax possible outcome broad december specialist expertise assess appropriateness group recognise current income tax liability key assumption management conclude chf million include accrual uncertain good estimate outcome tax position audit approach include additional audit procedure focus area uncertainty perform group level consider uncertain tax position estimate amount tax receivable payable arising group particular respect transfer require significant level expertise pricing arrangement good service transaction judgement relate tax matter information uncertain tax position refer follow significant accounting policy note general accounting principle key accounting judgement estimate assumption note page financial disclosure note income taxesfinance report statutory auditor report roche group acquisition spark therapeutics inc key audit matter response group acquire spark therapeutics inc spark audit procedure relation acquisition december total consideration spark include inspection legal chf million consideration primarily allocate agreement support transaction examine intangible asset chf million residual information contain diligence valuation chf million recognise goodwill report internal management presentation board director management require apply judgement identify value intangible asset defer tax asset challenge appropriateness methodology purchase price allocation exercise allocation assumption management value identify goodwill arise transaction appropriate cash intangible asset support valuation generating unit tax specialist evaluate appropriateness discount rate cost debt tax rate apply key assumption relate valuation intangible life science expert assist challenge key assumption asset include probability technical success revenue management determine revenue growth forecast consider competitive environment discount probability technical success competitive environment rate cost debt tax rate specifically relate large intangible asset identify goodwill arise transaction attribute roche pharmaceutical cashgenerating unit challenge key assumption base sector reflect benefit group research expertise reference available industry forecast development activity haemophilia treatment field analyst commentary compare management access spark gene therapy expertise assumption external datum available perform sensitivity analysis key assumption identify likely lead material misstatement focus work assess management allowance risk procedure challenge management external valuer obtain understanding spark integrate gene therapy platform comprise multiple element include inlicense inhouse develop technology expertise knowhow spark personnel process area vector design vector manufacturing investigational new drug enable study regulatory process gene therapy challenge level goodwill recognise assess appropriateness management decision allocate goodwill roche pharmaceutical cashgenerating unit base expected synergy roche business assess group disclosure relation acquisition meet requirement relevant accounting standard information acquisition spark therapeutics inc refer follow significant accounting policy note general accounting principle key accounting judgement estimate assumption note page financial disclosure merger acquisition note roche group statutory auditor report finance report information annual report board director responsible information annual report information comprise information include annual report include consolidated financial statement standalone financial statement company remuneration report auditor report thereon opinion consolidated financial statement cover information annual report express form assurance conclusion thereon connection audit consolidated financial statement responsibility read information annual report consider information materially inconsistent consolidated financial statement knowledge obtain audit appears materially misstate base work perform conclude material misstatement information require report fact report regard responsibility board director consolidate financial statement board director responsible preparation consolidate financial statement true fair view accordance ifrs provision swiss law internal control board director determine necessary enable preparation consolidated financial statement free material misstatement fraud error prepare consolidated financial statement board director responsible assess group ability continue go concern disclose applicable matter relate going concern go concern basis accounting board director intend liquidate group cease operation realistic alternative auditor responsibility audit consolidated financial statement objective obtain reasonable assurance consolidated financial statement free material misstatement fraud error issue auditor report include opinion reasonable assurance high level assurance guarantee audit conduct accordance swiss law isa swiss auditing standard detect material misstatement exist misstatement arise fraud error consider material individually aggregate reasonably expect influence economic decision user take basis consolidated financial statement audit accordance swiss law isa swiss auditing standard exercise professional judgment maintain professional scepticism audit identify assess risk material misstatement consolidated financial statement fraud error design perform audit procedure responsive risk obtain audit evidence sufficient appropriate provide basis opinion risk detect material misstatement result fraud high result error fraud involve collusion forgery intentional omission misrepresentation override internal control obtain understand internal control relevant audit order design audit procedure appropriate circumstance purpose express opinion effectiveness group internal control evaluate appropriateness accounting policy reasonableness accounting estimate related disclosure conclude appropriateness board director use go concern basis accounting base audit evidence obtain material uncertainty exist relate event condition cast significant doubt group ability continue go concern conclude material uncertainty exist require draw attention auditor report relate disclosure consolidate financial statement disclosure inadequate modify opinion conclusion base audit evidence obtain date auditor report future event condition cause group cease continue go concern evaluate overall presentation structure content consolidated financial statement include disclosure consolidated financial statement represent underlie transaction event manner achieve fair presentationfinance report statutory auditor report roche group obtain sufficient appropriate audit evidence financial information entity business activity group express opinion consolidated financial statement responsible direction supervision performance group audit remain solely responsible audit opinion communicate board director relevant committee matter plan scope time audit significant audit finding include significant deficiency internal control identify audit provide board director relevant committee statement comply relevant ethical requirement independence communicate relationship matter reasonably think bear independence applicable action take eliminate threat safeguard apply matter communicate board director relevant committee determine matter significance audit consolidated financial statement current period key audit matter describe matter auditor report law regulation preclude public disclosure matter extremely rare circumstance determine matter communicate report adverse consequence reasonably expect outweigh public interest benefit communication report legal regulatory requirement accordance article para item co swiss auditing standard confirm internal control system exist design preparation consolidated financial statement accord instruction board director recommend consolidated financial statement submit approve kpmg ag mark baillache marc ziegler license audit expert license audit expert auditor charge basel february kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member firm kpmg global organisation independent member firm affiliate kpmg international limited private english company limit guarantee right reserve roche group multiyear overview supplementary information finance report multiyear overview supplementary information multiyear overview statistic report income statement millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income attributable roche shareholder equity research development sale current ratio equity noncontrolle interest total asset human capital return investment ratio datum share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard apply dividend propose board director retrospectivelyfinance report multiyear overview supplementary information roche group multiyear overview statistic report income statement millions chf sale ebitda operating profit net income attributable roche shareholder research development balance sheet million chf noncurrent asset current asset total asset noncurrent liability current liability total liability net asset capital reserve attributable roche shareholder equity attributable noncontrolle interest addition property plant equipment personnel number employee end year key ratio net income attributable roche shareholder sale net income attributable roche shareholder equity research development sale current ratio equity noncontrolle interest total asset human capital return investment ratio datum share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf information table state report change accounting policy arise change international financial reporting standard apply dividend propose board director retrospectively roche group multiyear overview supplementary information finance report sale division millions chf pharmaceutical diagnostic total sale geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total addition property plant equipment division millions chf pharmaceutical diagnostic corporate total finance report multiyear overview supplementary information roche group addition property plant equipment geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche group multiyear overview supplementary information finance report alternative performance measure financial information include financial review include certain alternative performance measure apm accounting measure define ifrs particular core result net work capital net operating asset free cash flow constant exchange rate apm instead consider alternative group consolidated financial result base ifrs apm comparable similarly title measure disclose company apm present financial review relate performance current year comparative period core result core result allow assessment group actual result define ifrs underlie performance business core result concept internal management business base ifrs result follow adjustment global restructuring plan note exclude amortisation impairment intangible asset note exclude commercial software intangible asset impairment goodwill note exclude acquisition accounting impact accounting merger acquisition transaction alliance arrangement financial review exclude discontinued operation currently exclude legal environmental case financial review exclude global issue outside healthcare sector group control exclude material treasury item major debt restructuring currently exclude pension plan settlement note exclude tax benefit record ifrs respect equity compensation plan ecp vary accord price underlie equity replace normalise tax benefit ifrs expense multiply applicable tax rate note core result concept describe october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm group ifrs result include divisional breakdown reconcile core result table calculation core eps give table additional commentary adjustment item give financial reviewfinance report multiyear overview supplementary information roche group core result reconciliation millions chf intan intan pension normali global gible gible alliance legal plan sation restruc amorti impair trans environ settle global ecp tax ifrs ture sation ment action mental ment issue benefit core sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest core result reconciliation millions chf intan intan pension normali global gible gible alliance legal plan sation restruc amorti impair trans environ settle global ecp tax ifrs ture sation ment action mental ment issue benefit core sale royalty operating income cost sale marketing distribution research development general administration operating profit financing cost financial income expense profit taxis income taxis net income attributable roche shareholder noncontrolle interest roche group multiyear overview supplementary information finance report divisional core result reconciliation millions chf intan intan pension global gible gible alliance legal plan restruc amorti impair trans environ settle ifrs ture sation ment action mental ment core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operating profit divisional core result reconciliation millions chf intan intan pension global gible gible alliance legal plan restruc amorti impair trans environ settle ifrs ture sation ment action mental ment core pharmaceutical sale royalty operate income cost sale marketing distribution research development general administration operate profit diagnostic sale royalty operating income cost sale marketing distribution research development general administration operating profit corporate general administration operate profit finance report multiyear overview supplementary information roche group core ep basic core net income attributable roche shareholder chf million weight average number share nonvoting equity security issue calculate basic earning share million core earning share basic chf core ep diluted core net income attributable roche shareholder chf million increase noncontrolle interest share core net income assume outstanding chugai stock option exercise chf million net income calculate diluted earning share chf million weight average number share nonvoting equity security issue calculate diluted earning share million core earning share diluted chf free cash flow free cash flow assess group ability generate cash require conduct maintain operation indicate group ability generate cash finance dividend payment repay debt undertake merger acquisition activity free cash flow concept internal management business operate free cash flow calculate base ifrs operating profit adjust certain noncash item movement net work capital capital expenditure investment property plant equipment intangible asset principal portion lease liability pay lease asset operate free cash flow different cash flow operating activity define ias include capital expenditure responsibility divisional management exclude income taxis pay responsibility divisional management cash outflow define benefit plan allocate operate free cash flow base current service cost residual allocate treasury activity free cash flow calculate operate free cash flow adjust treasury activity taxis pay free cash flow different total cash flow define ia exclude dividend payment cash inflowsoutflow financing activity issuancerepayment debt purchasesale marketable security cash inflowsoutflow merger acquisition divestment roche group multiyear overview supplementary information finance report operate free cash flow free cash flow calculate show table additional commentary adjustment item give financial review operate free cash flow reconciliation million chf cash flow operating activity ifrs basis accordance ia add income taxis pay deduct investment property plant equipment principal portion lease liability pay investment intangible asset disposal property plant equipment disposal intangible asset pension postemployment benefit add total payment define benefit plan deduct allocation payment operate free cash flow acquisitionrelate item include transaction cost operate item operate free cash flow free cash flow reconciliation million chf cash flow operating activity ifrs basis accordance ia deduct investment property plant equipment principal portion lease liability pay investment intangible asset disposal property plant equipment disposal intangible asset interest pay operating item include acquisitionrelate item treasury item free cash flow finance report multiyear overview supplementary information roche group supplementary information calculate divisional operate free cash flow show table divisional operate free cash flow information million chf pharmaceutical diagnostic corporate group depreciation amortisation impairment depreciation property plant equipment depreciation rightofuse asset amortisation intangible asset impairment reversal property plant equipment impairment reversal rightofuse asset impairment goodwill impairment intangible asset total adjustment add expense equitysettle equity compensation plan net income expense provision net gain loss disposal noncash work capital item deduct utilisation provision proceed disposal total operating profit cash adjustment roche group multiyear overview supplementary information finance report ebitda group use earning interest tax depreciation amortisation ebitda internal management report external communication opinion group management operate free cash flow give useful consistent measurement cash earning ebitda include noncash item provision allowance trade receivables inventory certain noncash entry arise acquisition accounting pension accounting operate free cash flow include cash investment property plant equipment lease asset intangible asset ebitda exclude cost cash outflow item convenience reader use ebitda provide table start point use core result exclude amortisation impairment goodwill intangible asset ebitda core result million chf pharmaceutical diagnostic corporate group ebitda core operate profit depreciation impairment property plant equipment core basis depreciation impairment rightofuse asset core basis ebitda margin sale finance report multiyear overview supplementary information roche group net operating asset net operating asset allow assessment group operate performance business independently finance tax activity net operating asset calculate property plant equipment lease asset rightofuse asset goodwill intangible asset net work capital longterm net operating asset minus provision calculation net operating asset disclose note annual financial statement show table net operating asset reconciliation millions chf treasury pharmaceutical diagnostic corporate taxation group property plant equipment rightofuse asset goodwill intangible asset inventory provision current income tax net liability defer tax net asset define benefit plan net liability lease liability marketable security cash cash equivalent debt net asset liability net work capital longterm net operating asset total net asset net operating asset reconciliation millions chf treasury pharmaceutical diagnostic corporate taxation group property plant equipment rightofuse asset goodwill intangible asset inventory provision current income tax net liability defer tax net asset define benefit plan net liability lease liability marketable security cash cash equivalent debt net asset liability net work capital longterm net operating asset total net asset roche group multiyear overview supplementary information finance report net debt net debt monitor group overall short longterm liquidity net debt calculate sum total debt longterm shortterm marketable security cash cash equivalent net debt calculation include detail movement current year show table financial review net work capital net working capital assess group efficiency utilise asset shortterm liquidity net trade work capital calculate trade receivables inventory minus trade payable net work capital calculate net trade work capital adjust receivables payable net work capital net trade work capital calculation show table pharmaceutical division diagnostic division corporate financial review constant exchange rate certain percentage change financial review calculate constant exchange rate cer allow assessment group financial performance effect exchange rate fluctuation eliminate percentage change constant exchange rate calculate simulation reconsolidate current report period prior period number constant currency exchange rate equal average exchange rate prior year example cer change line item equivalent calculate average exchange rate year end december line item line item subsequently calculate change percent respect recalculate number foreign exchange gain loss exclude calculation cer growth rate earning share disclosure country significant devaluation local currency current year simulation use average exchange rate current year instead prior year avoid cer growth rate artificially inflatedfinance report roche security roche group roche security price development share chf roche share swiss market index rebase price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebase price development american depositary receipt adr usd roche adr standard poors index rebase roche american depositary receipt adr equivalent nonvoting equity security genussschein adrs trade overthecounter market july roche group roche securities finance report number share nonvoting equity security number share nominal value chf number nonvoting equity security genussscheine nominal value total number share nonvoting equity security genussscheine hold total issue datum share nonvoting equity security chf earning basic earning dilute core earning basic core earning dilute equity attributable roche shareholder dividend c stock price share b open high low yearend stock price nonvoting equity security genussschein b open high low yearend market capitalisation millions chf yearend key ratio yearend dividend yield share dividend yield nonvoting equity security genussscheine priceearning share priceearning nonvoting equity security genussscheine nonvoting equity security genussschein confer right share participate available earning remain proceed liquidation follow repayment nominal value share participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction ownership share nonvoting equity securities b stock price datum reflect daily closing price c dividend propose board director stock code share nonvoting equity security american depositary receipt adr swiss exchange ro rog bloomberg ro sw rog vx rhhby reuters ros rogvx rhhbypkfinance report roche holding ltd basel roche holding ltd basel financial statement note financial statement summary significant accounting policy significant shareholder hareholder equity fulltime equivalent employee contingent liability board executive shareholding appropriation available earning statutory auditor report general meeting roche holding ltd basel roche holding ltd basel financial statement finance report financial statement balance sheet millions chf december december current asset cash cash equivalent marketable security account receivable group company shortterm loan group company total current asset noncurrent asset longterm loan group company investment total noncurrent asset total asset shortterm liability account payable group company interestbeare liability group company shortterm liability total shortterm liability longterm liability provision total longterm liability total liability shareholder equity share capital nonvoting equity security genussscheine pm pm legal retain earning general legal retain earning voluntary reserve retain earning free reserve special reserve available earning balance bring forward previous year net income year total shareholder equity total shareholder equity liability pm pro memoria nonvoting equity security genussscheine nominal valuefinance report financial statement roche holding ltd basel income statement millions chf year end december income income investment dividend income financial income interest income loan group company income marketable security guarantee fee income group company income total income expense administration expense expense financial expense direct taxis total expense net income roche holding ltd basel note financial statement finance report note financial statement summary significant accounting policy basis preparation financial statement roche holding ltd basel company prepare accordance provision swiss law accounting financial report nd title swiss code obligation co prescribe law significant accounting principle apply describe company prepare consolidated financial statement accordance recognise accounting standard international financial reporting standard accordance co company decide forgo present additional information audit fee note cash flow statement valuation method translation foreign currency marketable security report low cost market value financial asset include investment report cost appropriate writedown equity instrument recognise cost deduct equity time purchase equity instrument sell gain loss recognise income statement asset liability denominate foreign currency translate swiss franc yearend rate exchange investment translate historical rate transaction year denominate foreign currency translate exchange rate effective relevant transaction date result exchange gain loss recognise income statement exception unrealise gain defer investment direct indirect investment company list note roche group annual financial statement list exclude chugais subsidiary company material notably company inactive dormant liquidation ownership interest equal voting right taxis direct taxis include corporate income capital taxesfinance report note financial statement roche holding ltd basel shareholders equity share capital previous year share capital amount chf million share capital consist bearer share nominal value chf include equity nonvoting equity security genussscheine share capital confer voting right nonvoting equity security confer right share participate available earning remain proceed liquidation follow repayment nominal value share capital participation certificate equity instrument december company hold roche share nonvoting equity security company purchase sell roche share nonvoting equity security company subsidiary meet definition requirement article b co hold equity instrument roche group annual financial statement entity mainly foundation include consolidation qualify subsidiary article b co movement recognise amount million chf voluntary reserve retain earning legal retain special available equity share capital earnings free reserve reserve earning instrument total equity january net income dividend transaction equity instrument december net income dividend transaction equity instrument december net income dividend transaction equity instrument december roche holding ltd basel note financial statement finance report contingent liability guarantee company issue guarantee certain bond note commercial paper note credit facility group company nominal outstanding december chf billion chf billion describe note roche group annual financial statement significant shareholder share company bearer share reason company register shareholder follow figure base information shareholder shareholder validation check annual general meeting march information available company control shareholder december base information supply group shareholder group pool voting right own share represent issue share december shareholder group announce continue shareholder pool agreement modify shareholder composition group consist mr andr hoffmann ms marieanne hoffmann ms vera michalski mr alexander hoffmann mr frederic hoffmann ms isabel hoffmann mr lucas hoffmann ms marina hoffmann ms kasia barbotinlarrieu ms tatiana fabre mr andreas oeri ms catherine oeri ms sabine duschmal mr jrg duschmal mr lukas duschmal charitable foundation wolf artuma holding ltd shareholder pooling agreement exist duration pool extend indefinite period figure include share pooled voting right hold outside group individual member group ms maja oeri member pool hold share represent voting right independently pool december base information supply group share share own novartis hold ag basel participation fulltime equivalent employee annual average number fulltime equivalent employee exceed peoplefinance report note financial statement roche holding ltd basel board executive shareholdings board director director mr andr hoffmann dr jrg duschmal certain member founder family closely associate belong shareholder group pool voting right dr andreas oeri previously member board director stand reelection annual general meeting end shareholder group hold share issue share detailed information group give note addition end year member board director person closely associate hold share nonvoting equity security genussscheine show table shareholding member board director nonvoting equity security share genussscheine c franz hoffmann j bell na na j brown p bulcke h clevers j duschmal na na p frost na na hauser r p lifton e oeri na na b poussot schwan b c suessmuth dyckerhoff c c total include share hold shareholder group pool voting right b member corporate executive committee dr schwans shareholdings disclose table c jointly hold close relative close relative hauser hold nonvoting equity security genussscheine e r p lifton hold roche american depositary receipt adr adr equivalent nonvoting equity security genussschein adrs trade overthecounter market july corporate executive committee end year member corporate executive committee person closely associate hold share nonvoting equity security show table shareholding member corporate executive committee nonvoting equity security share genussscheine schwan b anderson hippe g keller na na b schinecker c wilbur total equity compensation award ssar rsus roche performance share plan b december close relative dr keller hold roche share roche holding ltd basel note financial statement finance report remuneration equity compensation plan member corporate executive committee complement restrict stock unit rsus compose stocksettle stock appreciation right ssar rsus new performance share plan psp award grant december member corporate executive committee hold stocksettle stock appreciation right ssar show table term vest condition award disclose note roche group annual financial statement additional supplementary information give remuneration report include annual report page ssar award grant member corporate executive committee vest year award grant vest year ssar award hold december year issue total schwan b anderson hippe schinecker c wilbur total strike price chf expiry date mar mar mar mar mar mar mar december members corporate executive committee hold restrict stock unit rsus show table term vest condition award disclose note roche group annual financial statement additional supplementary information give remuneration report include annual report page rsu award grant member corporate executive committee vest year award grant vest year nonvoting equity security andor share remain block year rsu award hold december year issue total schwan b anderson hippe schinecker c wilbur total december member corporate executive committee hold performance share plan psp award term vest condition award remain cycle disclose note roche group annual financial statement additional supplementary information give remuneration report include annual report page award result zero nonvoting equity security share value adjustment depend achievement performance target discretion board director vest nonvoting equity security share remain block year end remain cycle performance target achieve accordingly participant receive originally target nonvoting equity security new psp award grant member corporate executive committee information relate number value right option award grant employee roche group member board director corporate executive committee company disclose note note roche group annual financial statementsfinance report appropriation available earning roche holding ltd basel appropriation available earning proposal annual general meeting chf available earning balance bring forward previous year net profit year total available earning appropriation available earning distribution ordinary dividend chf gross share nonvoting equity security genussschein chf year total appropriation available earning carry forward account roche holding ltd basel statutory auditor report finance report statutory auditor report general meeting roche holding ltd basel report audit financial statement opinion audit financial statement roche holding ltd comprise balance sheet december income statement year end note financial statement include summary significant accounting policy opinion financial statement page year end december comply swiss law company article incorporation basis opinion conduct audit accordance swiss law swiss auditing standard responsibility provision standard describe auditor responsibility audit financial statement section report independent entity accordance provision swiss law requirement swiss audit profession fulfil ethical responsibility accordance requirement believe audit evidence obtain sufficient appropriate provide basis opinion report key audit matter base circular federal audit oversight authority key audit matter matter professional judgement significance audit financial statement current period determine key audit matter communicate report responsibility board director financial statement board director responsible preparation financial statement accordance provision swiss law company article incorporation internal control board director determine necessary enable preparation financial statement free material misstatement fraud error prepare financial statement board director responsible assess entitys ability continue go concern disclose applicable matter relate going concern go concern basis accounting board director intend liquidate entity cease operation realistic alternative auditor responsibility audit financial statement objective obtain reasonable assurance financial statement free material misstatement fraud error issue auditor report include opinion reasonable assurance high level assurance guarantee audit conduct accordance swiss law swiss auditing standard detect material misstatement exist misstatement arise fraud error consider material individually aggregate reasonably expect influence economic decision user take basis financial statementsfinance report statutory auditor report roche holding ltd basel audit accordance swiss law swiss auditing standard exercise professional judgement maintain professional scepticism audit identify assess risk material misstatement financial statement fraud error design perform audit procedure responsive risk obtain audit evidence sufficient appropriate provide basis opinion risk detect material misstatement result fraud high result error fraud involve collusion forgery intentional omission misrepresentation override internal control obtain understand internal control relevant audit order design audit procedure appropriate circumstance purpose express opinion effectiveness internal control evaluate appropriateness accounting policy reasonableness accounting estimate related disclosure conclude appropriateness board director use go concern basis accounting base audit evidence obtain material uncertainty exist relate event condition cast significant doubt entitys ability continue go concern conclude material uncertainty exist require draw attention auditor report relate disclosure financial statement disclosure inadequate modify opinion conclusion base audit evidence obtain date auditor report future event condition cause entity cease continue go concern communicate board director relevant committee matter plan scope time audit significant audit finding include significant deficiency internal control identify audit provide board director relevant committee statement comply relevant ethical requirement independence communicate relationship matter reasonably think bear independence applicable relate safeguard matter communicate board director relevant committee determine matter significance audit financial statement current period key audit matter describe matter auditor report law regulation preclude public disclosure matter extremely rare circumstance determine matter communicate report adverse consequence reasonably expect outweigh public interest benefit communication report legal regulatory requirement accordance article para item co swiss auditing standard confirm internal control system exist design preparation financial statement accord instruction board director confirm propose appropriation available earning complie swiss law company article incorporation recommend financial statement submit approve kpmg ag mark baillache marc ziegler license audit expert license audit expert auditor charge basel february kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member firm kpmg global organisation independent member firm affiliate kpmg international limited private english company limited guarantee right reservedpublishe cautionary statement forwardlooke statement f hoffmannla roche ltd finance report contain certain forwardlooking statement group communication forwardlooke statement identify word basel switzerland believe expect anticipate project intend tel seek estimate future similar expression wwwrochecom discussion thing strategy goal plan intention factor cause actual result differ orderdownload publication materially future reflect forwardlooke internet rochecompublication statement contain annual report email baselwarehouseservicesrochecom pricing product initiative competitor legislative fax regulatory development economic condition delay inability obtain regulatory approval bring media relation product market fluctuation currency exchange rate tel general financial market condition uncertaintie email mediarelationsrochecom discovery development marketing new product new use exist product include limitation negative result investor relation clinical trial research project unexpected effect tel pipeline market product increase government pricing email investorrelationsrochecom pressure interruption production loss inability obtain adequate protection intellectual property right corporate sustainability committee litigation loss key executive employee tel adverse publicity news coverage email corporatesustainabilityrochecom statement earning share growth profit annual general meeting forecast interpret mean roche march earning earning share subsequent period necessarily match exceed historical publish earning earning share roche trademark legally protect link thirdparty page provide convenience express opinion content thirdparty page expressly disclaim liability thirdparty information use roche finance report publish german english case doubt difference interpretation english version shall prevail german text reporting consist actual annual report finance report contain annual financial statement consolidated financial statement regard content management report article incorporation consist aforementioned report exception remuneration report print nonchlorine bleach fsccertifie paperf hoffmannla roche ltd basel switzerland trademark legally protect wwwrochecom troper ecnanif e roche finance report